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ABSTRACT 
 
MAIREAD EASTIN MOLONEY: Up all night: The medicalization of sleeplessness. 
(Under the direction of Victor Marshall) 
 
 
Sleeplessness – a universal experience with a variety of causes – may be increasingly 
diagnosed and treated as the medical condition insomnia, or “medicalized.”  This research 
provides quantitative and qualitative evidence of the medicalization of insomnia at the level 
of patient-physician interaction. I analyze 14 years (1993-2006) of data from the National 
Ambulatory Medical Care Survey, a nationally representative dataset of physician office 
visits. I describe trends over time for: complaint of sleeplessness, diagnosis of insomnia and 
prescription of sedative hypnotics (select benzodiazepines, Trazodone and non-
benzodiazepine sedative hypnotics [NBSHs]). Independent variables are age, gender, race 
and insurance status.  To measure change over time, I conduct linear regressions using 
weighted visits, calculate slope estimates and report P-values. I also carry out semi-structured 
qualitative interviews with patients (N=27) prescribed a sedative hypnotic, and their 
physicians (N=8).  
Between 1993 and 2006 complaint of sleeplessness increased 30% (3.3 million to 4.7 
million); diagnosis increased 6-fold (869,000 to 5.2 million) and prescriptions for all sedative 
hypnotics increased. Most notable was the 23-fold increase in NBSHs (550,000 to 12.8 
million).  Slope change and differences in proportion were positive and significant for 
insomnia diagnoses, NBSHs and Trazodone. Female gender was significantly associated with 
iv 
 
prescriptions of Trazodone. Patients 55+ were significantly more likely to receive a 
prescription for a benzodiazepine or a NBSH. 
Physicians were cognizant and critical of medicalization. They conceptualized 
insomnia as a symptom, part of the aging process, or a reaction to stress – not a disease. 
Despite stated bias, respondents prescribed sleep aids at least some of the time. Compliance 
was influenced by time constraints, consumerism, and pre-existing prescriptions. Patients 
entered their office with medical knowledge from non-medical sources including the Internet, 
social networks and direct to consumer advertising. 
Patients said that insomnia was a symptom of stress, anxiety or comorbid illness. Fear 
of addiction to sleep aids was common. Factors mediating their physician interaction were 
time constraints, pre-existing prescriptions and consumerism.  
These data elucidate both the increased medicalization of sleeplessness and micro and 
macro fueling factors. Even when not formally re-defined as insomnia, sleeplessness is 
increasingly treated with medical solutions.  
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CHAPTER 1 
OVERVIEW OF THE MEDICALIZATION OF SLEEPLESSNESS 
 
Introduction 
The goals of this dissertation are: 1) to document and provide quantitative and 
qualitative evidence that sleeplessness, a universal experience with a variety of causes, is 
being re-conceptualized and increasingly diagnosed as the medical condition insomnia; and 
2) to argue that key aspects of the medicalization process cannot be adequately understood 
without greater scrutiny of the doctor-patient interaction and the forces that influence its 
outcomes. 
Medicalization is the process by which a formerly non-medical issue comes to be 
described, accepted or treated as a medical problem (Conrad and Schneider 1992; Zola 1986; 
Williams 2005). Medicalization theory has offered insight into the social construction of a 
number of disorders, but sleep and sleep disorders are relatively new fields of study for both 
the biological and social sciences (Williams 2005; IOM 2006). Traditional medicalization 
analysis offers insight into the social construction of illness primarily at the conceptual and 
institutional levels; these levels describe the ways in which concepts of illness are conceived, 
described and legitimized (Conrad and Schneider 1992; Conrad 2007).  
I argue that these traditional analyses ignore a key component of the medicalization 
process – the interaction between patient and physician. I suggest that multiple mechanisms 
may be influencing the outcome of the patient physician interaction and providing 
2 
momentum to the medicalization of sleeplessness: a) the pharmaceutical industry as a key 
stakeholder in the disorder of insomnia and “educator” of both patients and physicians and b) 
an increased propensity for patients to act as consumers. In order to investigate the 
medicalization of sleeplessness, I use a mixed methods approach that is both descriptive and 
exploratory.  
First, in order to address the research question, Is there evidence of the 
medicalization of sleeplessness at the level of doctor-patient interaction?, I conduct 
secondary analysis of the National Ambulatory Medical Care Survey [NAMCS], a nationally 
representative data set of physician office visits. My analyses focus on the outcomes of these 
office visits and measurable trends related to complaint, diagnosis, and treatment, that may 
be indicative of medicalization. These results provide a partial answer to the research 
question, as well as a framework for my qualitative analyses. 
I also conducted interviews with both patients who sought medical attention for 
symptoms of insomnia and the physicians who treated them. The qualitative data address the 
aforementioned research question and offer greater insight into the manifestation of meso-
level theoretical constructs within the patient-physician interaction. 
This research contributes to the literature by expanding the limited sociological 
literature on the medicalization of illness at the interactional level and incorporating the 
example of insomnia. The intention of this research is not to determine whether the insomnia 
“epidemic” represents the increased prevalence of a “real” disease. Rather, I am interested in 
examining the social forces that may be fueling the perceived epidemic and how they may 
manifest in the interaction between doctor and patient in the form of increased patient 
complaint, diagnoses and prescriptions of sedative hypnotics.   
3 
In the following pages, I offer background information regarding sleeplessness 
including reported rates, risks and comorbidities, describe the social and economic costs of 
insomnia, and offer alterative explanations for an increase in sleeplessness. In Chapter 2, I 
discuss how medicalization theory informs my research, note my hypotheses and provide a 
brief overview of my methods. In Chapter 3, I provide detailed methodology, findings and a 
brief discussion about my quantitative analyses. Chapter 4 provides detailed qualitative 
methodology, as well as findings from physician interviews. In Chapter 5, I present data from 
patient interviews. Finally, in Chapter 6, I provide discussion linking together the 
quantitative and qualitative data. In addition, implications and future research opportunities 
are noted.  
 
Background and Significance 
Sleep is a socially meaningful activity (Williams 2005; Hislop and Arber 2003; Kroll-
Smith and Gunter 2005).1 We routinely discuss our sleep, or lack thereof, with friends, 
partners and colleagues. The occasional inability to sleep, or sleeplessness, is part of the 
universal human experience and has been recorded by authors both ancient and modern, 
including the Roman poet Horace, William Shakespeare and Franz Kafka (Goldberg and 
Kaufman 1990; Bains 2006). Ancient Egyptians “record a lament for three living hells, one 
of which is ‘to be in bed and sleep not’” (Goldberg and Kaufman 1990: 8). Sleeping aids, in 
the forms of potions, herbs and rituals have been used for thousands of years, with varying 
degrees of success (Goldberg and Kaufman 1990; Williams 2005). Despite the endurance 
and prevalence of the experience of sleeplessness, recent publications in both the lay and 
                                                          
1
 Simon Williams, whom I cite frequently throughout this proposal, has written perhaps the current definitive 
work on the sociology of sleep. Included in his book is a thorough and riveting discussion on the social history 
of sleep, which I will not attempt to reproduce here.  
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medical literatures have proclaimed sleeplessness an “epidemic” and insomnia is being 
labeled an “unmet public health problem” (Namen et al. 2002; Hamilton 2006; IOM 2006). 
 
Rates of sleeplessness 
Have we truly become a nation of insomniacs? When defined as the inability to fall or 
stay asleep, insomnia is estimated to affect millions of individuals (IOM 2006; Baines 2006). 
However, due to vast differences in definitional criteria and reporting methods, it is debatable 
exactly how many adults are affected. Insomnia symptoms are variably reported as affecting 
ten to fifty percent of the US population (Goldberg and Kaufman 1990; IOM 2006). Most 
sources report that approximately 85 million to 100 million US adults experience at least 
occasional insomnia (IOM 2006; Nelson 2007). Approximately thirty million people, or 10% 
of the US population, are thought to suffer from chronic insomnia – a more persistent form of 
sleeplessness that is often linked to poor health outcomes  (IOM 2006; Bains 2006; Nelson 
2007).  
Recent national surveys, such as the NSF Gallup poll (see Bains 2006), confirm an 
increase in reported symptoms of insomnia among the general public. Diagnoses of insomnia 
in a clinical context also appear to be on the rise. Data from the National Ambulatory 
Medical Care Survey [NAMCS], a nationally representative data set of physician office 
visits, indicates that office visits resulting in a diagnosis of insomnia increased fourfold 
between 1990 and 1998, from about 800,000 per year to 2.7 million2 (Namen et al. 2002). 
There is evidence that patients presenting with sleeplessness as a reason for office visit are 
increasingly likely to receive a diagnosis of insomnia; previously, patients with the same 
                                                          
2
 My 1998 estimates differ slightly, but not substantially, from those of Namen et al., due to differences in the 
scope of diagnostic codes used. 
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complaint were more likely to receive a diagnosis of depression or anxiety (Skaer et al. 
1999).  
 
Risk and comorbidity 
Insomnia appears to be most prevalent in women and older adults (IOM 2006; Bains 
2006). African American and Asian individuals are less likely than whites to report insomnia 
or trouble sleeping (Pearson et al. 2006). Insomnia is more likely to occur in individuals of 
low socio-economic status [SES]; these individuals report greater subjective impairments 
such as excessive daytime sleepiness than their higher SES peers (Gellis et al. 2005). Other 
risk factors include mental illness, family history of insomnia, stressful lifestyle, and 
participation in shift work (Edinger and Means 2005). 
Insomnia is highly comorbid with a number of physical and mental conditions. A 
recent national survey found that, of individuals who reported insomnia or trouble sleeping, 
only 4.1% did not have a co-occurring mental or physical health condition (Pearson et al. 
2006). Physical and neurological conditions that are commonly comorbid with insomnia 
include obesity, congestive heart failure, hypertension, chronic pain syndromes, chronic renal 
failure, Parkinsonism, epilepsy and multiple sclerosis (Bains 2006; Pearson et al. 2006).  
It is estimated that at least 40% of persons with insomnia suffer from mental illness 
(Ford and Kamerow 1989). Insomnia is often seen in conjunction with depression, anxiety 
disorders and even substance abuse (IOM 2006; Zee and Turek 2006). However, direction of 
causation is difficult to pinpoint. For instance, a study by Ford and Kamerow (1989) found 
that individuals suffering from persistent insomnia were more likely to develop major 
depression at a later date. While insomnia is considered a risk factor for disorders including 
6 
depression, anxiety and substance abuse, it may also be the result, or a symptom, of these 
disorders. 
 
The social and economic costs of sleeplessness 
Related to the medicalization process is the concept of ‘healthicization’ or 
‘surveillance medicine’ (Armstrong 1995; Conrad 2007; Seale et al. 2007). Healthicization 
promotes the idea that responsible citizens are morally obligated to take charge of their own 
health outcomes, both for the good of themselves and the good of the public (Seale et al. 
2007). The social and legal consequences for not taking responsibility for one’s sleep habits 
are increasingly punitive. Excessive daytime sleepiness (EDS) has emerged as a medical 
diagnosis and is thought to affect approximately 10% of the population (Rosenthal 2005).  
In a relatively short period of time EDS has evolved from “a virtually unknown medical 
condition” to a “known public health risk” (Rosenthal 2005; 485).3  
The most common cause of EDS is insufficient sleep, although it may be caused by, 
among other things, sedating medications or shift work (Rosenthal 2005). The consequences 
of EDS include “drowsy driving”; a behavior increasingly viewed as deviant and subject to 
social control. In many states, legislation has been passed to combat and penalize drowsy 
driving (NCSL 2007). “Driving while fatigued” is labeled a crime and, in cases of vehicle 
accidents with proof of driver fatigue, harsher penalties are enacted (NCSL 2007). In New 
York, legislation was recommended that would require medical examinations and mandatory 
sleep apnea testing for persons holding a commercial driver’s license (NCSL 2007). In the 
documentary Wide Awake, by insomniac Alan Berliner, a physician notes that scientists are 
                                                          
3
 As Conrad astutely observes of EDS, “if this is a ‘disorder,’ it has a reasonably high prevalence among college 
students attending early or late classes!” (Conrad 2007: 12). 
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working to develop a “sleep-a-lyzer” to better detect the level of sleep deprivation in a 
reckless driver (2007). 
Where once insomnia might have been seen as nothing more than an inconvenience, 
it is increasingly portrayed as a threat to both individual well-being and society at large. In 
addition to the aforementioned daytime sleepiness and drowsy driving, negative outcomes of 
insomnia are thought to include: decreased physical and mental health, reduced quality of 
life, decreased productivity, difficulty with memory, decreased work performance, increased 
absenteeism, and increased use of health care services (Bains 2006). Disasters of enormous 
proportion, including the Exxon Valdez oil spill and the Challenger space shuttle explosion, 
are currently thought to be the results of errors made by sleep-starved workers (Williams 
2005). Economic costs of insomnia include substances used to treat sleeplessness, increased 
use of health care services, increase in workplace accidents and increased morbidity. For 
more detailed listing of the direct costs of insomnia, please see Table 1. 
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Table 1: The Direct Costs of Insomnia in the United States for 1995. 
(Reproduced directly from IOM 2006: 159) 
 Cost (millions $) 
Substances used for insomnia  
Prescription Medications 809.92 
Nonprescription medications 325.80 
Alcohol 780.39 
Melatonin 50.00 
Total cost of substances 1,966.11 
  
Health care services for insomnia  
Outpatient physician visits 660.00 
Psychologist visits 122.40 
Social working visits 75.30 
Sleep specialist visits 18.20 
Mental health organization 153.00 
In-patient hospital care 30.80 
Nursing home care 10,900.00 
Total 11,960.70 
  
Total direct costs 13,926.11 
SOURCE: Walsh, JK, Engelhardt CL. 1999. The direct economic costs of insomnia in the 
United States for 1995. Sleep 22 (suppl 2):S386-S393. 
 
Current explanations 
Despite a measurable increase in the reported rates of insomnia symptoms and 
insomnia diagnoses, I believe that we should exercise caution in assuming that these 
indicators are tantamount to an increase in clinically significant insomnia at the population 
level. Arguably, a shift in the conceptualization of sleeplessness has taken place – from a 
symptom of a disorder to a disorder in and of itself - and while we may only speculate as to 
cause, the social and economic consequences of this trend make it worthy of further 
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investigation. In this section I outline three possible explanations for the sleeplessness 
“epidemic.” 4 
Changing cultural norms may be one factor fueling the sleeplessness epidemic 
(Mooallem 2007; Zee and Turek 2006). Technology allows us to participate in a global 
economy and a “24-hour workday.”  In some workplace cultures, visible fatigue, whether 
from non-stop international travel or 18-hour workdays, is a badge of honor and proof of 
commitment to one’s company (Mooallem 2007). In addition, the ‘sandwich generation’ – 
adults who have both children living at home and parents who require substantial assistance - 
is expected to perform dual-duty caregiving and breadwinning roles, resulting in less sleep 
and poor health outcomes (Meltzer and Mindell 2006). Finally, an apparent cultural 
imperative to engage in excess – whether in work or play – has given rise to a new American 
motto: “You can sleep when you’re dead.” 5 
Dr. Thomas Roth, director of the Sleep Disorder and Research Center at Henry Ford 
Hospital in Detroit, “is cynical about the nation’s discussion on sleep” and describes public 
interest as “fashionable” (Hamilton 2006). Sleep has been dubbed “the new bottled water” 
and the cultural imperative to achieve the elusive 8 hours per night has begotten a multi-
billion dollar industry (Singer 2007). A variety of consumer products including special 
pillows, mattresses, aromatherapies, lotions and soothing CDs are marketed to aid in the 
achievement of the ‘ideal’ eight hours of sleep per night (Williams 2005; Seale et al. 2007). 
Americans spend $4.5 billion annually on prescription and non-prescription sleep 
medications combined. Nap centers, spa-like businesses where customers are allowed to 
                                                          
4
 Hereafter, I will use the word “epidemic” sans quotation marks. This acknowledges that an insomnia epidemic 
– whether socially or biologically based – is in fact occurring.  
5
 The exact origin of the phrase is unclear, but it is commonly associated with an infamous memo sent by 
Amazon.com management to its employees in a customer-service call center (Leibovich 1999).  
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comfortably recline in a dimly lit room for 20-40 minutes, are gaining in popularity 
(Hamilton 2006; Singer 2007). These centers are particularly popular in urban hubs of 
business; in New York City a twenty-minute nap can cost $15 (Singer 2007).  
Along with changing cultural norms, shifting US demographics may be playing a role 
in the insomnia epidemic. The US ‘Baby Boom’ generation, typically thought of as 
individuals born between the years 1946-1964, is now entering late-middle and older age. 
The need for sleep appears to decrease with age (Grigg-Damberger 2006). There is debate 
about whether this decrease in sleep time is ‘natural’ for older adults or the result of an 
increased likelihood of chronic illness or discomfort (Grigg-Damberger 2006; Zee and Turek 
2006). 
Regardless, men typically begin to experience decreased sleep time in their forties 
and women in their fifties; this reduction in sleep is typically caused or compounded by an 
increase in the number of times an individual wakes up during the night (Grigg-Damberger 
2006). Many of the factors associated with sleeplessness – female gender, chronic illness and 
low SES – are more frequently found in older populations (Zee and Turek 2006). As noted 
by Barsky and Boros (1995), the ‘Boomer’ generation is also known for its decreasing 
tolerance for any ills or discomforts, resulting in increased visits to the doctor and demand 
for new and better drug treatments.  
While cultural trends and an aging population are two possible factors fueling the 
insomnia epidemic, a recent essay in the New York Times, written by doctors, argues that the 
real epidemic is not in experiences such as insomnia, which they describe as “everyday,” but 
in the epidemic of diagnoses that translate normal human experience into illness or disorder 
(Welch et al. 2007). Highlighted in their critique are the following factors: a) the 
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medicalization of everyday life compounded by a decreased tolerance for discomfort, b) our 
country’s large but poorly directed investment in health care, and c) the drive to discover 
diseases early, resulting in “pre” diagnoses like pre-hypertension, pre-diabetes and even pre-
cancer. The end result is that more than 50% of the population receives a diagnosis of 
disease. This begs the question, “If more than half of us are sick, what does it mean to be 
normal?” (Welch et al. 2007).  
Diagnoses confer a variety of both positive and negative connotations and 
consequences. Having a recognized disease provides benefits including personal validation, 
relief from guilt or anxiety, a social network and medical support (Ziporyn 1992). Some 
individuals desire the legitimacy afforded by medicalized disorders and may form support 
groups or grassroots organizations in an effort to leverage power and demand this recognition 
and its subsequent benefits (Barker 2008; Ziporyn 1992). Chronic Fatigue Syndrome (CFS) 
is an example of a disorder that lacks a biomedical blueprint at this time, but individuals 
(mostly women as they are the most common sufferers of CFS) have organized to fight for a 
medical definition and official diagnostic recognition (Richman and Leonard 2001).  
From the sociological perspective, expansion and proliferation of diagnoses, 
including insomnia, appear to be on the rise. As I have summarized, changing cultural norms, 
an aging population or the medicalization process may each be fueling the insomnia 
epidemic. To some degree, all three factors are likely contributors. The focus of this 
dissertation, however, will be on the process of medicalization.  
 
  
CHAPTER 2 
THEORY OF MEDICALIZATION AND HYPOTHESES 
 
In the following section I will outline the types of medicalization, levels of the 
medicalization process, and some of the forces that fuel it. I will focus on the pharmaceutical 
industry and increased consumerism, two factors that I believe are fueling the medicalization 
of insomnia at the level of physician-patient interaction. Finally, I will note the challenges of 
measuring medicalization.  
 
Types of medicalization 
Two major categories of ‘ills,’ expanding beyond biological or organic disease, are 
encompassed by medicalization: ‘deviant’ behavior and formerly ‘natural’ biological 
processes. Examples of deviance that have been partially or fully medicalized include: 
Attention Deficit Hyperactivity Disorder [ADHD], alcoholism, spousal abuse, child abuse, 
and social anxiety (Conrad and Schneider 1992; Lane 2007). Examples of natural processes 
that have become partially or fully medicalized include: pregnancy, pre-menstrual syndrome 
[PMS], fertility, overweight, aging, erectile dysfunction and (female and male) menopause 
(Armstrong 2003; Jutel 2006; Groopman 2002; Lock 1993; Rosenfeld and Faircloth 2006).  
Categories of deviance and biological processes are not mutually exclusive. 
Sleeplessness is a salient example of a disorder that contains both of these elements. Sleep is 
a biological process, but as noted previously, excessive daytime sleepiness (EDS), a 
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consequence or symptom of insomnia, is increasingly considered a deviant behavior with 
punitive consequences, particularly in the context of “driving while fatigued” (NCSL 2007).  
 
Levels of medicalization 
The process of medicalization occurs at three levels: institutional (codification and 
bureaucratization) conceptual (construction and use of medical vocabulary) and interactional 
(typically conceptualized as patient-physician but may include other individual level 
interactions). These levels are loosely viewed as hierarchical, particularly in earlier 
conceptualizations of medicalization, but are in fact iterative and influence one another. For a 
visual representation of this process, please see Figure 1.  
Figure 1: Levels of the Medicalization Process 
 
 
 
 
 
 
 
 
 
 
 
Conceptual  
(definition, medical vocabulary) 
Institutional  
(Board certification, medical school curriculum, 
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Traditional analyses of the medicalization process rely on evidence at the conceptual 
or institutional levels. According to Conrad and Potter (2000), the conceptual level is the 
“key” to the medicalization process. By definition, they assert, medicalization implies 
expansion of medical boundaries; one means of boundary expansion is altering parameters of 
diagnoses (Conrad and Potter 2000). Conceptual expansion of a previously defined disorder 
means that formerly excluded populations may be diagnosed and treated (Conrad and Potter 
2000; Barker 2008). From the viewpoint of patients this may be a desirable outcome, as 
medical diagnoses offer legitimacy and affirmation of the illness experience (Barker 2008; 
Kroll-Smith and Floyd 1997). For drug companies, this outcome ensures a greater number of 
prescriptions may be written for a larger population of ‘sick’ individuals.  
 For instance, Attention Deficit Hyperactivity Disorder [ADHD] was initially 
conceptualized as a diagnosis of hyperactivity and inattention in children (Conrad and Potter 
2000). Symptoms of ADHD were exhibited primarily in school settings and most children 
were expected to “outgrow” these symptoms by the time they reached adolescence (Conrad 
and Potter 2000). However, beginning in the 1980’s, a movement to recognize “adult 
hyperactives” was fueled by the “medicalization of underperformance” and increased 
availability of disability rights (Conrad and Potter 2000). Symptomatology expanded from 
the classroom to the workplace and even into the realm of interpersonal relationships. 
Thousands of adults, in turn, proclaimed via a deluge of medical and lay press that they 
“recognized” themselves in the descriptions of adult suffers of ADHD. This conceptual 
expansion enabled thousands of previously undiagnosed adults and adolescents to receive a 
diagnosis of ADHD and to be treated accordingly, most often with prescription stimulants 
such as Ritalin (Conrad and Potter 2000). 
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Disease conceptions that are medicalized at the institutional level are typically 
guaranteed access to and influence on large sections of the population. Organizations may 
not only manage illnesses, but also create and promote them as well. The ‘disease’ of 
alcoholism serves as an example of this latter phenomenon. Medical professionals, though 
“not hapless bystanders…were not the leading crusaders” in the medicalization of alcoholism 
(Conrad and Schneider 1992: 73). The Yale Research Center of Alcohol Studies and the self-
help group Alcoholics Anonymous were actively involved in influencing modern 
conceptions of excessive alcohol use (Conrad and Schneider 1992). These organizations were 
in large part responsible for re-casting chronic drunkenness as a disease instead of a sin or 
moral failing. In addition, E.M. Jellinek, early director of the Yale center, created the phase 
progression model of alcoholism and cemented the idea of alcoholism as a progressive, 
diagnosable, treatable disease (Conrad and Schneider 1992).  
 There is some evidence that insomnia has been medicalized at the conceptual and 
institutional levels. Conceptually speaking, one may point to the expansion of insomnia 
definitions, their increased number and the striking disparity6 amongst them as evidence of 
medicalization. In 2004 the ICD-9-CM (International Classification of Diseases) 
Coordination and Maintenance Committee Meeting proposed expansion of the diagnostic 
categories for the following sleep disorders: insomnia, hypersomnia and sleep apnea. Their 
stated justification read: “Sleep medicine is a new but growing medical subspecialty” (2004: 
29). Regarding insomnia, the committee proposed multiple new codes and subcategories to 
the existing ICD-9 codes. By their admission, these additions were intended to better align 
their diagnostic categories with the American Academy of Sleep Medicine’s manual “The 
                                                          
6
 A disparity in definitions is potentially indicative of the medicalization process in that it indicates a lack of 
certainty of the ‘disease’ parameters or symptoms, while conversely ‘making it’ medical by use of a set medical 
definition. 
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International Classification of Sleep Disorders.” They promised, “In future revision, 
additional modifications will be proposed for other sleep disorders.” Though the proposed 
additions related to insomnia diagnoses are too extensive to list here, I include them in 
Appendix 1. 
 As previously noted, disparity amongst and between insomnia criteria makes for 
wildly divergent estimates of prevalence in epidemiological studies. This fact is not lost on 
clinicians and researchers and several have called for the construction and use of uniform 
criteria (Lichstein et al. 2003; Ohayon et al. 1997). In an effort to produce cohesive criteria, 
Lichstein and colleagues “reviewed two decades of psychology clinical trials…to determine 
common practice with regard to frequency, severity and duration [of insomnia]” and 
constructed quantitative criteria (2003: 427). Competing diagnostic methods lacking 
uniformity of criteria may serve to over-diagnose borderline populations and/or populations 
who would not meet different definitional criteria. While the quantification of insomnia 
symptoms may be useful in eliminating or reducing disparity in prevalence rates, it assumes a 
neutrality and objectivity that belies the qualitative context inherent in patient-physician 
interactions – a dimension I further explore in my research. Further exploration of the 
conceptualization of insomnia including the history of diagnoses construction and the current 
state of disparity, while beyond the scope of this study, would be a worthwhile topic for 
future research.  
The institutionalization of sleep and sleep disorders is both relatively recent and, it 
seems, increasingly popular. One example of the institutionalization of insomnia, or more 
accurately its consequences, is evident in the aforementioned criminalization of “driving 
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while fatigued” (see page 6) (NCSL 2007). As noted by Conrad and Schneider (1992) the 
criminalization of deviance cannot occur without the specific sanction of the state.  
Another indicator is the establishment of a myriad of organizations dedicated to 
raising education and awareness of sleep disorders. The National Sleep Foundation (NSF), a 
self-proclaimed “independent non-profit” organization that seeks donations (including the 
nonprofit staple: “Donate your old vehicle”) on its website, recently sponsored Drowsy 
Driving Prevention week November 5-11, 2007 (www.sleepfoundation.org). In addition, the 
NSF website offers a multitude of sleep “facts,” resources to facilitate sleep “at all ages,” a 
convenient online “sleep shop” and ways to get involved in “sleep advocacy.” The motto of 
the NSF is “Waking America to the Importance of Sleep” and their oft-cited 2005 sleep 
survey revealed that less than half of Americans report getting a good night’s sleep on a 
nightly, or near-nightly basis (NSF 2005). Interestingly, a recent New York Times article 
revealed that the NSF is “largely financed by the pharmaceutical industry” (Mooallem 2007). 
The institutionalization of sleep disorders in the realm of medical education and 
specialization is relatively recent. In 1978, its inaugural year, the American Sleep Disorders 
Association (now the American Academy of Sleep Medicine [AASM]) created an 
examination committee for clinical polysomnography (an overnight test in a sleep laboratory 
that records physiological signs) and 21 candidates passed the exam (IOM 2006). The 
number of candidates completing the certification process grew exponentially and in 2005, 
approximately 32,000 candidates became “diplomats” of the AASM (IOM 2006). However, 
for many years AASM certification was not formally recognized by the American Board of 
Medical Specialties (ABMS). Responding to growing demand, the ABMS reconsidered its 
position. In 2007 the ABMS allowed physicians to become board certified in Sleep 
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Medicine. Although sleep medicine encompasses multiple sleep disorders, insomnia is by far 
the most commonly diagnosed and treated sleep disorder in the U.S. (IOM 2006; Bains 
2006). 
While institutional stakeholders and medical vocabulary may be powerful instigators 
and indicators of change, respectively, these phenomena may not seem highly relevant to 
individuals engaged in the illness experience. After all, it is within the physician office visit 
that patients share their perceived health issues and, in turn, physicians offer medical 
diagnoses and treatments. It is within this interaction that life problems are transformed into 
medical problems by the power of medical authority and thus, the outcomes of these 
interactions, taken together, have a major impact on the medicalization process. Put bluntly, 
if insomnia diagnoses are not being made and sedative hypnotics are not being prescribed 
then how can we assert that the process of medicalization is in fact occurring?  
Although I have noted examples suggestive of the medicalization of insomnia at the 
conceptual and institutional levels, little sociological work has been done that examines 
individual experiences of sleeplessness. One exception is the work of Hislop and Arber 
(2003). Hislop and Arber (2003) examined the coping strategies of a small sample of women 
dealing with sleep problems. They concluded that the ‘personalized strategies’ used by their 
participants, (e.g., relocating to another room for sleep, taking warm baths or drinking warm 
milk) were evidence of the demedicalization of sleep disorders. However, as pointed out by 
others (see Williams 2005; Conrad 2007; Lowenberg and Davis 1994), the use of personal or 
holistic strategies to manage a problem is not necessarily evidence in favor of 
demedicalization. Nevertheless, I believe that Hislop and Arber offer a significant 
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contribution to the literature by providing insight into the medicalization of sleep disorders at 
the individual level.  
 
Forces of medicalization 
The forces that drive the medicalization process vary over time. Medicalization 
theory evolved from claims that medical professionals engaged in appropriating social ills as 
medical problems and claimed expertise in both diagnosis and treatment of these ills (Zola 
1986; Conrad and Schneider 1992). In the previous century, the authority of the medical 
profession, medical and scientific discoveries, and increased specialization in the medical 
profession were highlighted as among the foremost factors fueling medicalization (Conrad 
2005). In recent years, biotechnology (e.g. pharmaceuticals and genetics), patients acting as 
consumers, and ‘managed care’ have all been hypothesized as key agents of medicalization 
(Conrad and Leiter 2004).  
I assert that, in the case of sleeplessness, two of these factors, the pharmaceutical 
industry and increasing consumerism among patients, are working symbiotically to further 
the medicalization process at the individual level. Considered contextually, these factors both 
instigate and are the result of shifting power dynamics between patients and physicians. In 
the following paragraphs I provide further detail on the pharmaceutical industry and 
consumerism, as well as introduce meso-level theoretical constructs that result from these 
macro level forces and potentially moderate the patient-physician interaction. For a visual 
representation of my conceptual model, please see Figure 2. 
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Figure 2: Conceptual Model 
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Pharmaceutical Industry 
The pharmaceutical industry is a key institutional stakeholder in the treatment of 
disease and disorder (Angell 2004; Elliott 2003; Rothman and Rothman 2003; Conrad 2005; 
Lane 2007). Many contend that drug companies do not merely sell drugs; they sell the 
disorders that create a need for their drug (Elliott 2003: Conrad 2005; Angell 2004; Lane 
2007). Pharmaceutical companies counter that they are doing a public service by raising 
awareness of under-diagnosed and under-treated illnesses (Gellad and Lyles 2007; Kessler 
and Levy 2007). Regardless of the true motive of the pharmaceutical industry, education for 
the public or profit for their shareholders, it is undeniable that the pharmaceutical industry 
possesses powerful and influential marketing tools that have altered patient-physician 
interaction.  
I argue that the pharmaceutical industry primarily targets consumers through direct to 
consumer (DTC) advertising and arms them with “rhetorical authority,” a form of medical 
knowledge gleaned from non-medical sources. Physicians also are targeted by sales visits, 
drug samples and/or gifts and continuing medical education (CME) courses are often 
sponsored and created by pharmaceutical companies. As sleep disorders are a minimal 
component of medical school curricula, these pharmaceutically sponsored forms of 
knowledge fill gaps in expertise and create “knowledge alignment” with the pharmaceutical 
companies. These factors, I suggest, may be moderating the patient-physician interaction. 
 
Targeting patients 
According to Conrad (2005:6) a successful pharmaceutical marketing campaign 
convinces the consumer that his/her perceived disorder is both “common and abnormal, thus 
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needing treatment.” The primary mechanism that pharmaceutical companies use to convince 
consumers that they “need” a particular drug is direct-to-consumer (DTC) advertising. 
Pharmaceutical companies posit that DTC advertisements are “educational tools” that 
empower patients, arming them with valuable knowledge (Kessler and Levy 2007). Most 
advertisements, however, combine facts and rationale with emotional appeal (Frosch et al. 
2007). Medication is seen as a socially sanctioned method of regaining control over a 
disorganized or unpleasant component of one’s life. Making changes to one’s lifestyle or 
other treatment options are rarely mentioned, if ever (Frosch et al. 2007). 
Some would argue that pharmaceutical companies are merely tapping into our current 
obsession with a “culture of enhancement” (Elliot 2003; Rothman and Rothman 2003). 
American culture appears to grow increasingly intolerant of even mild symptoms or benign 
problems (Barsky and Boros 1995). Non-life threatening conditions have become the focus 
of increased medical specialization (Elliot 2003; Barsky and Boros 1995). As a result, there 
is a great deal of money to be made from treating consumers and their rapidly multiplying ills 
(Barsky and Boros 1995; Nelson 2007).  
DTC advertisements urge consumers to “ask their doctor if [drug name here] is right 
for you.” Often patients are encouraged to visit the drug’s website where potential patients 
can play “games” or take quizzes that “test their knowledge” about a certain disorder. Both 
DTC advertisements and drug websites are designed to arm the patient with medical 
information from a non-medical source, a type of information Kroll-Smith has dubbed 
rhetorical authority (2003). Laypersons are encouraged to absorb the carefully delimited 
knowledge offered by the pharmaceutical company and use their rhetorical authority as a 
leveraging tool within the patient-physician encounter.  
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Websites for insomnia drugs are no exception. When I began this research in 2007 I 
visited both the Ambien and Lunesta websites. On the Lunesta website, I was encouraged to 
play a game, testing my knowledge of insomnia (Lunesta.com 2007). On the Ambien website 
I discovered a ‘helpful’ list of questions you can print and take to your doctor to aid him or 
her in making the correct diagnosis (of insomnia) (Ambien website 2007). At the end of the 
questionnaire, a 7-day free trial of Ambien CR was offered, as the patent for regular Ambien 
expired in that year. 
Revisiting this website in 2009, I was immediately re-directed to ambiencr.com. In 
just two years Sanofi-Aventis has done an impressive job of marketing to adults of all 
demographics, while emphasizing the vast superiority of Ambien CR to ‘regular’ or generic 
Ambien. The main graphic on the home page depicts five adults (appearing to be an Asian 
woman, an African American man, a Caucasian women, a Latino woman and an older 
Caucasian man) standing, smiling, on an enormous rotating Ambien CR tablet. The tagline 
seems to promise more than just a good night’s sleep. It reads “Want to get more out of life? 
See how Ambien CR may help.” The testimonials offered by the fake patients7 were 
fascinating and promised to restore one’s good humor, adventurous spirit, as well as one’s 
ability to be a good hostess, a “go-getter” at work, and a pancake-maker at home. 
 Lunesta has followed suit with a much expanded website including a “dream kit” 
offering helpful resources such as: “special savings,” a “doctor discussion guide”, a sleep 
calculator, an updated version of the 2007 game determining your lack of sleep, a sleep diary, 
sleep tips and a place to “share your story.” These tools not only offer rhetorical authority 
that can be leveraged in an office visit, but enable patients to self-identify as having a 
                                                          
7
 Sadly, this attractive and diverse group were “not actual patients” nor were their fascinating testimonials 
authentic (“The Good-humored man is back”, “Mr. Fix-It”, “How I conquered the morning”, “How I faced 
reality” and “The Hostess with the Most-ess”). 
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problem that is both common and abnormal (Conrad 2005). Self-diagnosis and deciding upon 
a preferred treatment may occur long before the office visit (Barker 2008).  
Pharmaceutical companies are committed to encouraging the use of sleep aids in 
particular because they are incredibly profitable (Saul 2007). In the first nine months of 2006, 
$362 million was spent on advertisements for “the most popular sleeping pills, marketing the 
idea that interrupted sleep or the lack of instantaneous sleep are alarming conditions that 
require intervention” (Singer 2007). A pharmaceutical industry journal article proclaims: 
“Pharma’s ultimate customers are overweight and can’t sleep” (Kelly 2006: 86). Between 
2001 and 2005, sales for prescription insomnia drugs have more than doubled, growing from 
$1.1 billion to $2.8 billion (Nelson 2007). The market is expected to double again by the year 
2010, with sales projected to reach the $5 billion mark (Nelson 2007).  
The introduction of Ambien in 1992 heralded the entry of a new, ostensibly more 
effective family of sedatives. Ambien was the first of a new class of hypnotics, the non-
benzodiazepine hypnotics, also commonly called the “z” drugs (due to the fact that their non-
brand names contain the letter “z”). This newer generation of sleep drugs, which in addition 
to Ambien include Lunesta, Sonata and Rozeram8 are thought to lack the negative side 
effects and risks of dependence present in the former hypnotic class of choice, the 
benzodiazepines.  
Recently, however, the “z” drugs have come under criticism for two major 
shortcomings: a) lack of effectiveness and b) disturbing side effects exhibited by some 
patients. Recent data indicate that, while more effective than placebo, the newer generation 
sleep drugs, on average, reduce the amount of time it takes to fall asleep by 12.8 minutes and 
                                                          
8
 Rozeram is technically not a “z” drug as it has a different mechanism of action and is promoted as strictly non-
habit forming. However, I include it here as it is often discussed alongside the “z” drugs.  
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extend sleep time by 11.4 minutes (Saul 2007). Despite this minor-seeming benefit they are 
“wildly popular” with consumers (Saul 2007). This popularity has not been tempered by 
recent reports of bizarre side effects.  In 2007, the FDA mandated the makers of Lunesta, 
Ambien and 11 other sleep medications to issue warnings about a host of reported risks 
including sleep-driving, sleep-eating, sleep-walking and making purchase while “asleep” 
(Saul 2007). One woman reported painting the front door of her house while “asleep” on 
Ambien (Saul 2007). 
Despite the considerable increase in prescriptions written and profits accrued, the 
pharmaceutical industry (as well as many health professionals) claim that insomnia remains 
under-diagnosed and under-treated (Baines 2006; Nelson 2007). This “under-diagnosis” 
creates a market with “vast potential” (Nelson 2007:64). “Through educational efforts, 
marketers can help increase [insomnia] diagnosis rates – and scripts” (Nelson 2007:64, 
emphasis my own). It is unclear what exactly comprises these “educational efforts.” What is 
clear is that these companies do not merely market drugs, they market the ideas that justify 
the drugs and use targeted information to arm patients with rhetorical authority. 
 
Targeting physicians 
Physicians may be increasingly relegated to the role of “gatekeeper” to technologies 
and pharmaceuticals, but they are still the individuals in control of the prescription pad, and 
pharmaceutical companies are keenly aware of this (Conrad 2005; Angell 2004; Lane 2007). 
While pharmaceutical companies spend billions of dollars to target patients, they spend even 
more money advertising to physicians (Angell 2004; IMS Health online 2007). In 2001, $6.4 
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billion dollars were spent trying to promote drugs to physicians. In contrast, the DTC budget 
that year for consumers was $2.6 billion (IMS Health online 2007). 
The key mechanisms used by pharmaceutical companies to target physicians are: 
“detailing” by drug representatives, providing samples of complimentary drugs to be 
dispensed to patients and sponsoring education through continuing medical education (CME) 
courses (Angell 2004). Another mechanism, advertising in medical journals, comprises less 
than 1% of the pharmaceutical industry’s marketing budget and thus is worthy of only a brief 
mention (Angell 2004). However, it has been suggested that since many medical journals are 
financially dependent on drug advertisements, it is possible that they are influenced in their 
choices of which articles to publish (Angell 2004).  
 In 2001, 88,000 drug sales representatives visited doctor’s offices and nearly $11 
billion in “free samples” were dispensed (Angell 2004). In addition to free samples, drug 
representatives commonly provide free gifts, free meals and other niceties to doctors and 
their office staff. As Angell (2004) makes the case, these gifts and samples are hardly “free.” 
They are intended to create and maintain a customer base for their latest drugs and the 
billions of dollars spent on gifts and samples must be recouped in the cost of the drug. In fact, 
while doctors may protest that they are not influenced by the “3 F’s” drug representatives are 
trained to proffer – “food, flattery and friendship” – it is human nature to engage in 
reciprocity and physicians’ prescribing patterns often reflect this (Angell 2004).  
 As new competitors have entered the insomnia market, drug representatives have 
targeted physicians with increased dispensation of drug samples (Nelson 2007). According to 
Impact Rx, Takeda, the company that makes Rozerem, allowed doctors to provide four out of 
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ten treatments to their patients at no charge. Comparatively, the market leaders Ambien CR 
and Lunesta provided free product for only two out of ten patients (Nelson 2007).  
 Targeting physicians in the marketing of sleep drugs may be particularly effective 
because, until quite recently, physicians were offered very little training on sleep disorders in 
their medical school curriculum. According to one estimate, physicians in Great Britain 
received a cumulative total of 5 minutes of medical school education devoted to sleep 
disorders (Williams 2005). In the United States, 2007 was the first year that a physician 
could receive board certification as a sleep specialist (NSF 2007). As a result, physicians may 
believe that their clinical knowledge of sleep disorders is sub-par. In a recent survey, 
physicians were asked to rate their knowledge of sleep disorders; the majority ranked their 
knowledge as “fair” (60%) or “poor” (30%). Only 10% of physicians surveyed rated their 
knowledge of sleep disorders as “good” (Papp et al. 2002).  
An effective way for drug companies to exploit this “gap” between education and 
practice is by sponsoring and influencing CMEs. CMEs allow pharmaceutical companies to 
tailor the information received by doctors about particular disorders, and particular drug 
treatments are often prominently featured (Angell 2004). Since physicians are required to 
regularly attend continuing education courses throughout their career, the CME’s meet a 
mutual need for doctors and drug companies (Angell 2004). I suggest that the combination of 
inveiglements – incentives, samples and CMEs - promote a knowledge alignment wherein 
doctor’s knowledge and skill gaps are filled by drug and disorder information presented by 
drug companies. 
 
 
28 
Patient as Consumer 
Patients wield increased power as they “consume” medical services and enter the 
doctor -patient relationship with the ability to self-diagnose and request a specific treatment 
(Conrad and Leiter 2004; Conrad 2005; Barker 2008). Even the pharmaceutical industry is 
recognizing the increased power of the patient (Kelly 2006). A pharmaceutical journal article 
proclaims “Consumers play a larger decision making role in their healthcare than ever before 
and they’re looking for ways to lead better lives” (Nelson 2007; 66). The idea of “better 
lives” is facilitated, in part, by the aforementioned burgeoning culture of enhancement.  
 No longer content with feeling or looking “normal,” expectations among the lay 
public have reached an all-time high as innovations in medical techniques and knowledge 
provide seemingly limitless opportunity for self-improvement (Rothman and Rothman 2003). 
Patients expect their state of health to be “better than well” and all it takes to achieve this 
state is the almighty dollar (Elliot 2003; Rothman and Rothman 2003; Greenhalgh and 
Wessely 2004). Consumer demand for cosmetic surgery, including breast enlargement, 
human growth hormone (HGH) therapy, and treatment for sexual “dysfunction” has 
increased exponentially (Rothman and Rothman 2003; Elliot, Conrad 2007; Wienke 2005; 
Rosenfeld and Faircloth 2006). 
It is no wonder then, that sleep has in many ways become just another commodity. 
Jessie Gruman, president of the non-profit Center for the Advancement of Health is quoted as 
saying “Now when people can’t sleep for a couple of nights, they think they are part of a 
national sleep epidemic and there should be something to fix it. You can buy sexual arousal, 
a new shape for your face, a skinnier silhouette, so why shouldn’t you be able to buy sleep?” 
(Singer 2007). I contend that this increased consumerism is in part a by-product of increased 
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rhetorical knowledge among patients and is facilitated by greater amounts of physician 
compliance. 
 
Physician compliance 
Physician compliance is “the expectation that physicians will accept patient 
expertise” regarding patient definition of the experience (i.e., diagnosis) and patient 
definition of the solution (i.e., treatment) (Freidson 1988; Barker 2008). As Barker 
demonstrates in a study of an online support group for Fibromyalgia syndrome (FMS) (2008) 
this type of encouragement was a prevalent theme among members. Members posting about 
negative physician experiences wherein their concerns were dismissed, their diagnosis not 
validated or their specific drug requests not prescribed, received sympathy from other online 
members and admonitions to search for a physician who would meet their requests. Patients 
seek physician compliance in an effort to have their illness experiences legitimized and 
treated. In the process, these patient-consumers are inadvertently reifying and expanding the 
boundaries of medical authority.  
Barker’s research, while fascinating, provides insight into only one side of the 
interactional dyad. What incentive, if any, would a physician have to accept patient 
expertise? According to some physicians, when patients offer expertise derived from DTC 
advertising, it is an “intrusion” in the patient-physician interaction (Stange 2007). Valuable 
time is taken away from an already brief encounter and the extraneous knowledge and self-
diagnosis may in fact obscure the underlying “true” issues that prompted the office visit 
(Stange 2007).  
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Why then, would some physicians be receptive when faced with a patient who 
demands their compliance in diagnosis and or treatment? Perhaps because, in some cases, it 
makes their jobs easier; physicians are faced with numerous barriers to doing their jobs 
properly. Outpatient visits average approximately 10 minutes of face-to-face time and 
physicians are expected to “prioritize, personalize, and integrate care for an average of 3 to 4 
problems” (Stange 2007; 2). Given this plethora of constraints and barriers to an ideal office 
visit, some physicians may view a patient’s specific demands as a time and energy saving 
asset, rather than a nuisance.  
In addition, physicians have long sought the goal of patient compliance, wherein 
patients adhere to their prescribed treatment regimen. Some medical sociologists have 
criticized the goal of patient compliance as a means of social control (Zola 1986). However, 
some physicians may view a patient’s request for a specific drug treatment as evidence that 
they will comply with the treatment regimen if they receive that particular drug. 
 
In sum… 
Unlike disorders that are recognized as being recently medicalized (e.g. chronic 
fatigue syndrome, multiple chemical sensitivity), sleeplessness is a condition that has existed 
and been recognized as part of the human condition for thousands of years (Goldeberg and 
Kaufman 1990). As previously noted, it is universally experienced (Bains 2006). Why then 
might rates of insomnia be increasing so rapidly?  
As evidenced by Barker (2008) and others, the office visit can be used as a vehicle for 
constructing and expanding the boundaries of medical authority while simultaneously 
offering legitimacy to the patient’s perceived problems (see also Kroll-Smith and Floyd 
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1997). The patient and physician both bring knowledge to this interaction that is influenced 
and shaped, to some degree, by the pharmaceutical industry. The pharmaceutical industry 
uses a variety of advertising and “educational” strategies to imbue patients with rhetorical 
authority and to increase knowledge alignment among physicians. Rhetorical authority may 
reify consumerist tendencies among patients and prompt them to demand physician 
compliance. In turn, physicians may be more receptive to pharmaceutically induced 
rhetorical authority as it aligns with their own pharmaceutical-industry-influenced knowledge 
base. Some physicians may see offering acquiescence as a means of increasing patient 
compliance and increasing the efficiency of their interaction.  
While it is evident that the outcomes of the patient-physician interaction are critical to 
the medicalization process, these processes are not well understood (Conrad and Schneider 
1992; Barker 2008). Using the example of sleeplessness, I explore and describe the 
medicalization process at the interactional level. The following sections provide an overview 
of my research. 
 
Measuring Medicalization 
How do we know when medicalization occurs at the interactional level? What does 
this part of the medicalization process look like? These are profound questions and they have 
not been sufficiently explored. There is debate about the amount of medicalization that 
occurs at the doctor-patient level, but “research on the medicalization of perceptions and 
practices in everyday medical practice could be illuminating” (Conrad and Schneider 1992: 
82). While many have written about the medicalization process, few have attempted to 
measure it – on any level (Conrad 2007). Currently, there is no universally accepted, 
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quantitative or qualitative method for the measurement or tracking of the medicalization 
process (Conrad 2007). Typically medical sociologists describe the medicalization process 
using a combination of qualitative and quantitative methods. Commonly used methods 
include: tracking diagnosis conceptualization and/or expansion; measuring 
growth/dissipation of a diagnosis in a population; analyzing direct to consumer advertising 
and preferred method of treatment; measuring mentions within the lay press, assessing 
changes in medical literature or internet hits over a period of time; and/or noting the creation, 
number and type of institutional stakeholders. It is noteworthy that many of these measures 
are situated at the macro level and intended to describe trends at that level. Since the focus of 
this research is at the micro, or individual level, a mixture of qualitative and quantitative 
methods are used to explore and describe the medicalization of insomnia at the interactional 
level. 
Specifically, using data from the National Ambulatory Medical Care Survey 
(NAMCS), a nationally representative dataset of physician office visits, I describe trends in 
patient reasons for office visit, diagnoses made and prescriptions written. Using qualitative 
interviews I ask the key players – patients and physicians – to provide their perspective and 
insights regarding observed trends. Using a semi-structured interview format that hones in on 
the factors that may influence the patient-physician interaction (including, but not limited to, 
advertising on the part of pharmaceutical companies and consumerism) and describing the 
outcomes of these interactions (e.g., patient complaint, physician diagnosis and treatment 
plan) via a nationally representative data set of office visits, I offer much-needed insight into 
the medicalization of sleeplessness at the interactional level. 
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Hypotheses 
I argue that the pharmaceutical industry is a key institutional stakeholder in 
promoting sleeplessness as a treatable medical disorder. Its “educational” and advertising 
efforts are targeted at the level of individuals – both patients and physicians. While it is 
difficult to directly measure the effects of Direct to Consumer (DTC) advertising on patients 
and drug representative interaction with physicians, I believe that successful influence of the 
pharmaceutical companies on doctors and patients, in tandem with an increased likelihood 
for patients to act as consumers, results in measurable trends. My guiding hypotheses are: 
Over a fourteen year period (1993-2006) I expect to find that the following office visit 
outcomes will increase significantly over time: 
H1: The estimated mean number of office visits with a complaint of sleeplessness 
(insomnia). 
H2: The estimated mean number of office visits that result in a diagnosis of insomnia. 
H3: The estimated mean number of office visits that result in a prescription of a 
sedative hypnotic.9 (This will not necessarily be dependent on a diagnosis of insomnia.) 
These hypotheses represent different levels of medicalization. As previously noted, 
complaints of sleeplessness have been recorded since ancient times and therefore complaint 
alone is not necessarily an indicator of medicalization, although it may be a precursor to an 
office visit. The labeling of the complaint as the medical condition insomnia is indicative of 
medicalization at the conceptual level. Still, a diagnosis may or may not result in a 
prescription. In terms of measurement, I argue that the prescription of a sedative hypnotic –
                                                          
9
 In this dissertation, “sedative hypnotic” will refer to a combination of the following drugs: the five 
benzodiapines approved for use in insomnia, the non-benzodiazepine sedative hypnotics and the anti-depressant 
Trazodone. 
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with or without an accompanying diagnosis – is the most compelling evidence of the 
medicalization process.  
In some cases, the medicalization of a particular disorder (e.g. gastric bypass and 
obesity, hormone replacement therapy and menopause) appears to be linked to the 
development and promotion of related medical or pharmaceutical treatments (Rothman and 
Rothman 2003; Conrad 2007). I believe the development and promotion of non-
benzodiazepine hypnotics, introduced to the US market in 1993, has been concomitant with 
increased diagnosis of insomnia in individuals presenting with insomnia as a reason for 
physician visit (Skaer et al. 1999), as well as increased prescriptions. Unlike 
benzodiazepines, which are commonly prescribed for anxiety as well as sleeplessness, non-
benzodiazepine sedative hypnotics are primarily indicated10 to alleviate sleeplessness and 
thus I run a separate analysis for non-benzodiazepine hypnotics.  
H4: Over a fourteen year period (1993-2006) there will be a significant increase in the 
mean number of prescriptions for a non-benzodiazepine hypnotic. (This will not 
necessarily be dependent on a diagnosis of insomnia.) 
Because DTC advertisements and websites for insomnia feature actors who represent 
non-traditional sufferers of insomnia (e.g. men, younger persons, minorities), I expected that: 
H5: Over a 14 year period (1993-2006) the estimated proportion of individuals from 
“non-traditional” populations (those who are male, non-white, and/or younger) who 
receive a diagnosis of insomnia and/or a prescription for a sedative hypnotic will 
increase significantly. 
I use the NAMCS dataset to test these hypotheses. 
                                                          
10
 Recently, zolpidem has been used off-label for the treatment of restless leg syndrome (RLS), but it is not 
indicated for RLS, nor is it necessarily effective. 
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 While NAMCS data provide evidence of increased insomnia-related outcomes, these 
descriptive statistics do not provide insight into the dynamics of the patient-physician 
interaction; rather, they describe only the outcome of the office visit. In order to provide an 
interpretative context for these data, I conducted a series of interviews with both patients and 
physicians. These exploratory and semi-structured interviews offer insight into the patient-
physician interaction surrounding sleeplessness. I also explore the concepts of rhetorical 
authority, physician compliance, patient compliance and knowledge alignment and how they 
may be moderating the patient-physician interaction. 
 
Overview of Methods 
I conducted secondary analysis of the National Ambulatory Medical Care Survey 
[NAMCS], a nationally representative data set of physician office visits. I believe that 
NAMCS is an ideal data set to track the results of interactions between patient and physician. 
NAMCS provides data on “patient’s complaint(s), symptom(s) or other reason(s) for this 
visit (in patient’s own words)” and “[n]o similar data for visits to office-based physicians are 
available anywhere” (NAMCS 1996: 45). In order to maintain consistency of prescription 
and diagnostic codes I analyze 14 consecutive years of NAMCS data, beginning in 1993. I 
identify the following trends over time: insomnia as a patient reason for visit, physician 
diagnosis of insomnia and sedative hypnotics prescribed or continued. I report my findings 
on both the aforementioned dependent variables as well as the following independent 
variables: sex, age, race and insurance status.  
 In addition, I conduct semi-structured interviews with 27 patients and the 8 
physicians who treated them for sleeplessness at a large Southeastern medical center. Patients 
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had received a prescription within the 6 months prior to being contacted for an interview and 
were asked to describe their insomnia experiences, treatments tried, and interactions with 
physicians. Physicians were asked to describe their experiences diagnosing and treating 
patients who complained of sleeplessness.     
 Detailed methodology for both qualitative and quantitative analyses is presented in 
the subsequent findings chapters. The use of both qualitative and quantitative methods 
provides triangulation and aids in the description and development of this understudied issue. 
As this research is largely exploratory in nature, the data analyses are complementary; 
overlapping and allow different facets to emerge, much like “peeling the layers of an onion” 
(Creswell 1994: 175). This research is a first step in a larger body of research. At the 
conclusion of this dissertation, I provide a section on ‘next steps.’ 
  
CHAPTER 3 
A QUANTITATIVE PERSPECTIVE ON THE MEDICALIZATION OF SLEEPLESSNESS 
 
This research examines the problem of sleeplessness, its transformation into the 
medical diagnosis of insomnia and focuses on the interaction between patient and physician. 
This interaction results in, arguably, the most tangible indicators of medicalization – 
increases in diagnoses and drug prescriptions.  
The goal of this dissertation is to answer the question: Is there evidence of the 
medicalization of sleeplessness at the level of doctor-patient interaction? The objective of 
this chapter is to measure and describe insomnia-related trends over time that might be 
indicative of the medicalization process. In addition, I expect these analyses to suggest 
further steps in my research agenda11, as well as provide a macro-level context for patient 
and physician interview data. I use the following hypotheses to guide my analyses. 
Over a fourteen year period (1993-2006) I expect to find the following office visit 
outcomes will increase significantly over time: 
H1: The estimated mean number of office visits with a complaint of sleeplessness 
(insomnia). 
H2: The estimated mean number of office visits that result in a diagnosis of insomnia. 
                                                          
11
 To be explored in my post-doctoral work. 
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H3: The estimated mean number of office visits that result in a prescription of a 
sedative hypnotic12 (This will not necessarily be dependent on a diagnosis of insomnia). 
H4: The estimated mean number of office visits that result in a prescription of a non-
benzodiazepine sedative hypnotic (This will not necessarily be dependent on a diagnosis 
of insomnia). 
In this same time period: 
H5: The estimated proportion of individuals from “non-traditional” populations (those 
who are male, non-white, and/or younger) who receive a diagnosis of insomnia and/or a 
prescription for a sedative hypnotic will increase significantly. 
 
Methods 
Study Design 
I use the National Ambulatory Medical Care Survey [NAMCS], a population based, 
nationally representative survey of office-based physician visits in the US, to track insomnia-
related trends over time. NAMCS is a national probability sample designed and managed by 
the National Center for Health Statistics (NCHS) of the US Centers for Disease Control and 
Prevention. Data collection has been conducted annually since 1989. NAMCS provides 
information from office-based physician visits comprised of both private-pay and public 
sector patients. Names are provided by the American Medical Association and the American 
Osteopath Association. Physicians who are hospital-based, federally employed, primarily 
engaged in teaching or research, or those who specialize in radiology, pathology and 
anesthesiology are excluded from the sample.  
                                                          
12
 In this dissertation, “sedative hypnotic” will refer to a combination of the following drugs: the five 
benzodiazepines approved for use in insomnia, the non-benzodiazepine sedative hypnotics and the anti-
depressant Trazodone. 
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A probability sample is drawn from counties, groups of counties, county equivalents, 
townships or towns. Next, a probability sample is drawn from the geographic unit sample and 
practicing physicians are identified. Approximately 3000 physicians, per year, are randomly 
chosen. Physician offices chosen through this method are randomly assigned a one-week 
period during which the physician or office staff must record each patient visit. For some 
larger practices, this is not feasible and a sample as low as 20% may be collected over the 
one-week data collection period.  
Information is collected on patient demographics, services provided, diagnoses made 
and treatments prescribed. The National Center for Health Statistics considers cell sizes less 
than 30 to be unreliable.  The basic sampling unit is the office visit. Data are weighted to 
reflect annual visit rates. Additional detail related to the three-stage probability sampling 
procedure, sampling variation and estimation procedures are described in depth on the 
NAMCS website, available at: (http://www.cdc.gov/nchs/about/major/ahcd/ahcd1.htm).  
I use data from the time period 1993-2006. This 14-year period reflects consistency in 
the ICD-9 codes used for diagnosis of insomnia and several years before and after the FDA 
Modernization Act of 1997.13  Ambien (zolpidem), the first of a new generation of sleep aids, 
was FDA approved in 1993 and entered the NAMCS database the following year. 
My analytic sample included a mean of 27,896 observations (office visits) per year 
(low: 20,760; high 36,875). These cases were weighted to represent between 681,457,491 
and 963,617,399 annual office visits in the US.  
 
                                                          
13
 The FDA Modernization Act of 1997 greatly increased the scope and frequency of direct-to-consumer 
advertising by pharmaceutical companies.  
40 
Variables 
My dependent variables are: a) complaint of insomnia as reason for office visit b) 
diagnosis of insomnia and c) the prescription of sedative hypnotics. 
Reason for visit. NAMCS allows physicians to list up to three reasons for office visit. 
Complaint of insomnia as reason for office visit includes complaints of “sleeplessness,” 
“can’t sleep,” and “trouble falling asleep.” NAMCS uses the National Center for Health 
Statistics [NCHS] code 1135.1. 
Visit-associated diagnoses. Physicians provide up to three diagnoses per office visit. 
Diagnoses are classified using the International Classification of Diseases. For the years 
encompassed by this study, the ninth version was used (ICD-9). I analyzed the following 
ICD-9 diagnosis codes related to insomnia: 780.52 (Insomnia, unspecified); 780.50 (Sleep 
disturbance, unspecified); 307.47(Other dysfunctions of sleep stages or arousal from sleep); 
780.59 (Other sleep disturbances); 307.42 (idiopathic); 307.40 (Nonorganic sleep disorder, 
unspecified); 307.48 (Repetitive intrusions of sleep); 780.5 (Sleep disturbances); 780.56 
(Dysfunctions associated with sleep stages or arousal from sleep); 780.55(Disruptions of 24-
hour sleep-wake cycle); 307.41(Transient); 307.49 (Subjective complaint); 327.00 (Organic); 
327.09 (Organic, other).14 
Drug classes. The NCHS uses therapeutic classes based on the National Drug Codes 
(NDC). In 1993 and 1994, NAMCS allowed up to five medications to be listed. From 1995-
2002, this number increased to six. From 2003 to 2006, a total of 8 medications could be 
listed.15  Drug codes may be found at http://www2.cdc.gov/drugs/. 
                                                          
14
 The use of these codes for insomnia in analyzing NAMCS have precedent in the literature (see Balkrishan, 
Rasu and Rajagopalan 2005). 
15
 I recognize the potential interpretive problem this presents, and address it later in the chapter. 
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Based on preliminary interviews with physicians and the insomnia literature, I chose 
to analyze the following drugs from these classes: benzodiazepines, non-benzodiazepines and 
one drug from the class of anti-depressants. While many benzodiazepines are used to treat 
insomnia, they are also commonly used for the treatment of anxiety. I limit my sample to the 
five benzodiazepines that are specifically indicated for insomnia in the US: Triazolam, 
Temazepam, Estazolam, Flurazepam and Quazepam (Rasu, Shenolikar, Nahata et al. 2005). 
The FDA approved Ambien and subsequent non-benzodiazepine sedative hypnotics 
[NBSHs] for the “short term treatment of insomnia” (Physician’s Desk Reference 2006: 
2868). Prior to 2005, the only NBSH in the NAMCS dataset was Ambien (zolpidem). In 
2005, the following drugs were added: Lunesta (eszopiclone), Sonata (zaleplon) and 
Rozerem (ramelteon).16  
 Although insomnia and depression are highly comorbid, anti-depressants are not 
typically indicated for the treatment of insomnia symptoms (IOM 2006). However, after 
consulting with both primary care physicians and sleep specialists, I chose to include an anti-
depressant in my analysis – Trazodone. Trazodone is a tetracyclic antidepressant, initially 
manufactured under the brand name Desyrel17 and approved for use by the FDA in 1982. 
While Trazodone is primarily indicated for depression, a popular off-label use is the 
treatment of insomnia (Walsh et al. 1998). Trazodone is the first-line insomnia treatment of 
choice for many physicians due to its low cost, non-addictive nature, and lack of common or 
serious side effects (Walsh et al. 1998; also, personal communication Head of Psychiatry at 
UNC 2008). 
                                                          
16
 Rozeram has a different mechanism of action than the so-called  “z” drugs (e.g. zopiclone, zolpidem, 
eszopiclone and zaleplon) and is promoted as non-habit forming. However, I include it here as it is often 
discussed alongside the “z” drugs. 
17
 Trazodone is no longer manufactured under the brand name and is now only available as a generic. 
42 
For a list of all drugs used in this analysis and their NDC codes, please see Table 2. 
Table 2.  Medications by brand name, generic name and medication code.  
Brand Name Generic Name NAMCS Medication Code 
Benzodiazepines 
Prosom Estazolam 92080 
52068 
92123 
Dalmane Flurazepam 08390 
52350 
12810 
Doral Quazepam 92022 
55028 
10257 
92148 
Restoril Temazepam 26453 
55668 
30756 
Halcion Triazolam 13999 
93419 
96068 
55928 
Non-benzodiazepine 
Ambien Zolpidem 93347 
94035 
57048 
Sonata Zaleplon 00039 
70115 
Lunesta Esczopiclone 05033 
70988 
Rozerem Ramelteon 05244 
71023 
Anti-depressant 
Trazodone  (formerly 
Desyrel) 
Trazodone 31997 
55903 
40520 
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Independent variables 
Independent variables of interest are: sex (male and female), age (55+ and <54), race 
(Black, White, Hispanic, Asian, Other) and insurance status (private, government, self-
pay/other). Race categories mirrored the provided NAMCS categories. Insurance variables 
were collapsed into three categories and will be discussed in further detail in the section on 
“insurance status.” Age categories were divided at age 55, because it is well-established that 
insomnia is common in both men and women age 55 or older (Grigg-Damberger 2006; 
Ohayon 1997; Roth and Roehrs 2003).  
 
Limitations 
Although I feel it is the best currently available data set with which to do these 
analyses, the NAMCS data are limited in several respects. The NAMCS survey was not 
designed to capture or measure the medicalization process. NAMCS data include only 
individuals who have both the motivation and means to make it to a physician’s office. This 
selection effect may under-represent lower-income groups who mainly use emergency 
services as their primary means of accessing health services. In addition, the patient is not the 
unit of analysis; the unit of analysis is the office visit.  
Finally, the increasing number of drugs that physicians are allowed to list over time 
potentially complicates interpretation of my findings. How will I know if my drugs of 
interest are increasingly prescribed, or just more likely to be listed in the additional spaces? 
This is a serious limitation of the dataset as it relates to my research purposes, and I will 
address it at the end of the findings section. 
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Analytic method 
Data were imported using SAS software, version 9.0 (SAS Institute, Cary, NC). 
Program codes were created in SAS and then converted into SAS export files.  These files 
were then converted into Stata files. All analyses were conducted using Stata version 10.0 
(StataCorp, College Station, TX). I used the svy18 command, which controls for the complex 
sample design of the NAMCS data. In addition, weighting (svyset) was required to 
appropriately link the sample to the population. SAS and Stata codes to correctly weight the 
sample were provided in the NAMCS documentation. 
I computed descriptive statistics for all study variables. To examine changes in these 
insomnia related outcomes, I calculated the means for each dependent and independent 
variable. These means were multiplied by the estimated subpopulation to produce an 
estimated number of office visits; 95% confidence intervals (CIs) around these means were 
also calculated. To test the differences between certain means, I ran regressions of: insomnia 
as reason for office visit, insomnia diagnosis, and prescription of sedative hypnotics on 
various time periods. The first comparisons were across the entire period, comparing the 
means in 1993 to the means in 2006. Then, I divided the 14 year period into three analytic 
“regimes” and repeated the mean comparisons with first and last years from each regime. 
Similar comparisons of means for sex, race and age groups were computed by regime. In 
addition, linear trend statistics were calculated for the dependent variables in each regime and 
the overall time period. 
Regimes were created in order to: a) capture trends in the data that might be related to 
social or institutional ‘fault lines’ (noted below) b) provide aggregate estimates of the 
                                                          
18
 Prior to survey estimation commands the “svyset” command was used to specify the variables for sample 
weight, primary sampling unit and stratification variables. 
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relatively small number of minority patients with insomnia-related outcomes and c) describe 
trends in greater analytic detail than would be available from calculations of the overall 
period. 
Regime 1: 1993-1997 begins one year prior to the introduction of Ambien to the 
NAMCS dataset and ends the year the FDA Modernization Act was passed, capturing a 5 
year time period in which a) NBSHs were introduced to the market and b) mass-scale direct 
to consumer advertising [DTCA] was not yet used. 
Regime 2: 1998-2001 begins the year after the passage of the FDA Modernization 
Act and ends the year in which 9/11 occurred. This time period captures the first four years 
of DTCA and ends at the year of a great national tragedy. Other research has shown that 9/11 
was correlated with mood and sleep disorders and the uptake of negative coping behaviors 
such as drinking and use of drugs (Galea et al. 2002; MacGeorge et al. 2007; DiMaggio, 
Galea and Li 2009). Although stress effects may have been temporary (Knudsen et al. 2005), 
an uptake in sedative hypnotics is certainly plausible and worth exploring. 
Regime 3: 2002-2006 begins the year following 9/11 and ends with 2006 – the most 
recently available year of data available from NAMCS when this research began. In addition 
to capturing 5 years post-9/11, DTCA expenses were higher in Regime 3, compared to 
Regime 2, as seen in Table 15 (in Chapter 6, page 183). 
 
Overview of Findings 
In the following pages I will present, in text and in figures, the yearly mean estimates 
for each of my dependent variables (insomnia as reason for office visit; insomnia diagnoses; 
prescriptions of benzodiazepines; prescriptions of Trazodone; and prescriptions of non-
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benzodiazepine sedative hypnotics (NBSHs)) along with 95% confidence intervals (CIs). I 
will then provide a brief summary of comparative drug trends, in text and in figures.  
Next, I will present analysis of dependent variables by regime and overall time 
period. I use first and final year regression tests to determine significance of change over 
time. In addition, I provide linear trend statistics for overall periods and regimes. I then 
conduct significance tests by regimes using independent and dependent variables.  
Finally, I attempt to address one of the major limitations of the data - variation in the 
number of drug codes allowed - and end with a brief discussion. More in-depth discussion of 
these, and the qualitative findings, is in Chapter 6. 
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Findings 
An average of 27,896 physician office visits were recorded each year in NAMCS 
(low 20,760: high 36,875). As seen in Table 3, visits were weighted to represent between 
681,457,491 and 963,617,399 annual office visits in the US.  
Table 3. Yearly observations and weighted estimates for office visits in NAMCS, 1993-
2006. 
Year Observations Weighted Estimates 
1993 35,978 717,191,408 
1994 33,598 681,457,491 
1995 36,875 697,082,010 
1996 29,805 734,493,096 
1997 24,715 787,371,906 
1998 23,339 829,280,407 
1999 20,760 756,733,854 
2000 27,369 823,541,999 
2001 24,281 880,486,669 
2002 28,738 889,980,491 
2003 25,288 906,022,756 
2004 25,286 910,857,160 
2005 25,665 963,617,399 
2006 29,392 901,954,225 
 
Insomnia as reason for office visit increased over the 14 year study period, but at a 
relatively slower rate when compared to insomnia diagnosis; both of these outcomes were 
outpaced by prescriptions for sleep aids, particularly NBSHs. 
In 1993, insomnia was the reason for office visit in approximately 3.3 million cases 
(95% CI: 2.4, 4.1million), as shown in Figure 3.  By 1997, the mean number increased to 4.7 
million (95% CI: 3.0, 5.9million). After peaking in 2003 with approximately 6.4 million 
(95% CI: 4.9, 7.8 million) visits, the number decreased in 2006 to 4.9 million (95% CI: 3.8, 
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6.1 million). Comparing 1993 and 2006 there was about a 30% increase in complaint of 
insomnia as reason for office visit. 
Figure 3: Means and confidence intervals of insomnia as reason for office visit (1993-
2006). 
 
 During the same period, office visits resulting in a diagnoses of insomnia increased 
nearly six-fold, from an estimated mean of 869,164 (95% CI: 417,000; 1.3 million) in 1993 
to 5.2 million (95% CI: 3.7; 6.6 million) in 2006. 
Figure 4. Means and confidence intervals of insomnia diagnoses (1993-2006). 
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Prescriptions for all sedative hypnotics increased over time. Office visits resulting in 
a prescription for a benzodiazepine increased by 39% when comparing 1993 to 2006 
estimates. As seen in Figure 5, an estimated 2.5 million (95% CI: 1.7; 3.4 million) 
prescriptions were recorded in 1993. In 2006, benzodiazepines peaked with an estimated 3.5 
million office visits resulting in a prescription (95% CI: 2.5: 4.5 million). 
Figure 5: Means and confidence intervals of benzodiazepine prescriptions (1993-2006). 
 
As demonstrated by Figure 6, office visits resulting in a prescription of Trazodone 
nearly doubled when comparing 1993 and 2006 rates, going from an estimated 2.8 million 
(95% CI: 2.1; 3.5 million) to 5.8 million (95% CI: 4.6; 6.9 million). Prescriptions peaked in 
2005 with an estimated mean of 7.4 million (5.5; 9.3 million).  
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Figure 6. Means and confidence intervals of Trazodone (1993-2006) 
 
Figure 7 shows that office visits resulting in a prescription for a NBSH increased 
about 2000%, or 23-fold, when comparing 1994 to 2006. In 1994, Ambien garnered an 
estimated 550,345 (95% CI: 315,038; 785,584) prescriptions. Rates increased steadily, and 
by 2004, an estimated average of 8.5 million (95% CI: 6.3; 10.6 million) prescriptions were 
recorded. Lunesta, Sonata and Rozerem were added to the NAMCS survey in 2005. In 2006, 
nearly 12.8 million (95% CI: 10.5; 15 million) prescriptions were written for all NBSHs. 
Figure 7. Means and confidence intervals of NBSH prescriptions (1993-2006). 
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Summary of dependent variable trends 
As seen in Figure 8, over the same 14 year period, visits resulting in a prescription for 
benzodiazepines, NBSHs and Trazodone have had somewhat different trend lines. When 
compared to NBSHs and Trazodone, prescriptions of benzodiazepines have remained 
relatively stable over time. Trazodone, prescribed at a roughly similar rate to 
benzodiazepines in 1993, increased at a higher rate than benzodiazepines. Comparing rates 
from 1993 to 2006, we see that prescriptions of Trazodone have approximately doubled. The 
most striking trend line in Figure 8 is that of the NBSHs. Since their introduction in 1994, 
prescriptions of NBSHs have increased about 23-fold and have far outpaced those for either 
benzodiazepines or Trazodone. 
Figure 8. Trends in Sedative Hypnotic prescriptions over time (1993-2006). 
 
As seen in Figure 9,  insomnia as reason for office visit has typically been higher than 
insomnia diagnosis. However, in 2006, the trend lines for complaint and diagnosis seem to 
converge.  
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Figure 9. Trends over time in Insomnia Complaint, Diagnosis and prescription of Non-
benzodiazepines sedative hypnotics (1993-2006). 
 
As seen in Figure 9, office visits resulting in a prescription for a NBSH have, over time, far 
outpaced complaint and diagnosis of insomnia.   
 
Analysis of Dependent Variables by Regime 
I conducted significance tests comparing mean levels of the dependent variables in 
regimes. Linear regressions were conducted between the first year (1993) and the final year 
(2006) of analysis using weighted visits, as well as for the first and last years of regimes. In 
addition, slope estimates were calculated for the overall period and regimes. P values, mean 
proportion of visits at the beginning and end of each period, differences between proportions, 
slopes and a graph of the percent change by year are reported below.  
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Significance tests for complaint of insomnia  
The estimated mean number of complaints of insomnia, and percent change over 
time, are graphed in Figure 10.  As a reason for office visit, complaint of insomnia did not 
significantly change between the beginning and end of each regime and none of the regime 
slopes were significant either, as seen in Table 4. The slope for the entire period from 1993 to 
2006 is positive and statistically significant, however, this should be interpreted with caution 
because the sample consists of only 14 observations.  When assessing the slope of the overall 
line, and the three regimes, I find similar trends for the first and second regimes. The slopes 
for Regimes 1 and 2 are positive and not very different from each other and the overall trend. 
However, Regime 3 is very different and has a negative slope, indicating a downward trend 
in number of insomnia complaints.   
Figure 10. Insomnia as reason for office visit, percent change over time (1993-2006). 
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Table 4. Overall and Regime-based proportion differences and slopes for complaint of 
insomnia as reason for office visit.  
Period Proportion Difference P-value 
(difference) 
Slope P-value 
(slope) 
Overall:  
1993-2006 
0.0045 v. 
0.0055  
0.0010 0.307 218,398 0.000** 
Regime 1: 
1993- 1997 
0.0045  v. 
0.0060  
0.0015  0.127 321,819   0.094 
Regime 2: 
1998-2001 
0.0051 v. 
0.0058  
0.0007 0.522 271,437     0.464 
Regime 3: 
2002-2006 
0.0059 v. 
0.0055   
-0.0004 0.620 
 
-76,501  0.760 
* P<0.05 **P<0.01    
 
 Had I only assessed the overall time period, it would appear that the slope trend is 
significantly positive. Breaking the time period into three regimes allows me to gauge some 
of the subtleties present in the data trends, particularly the downward slope in Regime 3.  
 
Significance tests for insomnia diagnosis 
The estimated mean number of insomnia diagnoses, and percent change over time, 
are graphed in Figure 11. When comparing 1993 to 2006 there was a statistically significant 
increase in the proportion of insomnia diagnoses (at the 0.000 level), as seen in Table 5. 
However, when breaking this down by regimes, only Regime 1 (1993-1997) showed 
significant increase (at the 0.05 level). There was no significant change in Regimes 2 and 3. 
The slopes mirror these results.  
 Again, breaking the trend into three regimes gives a more nuanced picture of change 
over time, compared to looking at the entire period.  
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Figure 11. Insomnia diagnoses, percent change over time (1993-2006). 
 
 
Table 5.  Overall and Regime-based proportion differences and slopes for insomnia 
diagnoses.  
Period Proportion Difference P-value 
(difference) 
Slope P-value 
(slope) 
Overall: 
 1993-2006 
0.0012 v. 
0.0057  
0.0045 0.000** 290,571 0.000** 
Regime 1: 
1993- 1997 
0.0012 v. 
0.0030  
0.0018 0.032* 339,772 0.006** 
Regime 2: 
1998-2001 
0.0035 v. 
0.0033  
-0.0002 0.772 66,254 0.759 
Regime 3: 
2002-2006 
0.0038 v. 
0.0057  
0.0019 0.084 406,324 0.066  
* P<0.05 **P<0.01  
 
Significance tests for non-benzodiazepines 
The increase in office visits resulting in a prescription for a non-benzodiazepine 
sedative hypnotic was statistically significant in all of the regimes tested, as well as for the 
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overall period, as seen in Table 6. These tests did not include 1993, as NBSHs were not 
introduced into the NAMCS dataset until 1994.  
The Regimes indicate the increasing rate of growth in number of NBSHs prescribed, 
whereas looking at the whole time period slope implies a constant rate of change across the 
entire period. Thus, a single line is not a good representation of the curvilinear trend of this 
variable over time. The overall trend for annual estimated means, and percent change over 
time is seen in Figure 12. 
Figure 12: Prescriptions for Non-benzodiazepine sedative hypnotics, percent change 
over time (1993-2006) 
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Table 6.  Overall and Regime-based proportion differences and slopes for prescription 
of NBSHs. 
Period Proportion Difference P-value 
(difference) 
Slope P-value 
(slope) 
Overall: 
1994-2006 
0.0008 v.  
0.0141  
0.0133 0.000** 914,766  0.000** 
Regime 1: 
1994- 1997 
0.0008 v. 
0.0027  
0.0019 0.000** 511,319 0.002** 
Regime 2: 
1998-2001 
0.0026 v. 
0.0054  
0.0028 0.001**   886,543    0.036* 
Regime 3: 
2002-2006 
0.0049 v. 
0.0141  
0.0092 0.000 ** 2,286,887 0.004* 
* P<0.05 **P<0.01 
 
Significance tests for benzodiazepines 
The estimated mean number of office visits resulting in benzodiazepine prescriptions, 
and percent change over time, are graphed in Figure 13.  As seen in Table 7, the prescription 
of benzodiazepines does not appear to change significantly between 1993 and 2006. 
However, there is a statistically significant increase when comparing 2002 to 2006. The P-
value was not significant for other Regimes. 
Regimes 1 and 2 show no significant change in slope, however, the last Regime 
shows a significant increase. Looking at the overall slope, there is a significant increase in 
the number of benzodiazepines prescribed over this time period. 
 Once more, breaking the 14 year period into smaller blocks of time allows for greater 
detail of trends to emerge. 
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Figure 13. Prescriptions for benzodiazepines, percent change over time (1993-2006). 
 
 
Table 7.  Overall and Regime-based proportion differences and slopes for prescription 
of benzodiazepines. 
Period Proportion Difference P-value 
(difference) 
Slope P-value 
(slope) 
Overall: 
1993-2006 
0.0035 v. 
0.0039  
0.0004 0.652 107,575   0.002** 
Regime 1: 
1993- 1997 
0.0035 v.  
0.0023 
-0.0012 0.074 -124,690    0.201 
Regime 2: 
1998-2001 
0.0027 v. 
0.0036  
0.0009 0.245 282,106    0.146 
Regime 3: 
2002-2006 
0.0022 v. 
0.0039  
0.0017 0.014* 387289.2    0.020* 
* P<0.05 **P<0.01  
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Significance tests for Trazodone 
As seen in Table 8, when comparing 1993 to 2006, there is a positive, significant 
change in the number of Trazodone prescriptions recorded in NAMCS. However, when 
calculating by regime, only Regime 3 (2002 v. 2006) is significant. Similarly, when 
calculating the slopes, the overall period has a significant positive change over time. 
However, due to the positive and negative changes in the final two years of Regime 3 more 
or less cancelling one another out, the slope does not appear to change significantly (as seen 
in Figure 14), despite the fact that the number of office visits resulting in prescriptions does 
change quite a bit. 
Once more, the division of the overall period into 3 Regimes, offers a level of 
analytic detail that would have been obscured by calculation of just the overall period.  
Figure 14. Prescriptions for Trazodone, percent change over time (1993-2006). 
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Table 8.  Overall and Regime-based proportion differences and slopes for prescription 
of Trazodone. 
Period Proportion Difference P-value Slope P-value 
(slope) 
Overall: 
1993-2006 
0.0039 v. 
0.0064  
0.0025 0.003** 282,036 0.001** 
Regime 1: 
1993- 1997 
0.0039 v. 
0.0043  
.0004 0.589 132,743 0.366 
Regime 2: 
1998-2001 
0.0039 v. 
0.0034  
-0.0005 0.459 -105,625 0.781 
Regime 3: 
2002-2006 
0.0037 v. 
0.0064  
0.0027 0.002** 872,874 0.103 
* P<0.05 **P<0.01  
 
Significance Tests by Regime, using independent and dependent variables 
Estimated means were calculated and multiplied by the subpopulation in order to 
produce an estimated number of cases, by age group, sex, race and insurance status for the 
varying regimes. Regression tests were conducted to detect statistical significance. I report 
results by dependent variable and regime. For unweighted descriptive statistics of the study 
population by regime please see Table 9. Weighted totals for independent and dependent 
variables by regime are available in Table 10, Panels A through E, at the end of this chapter. 
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Table 9. Descriptive statistics of the study population by regime (unweighted numbers). 
All Visits Regime 1 
1993-
1997 
Proportion Regime 2 
1998-
2001 
Proportion Regime 3 
2002-
2006 
Proportion 
Total (%) 160,971  
(42%) 
 95,749  
(24%) 
 134,369 
(34%) 
  
Age       
<55 100,517 .62 57,675 .60 79,533 .59 
55+ 60,454 .38 38,074 .40 54,836 .41 
Sex       
Female 93,909 .58 54,646 .57 76,779 .57 
Male 67,062 .42 41,103 .43 57,590 .43 
Race       
White 130,581 .81 77,190 .81 104,030 .77 
Black 13,171 .08 8,204 .09 12,020 .09 
Hispanic 11,760 .07 6,826 .07 12,978 .10 
Asian 4,913 .03 3,038 .03 3,937 .03 
Other 546 <.01 491 <.01  1,404 .01 
Insurance 
status19 
      
Private 107,473 .67 56,172 .59 76,503 .57 
Government 51,229 .32 28,687 .30 45,394 .34 
Other 27,969 .17 13,415 .14 18,440 .14 
 
Age and Regimes 
I divide the regime populations into two age categories, age 55+, and those 54 and 
below. These categories were created because adults typically begin to experience sleep 
issues by their 6th decade of life (Grigg-Damberger 2006; Ohayon 1997; Roth and Roehrs 
2003) and this age division is sometimes used in clinical trials for sleep drugs (Siversten et 
al. 2006). In addition, the use of sedative hypnotics in older adults is increasingly under 
scrutiny as their use in this age group may lead to injurious falls (Siversten et al. 2006). In 
                                                          
19
 Insurance categories will add to more than the total, due to individuals having both public and private 
insurance 
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each regime, about 40% of the office visits were with patients over age 54. See Table 10 
(page 75) Panel A for further detail.  
Insomnia as reason for office visit increased for both age groups over time. Only in 
Regime 3 was the difference between the proportions of complaint of insomnia, by age 
group, statistically significant. Age was a significant predictor of an insomnia diagnosis only 
in Regime 1. These are interesting findings because they do not parallel the current literature 
on insomnia in older adults.  This may be due, in part to the fact that other analyses use the 
age groups of 65+ and below 65. Although I feel my decision to use the 55+ and under 55 
categories was supported by prevalence of insomnia and concerns over sedative use in this 
age group (Siversten et al. 2006; Grigg-Damberger 2006; Ohayon 1997; Roth and Roehrs 
2003), I plan to use the 65+ distinction in future analyses.  
Prescriptions for benzodiazepines increased over time, when comparing Regime 3 to 
the previous regimes. In each of the three time periods, individuals 55+ received a 
significantly higher proportion of the prescriptions, when compared to younger patients.   
In addition to seeing a large increase in the overall prescriptions for NBSHs over 
time, I found that a significantly higher proportion of patients aged 55+ received a 
prescription in each regime.  
Although prescriptions of Trazodone increased over time, age was not significantly 
associated with it in any of the regimes. The proportion of office visits with younger and 
older adults receiving a prescription for Trazodone was quite similar in each regime.  
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Sex and Regimes 
 NAMCS accurately reflects the fact that women are more likely to utilize health 
services than men in both younger and older adult populations (Green and Pope 1999; Kaye 
Crittendon and Charland 2008). In each of the three regimes, roughly 40% of the patients 
were males. 
 Estimated means were calculated by transforming sex into a dummy variable. 
Estimated means were multiplied by the subpopulation in order to get an estimated number 
of cases, by sex, for the varying regimes.  
Insomnia complaints for both sexes increased over time, but significant differences 
were not consistent. In Regime 1, the proportion of men who had a complaint of insomnia 
was significantly higher than the proportion of women. The opposite was true in Regime 2, 
and there was no significant difference in Regime 3. 
In all of the regimes, office visits with female patients were more likely to result in 
diagnoses for insomnia than those with male patients, but for these data, sex is not a 
significant factor in predicting insomnia diagnosis. Again, this is an interesting finding as it 
contradicts much of the current literature on insomnia. 
Sex of patient was not predictive of any prescription drug other than trazodone – 
women were more likely to receive it in all regimes. Women were also significantly more 
likely to receive a prescription for a NBSH, but only in the third regime. 
 
Race and Regimes 
NAMCS is limited by non-self-report of race. The physician, or staff member, who 
fills out the NAMCS forms supplies patient race. Population estimates for “other race” 
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(individuals whose race was not entered as Black, White, or Asian and whose ethnicity was 
not Hispanic) were calculated in order to ensure that the means added correctly to the total 
regime population mean. However, due to the very small Ns of “other race” and the high 
standard error (making estimates unreliable), I will not be reporting results for that particular 
variable.  
In Regime 2, Asians were significantly more likely to have an office visit with a 
complaint of insomnia than Caucasians or Blacks. Caucasians were significantly more likely 
than African Americans to have an office visit as a result of insomnia complaint in Regime 3. 
No other differences among races were significant. 
In Regime 2 similar proportions of office visits for African Americans and 
Caucasians resulted in a diagnosis of insomnia – both proportions were significantly higher 
when compared to Hispanic office visits. No significant differences were found in other 
regimes.  
Only in Regime 2 was there a statistically significant difference between races in 
comparing prescriptions of benzodiazepines  – Caucasians having a higher proportion of 
office visits resulting in a prescription for a benzodiazepine when compared to African 
American office visits.  
In every regime, Caucasians not only received the highest number of prescriptions for 
NBSHs but had significantly higher proportions of prescriptions compared to African-
Americans and Hispanics in Regime 1, Hispanics in Regime 2, and African Americans in 
Regime 3.  
In all three regimes, Caucasian office visits were significantly more likely to result in 
a prescription for Trazodone than the office visits of Asians. In Regimes 2 and 3, the 
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proportion of Caucasian office visits resulting in a prescription for Trazodone was also 
significantly higher than the proportion of Hispanic office visits resulting in the same 
prescription. In Regime 2, African American office visits were also significantly more likely 
to result in a prescription for Trazodone than Hispanic office visits. 
Among these inconsistent trends, it appears that Caucasians office visits are more 
likely to receive a prescription for a sedative hypnotic than the office visits of minorities. 
Some literature suggests that minorities are less likely to complain of insomnia, and would 
thus be less likely to receive a prescription (Pearson et al. 2006).20 
 
Insurance Status 
Insurance variables in NAMCS changed quite a bit over the years. In 1993 and 1994, 
they were dummy variables that included a category for HMO. In 1995 a categorical option 
was introduced into the survey. The categories included “PPO,” “Insured, fee for service,” 
“HMO/Other prepaid,” “Self-pay,” “No charge,” “Other,” and “Unspecified but insurance 
checked.” There were also dummy variables from the previous years that included Medicare, 
Medicaid, and Worker’s Compensation. In 1997, the categorical values changed yet again 
and most of the dummy variables were done away with. The “paytype” categories (private 
insurance, Medicare, Medicaid, worker’s comp, self-pay, no charge, other, unknown and 
blank) remained relatively stable over time until 2005 when dummy variables for the same 
categories were added back in. Combining the categories, trying to maintain a semblance of 
continuity and coding them in SAS was tedious, but I created four categories – private 
insurance, government insurance, self-pay and other. However, when running crosstabs for 
the independent and dependent variables by regime, I discovered that the cell sizes for self-
                                                          
20
 This may, in part, be due to a correlation between low-SES and race and the dispensing of free samples. 
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pay and other were at times less than 30.21 To correct this, I combined the two categories, 
creating “self-pay/other.” It is worth noting that office staff could code more than one 
insurance type for the patient, so numbers add up to more than 100%. This coding scheme is 
not ideal, but given the intricacies and lack of continuity in the NAMCS data, I feel it is the 
best option at this time.  
Insurance status in relation to complaint of insomnia was only statistically significant 
in Regime 2 when a higher proportion of office visits were paid for with government 
insurance, compared to both private and self-pay/other.  In Regime 1, a higher proportion of 
office visits resulting in an insomnia diagnosis were paid for by government insurance, 
compared to private. In terms of drugs prescribed, government insurance was often more 
significantly associated with the prescription of a sedative hypnotic at an office visit, when 
compared to either private or self-pay/other. This was true in all regimes for the 
benzodiazepines and Trazodone; in Regimes 1 and 3 it was also true for the NBSHs. 
 
Discussion 
In the final section of this chapter, I summarize my findings and discuss whether my 
original hypotheses were supported. I also address one of the major limitations of this dataset 
– the inconsistency of drug mentions over time in NAMCS. Finally, I discuss next steps for 
future analyses. In-depth discussion, linking both my quantitative and qualitative findings, is 
in Chapter 6. 
Summary 
Analyzing NAMCS data over a 14 year period, I found a striking difference in rates 
of insomnia complaint and diagnosis when compared to sleep aids prescribed. Prescriptions 
                                                          
21
 NAMCS documentation states that cell sizes <30 offer unreliable estimates, and should not be used. 
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for all sedative hypnotics have increased over time, some quite significantly. In particular, 
the 23-fold increase in the prescription of NBSHs has far outpaced the prescription of other 
sedative hypnotics, as well as the complaint and diagnosis of insomnia. Given that NBSHs 
are exclusively indicated for the treatment of sleeplesssness, the disparity between the 
prescription treatment and the complaint and diagnosis for which these drugs are meant to be 
used is remarkable and worthy of further exploration. I argue that medicalization theory may 
help explain the considerable disparity between complaint of insomnia, diagnosis of 
insomnia and the prescription of NBSHs.  
 Another interesting finding was the eventual convergence of the trend lines for 
insomnia complaint and diagnosis. Research has noted that, formerly, complaints of insomnia 
were more likely to result in a diagnosis for a mental illness (Skaer et al. 1999). While we 
can assume that not every complaint of insomnia results in a diagnosis, and that many 
insomnia diagnoses arise from an office visit scheduled for a different complaint, these trend 
lines suggest that insomnia complaint may increasingly lead to an insomnia diagnosis. 
Alternately, insomnia may be increasingly likely to be brought up by the patient or physician 
in the context of an office visit where insomnia was not initially a complaint. The latter 
scenario would be more in line with the medicalization hypothesis. 
 I am unsure why the number of office visits with an insomnia complaint would go 
down in the final year by 22%. However, diagnoses and most drug prescriptions for insomnia 
continue to increase. This disparity between complaint, diagnosis and treatment may offer 
further evidence of medicalization and will be discussed further in the conclusion chapter. I 
look forward to seeing if this trend continues when the NAMCS 2007 data set is released. 
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Analysis of Regimes offered nuanced detail of trends over time for both dependent 
and independent variables. In Regime 3, office visits for those aged 55 or over were 
significantly more likely to be the result of a complaint of insomnia when compared to those 
who were younger. Office visits resulting in a diagnosis were significantly associated with 
older age only in Regime 1. A significantly higher proportion of benzodiazepines were 
prescribed to office visits for those 55+ in each regime, compared to office visits for younger 
patients.  
Significant differences between male and female office visits were not consistently 
observed for insomnia complaint or diagnoses. Sex of patient was not significantly predictive 
of a prescription treatment other than trazodone; office visits for females were more likely to 
result in a trazodone prescription in all regimes.  
In terms of insomnia complaint, some significant differences in proportion of office 
visit by race were observed, but they were not consistent across regimes; similarly, there 
were no consistent, significant differences for race and diagnosis. Though trends were also 
inconsistent for treatment, it does appear that office visits by Caucasians were more likely to 
receive a prescription for a sedative hypnotic when compared to other groups. Reasons for 
this could include likelihood of complaint and likelihood of receiving a free sample instead 
of a prescription. 
In relation to complaint and diagnosis of insomnia, government insurance was 
significantly and positively related (compared to other forms of insurance) in Regime 2 and 
1, respectively. Government insurance was also positively and significantly associated with 
the prescription of a benzodiazepine and Trazodone in all regimes; in Regimes 1 and 3, this 
relationship was also true. 
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Initial Hypotheses 
I began this research with five hypotheses, which I restate and address here. 
Over a fourteen year period (1993-2006) I expect to find the following office visit 
outcomes will increase significantly over time: 
H1: The estimated mean number of office visits with a complaint of sleeplessness 
(insomnia). 
I cannot entirely reject the null hypothesis for H1. When comparing the proportions 
of office visits in 1993 to those in 2006 that were the result of a complaint of insomnia, the 
difference is small (0.0010) and the P-value insignificant. However, when evaluating the 
slope of the line over time, it appears that the slope trend is significantly positive 
(P<0.000**).  
H2: The estimated mean number of office visits that result in a diagnosis of insomnia. 
The p-values for both the comparisons of office visit proportion (1993 v. 2006) as 
well as the slope of the trend line indicate significant, positive change over time. Thus, I 
reject the null hypothesis for H2.   
H3: The estimated mean number of office visits that result in a prescription of a 
sedative hypnotic. (This will not necessarily be dependent on a diagnosis of insomnia.) 
When looking at the slopes for each of the sedative hypnotics measures 
(benzodiazepines, Trazodone and NBSHs), each shows a significant and positive increase 
over time. In addition, measuring the difference in proportion over time indicates significant, 
positive change for both Trazodone and the NBSHs, but not for the benzodiazepines.  Due to 
the inconsistency in the measures of change over time for the benzodiazepines, I cannot fully 
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reject the null hypothesis, but would argue that, when taken as a whole, the sedative 
hypnotics have seen significant and positive change between 1993 and 2006.  
H4: The estimated mean number of office visits that result in a prescription of a non-
benzodiazepine sedative hypnotic. (This will not necessarily be dependent on a diagnosis 
of insomnia.) 
Given the 23-fold increase in the number of office visits that resulted in a prescription 
of a NBSH, as well as the significant and positive p-values for both proportional difference 
and slope over time, I can unequivocally reject the null hypothesis in the case of H4. 
One potential explanation for the rise in the prescription of these sedative hypnotics is 
increased spending on direct to consumer advertising [DTCA]. As this is relevant to not only 
my quantitative, but qualitative findings, I will broach this subject in the general discussion 
in Chapter 6, and present, in text and figures, evidence from prior research estimating DTCA 
expenses for sleep drugs. 
In this same time period: 
H5: The estimated proportion of individuals from “non-traditional” populations (those 
who are male, non-white, and/or younger) who receive a diagnosis of insomnia and/or a 
prescription for a sedative hypnotic will increase significantly. 
Due to the small numbers available for each year for my independent variables, I was 
unable to use individual year data from NAMCS to create estimates of 1993 v. 2006 
proportions, nor did I calculate slope statistics (N would be equal to 3, and each of the points 
would represent either 4 or 5 years of data). Instead, I looked for significant differences 
among the aggregate data created for the Regime calculations. In looking at results from the 
regime tests, I concede that I cannot reject the null hypothesis for H5. 
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  With the exception of Trazodone  - women were significantly more likely than men to 
be prescribed Trazodone in all of the regimes tested - there were no consistent differences 
among the sexes. When comparing age groups, there were consistent trends only in the 
prescription of benzodiazepines and NBSHs. In each Regime, office visits for patients who 
were 55 or older were significantly more likely to result in a prescription for one of those 
drugs, compared to office visits for patients under age 55. While racial differences were 
inconsistent across dependent variables and regimes, Caucasians office visits were usually 
more likely to result in a diagnosis or a drug, if there was a significant difference at all. 
 
A notable limitation 
Overall, my most significant and striking finding is the increase in number of office 
visits that result in the prescription of a sedative hypnotic. However, one of the major 
limitations of this dataset is the inconsistency in number of drugs physicians were allowed to 
record, over the years. As previously mentioned, in 1993 and 1994, NAMCS allowed up to 
five medications to be listed. This number increased to 6 from 1995 to 2002, and then again 
to 8 in the final 4 years of data. This is a serious, potential confounder to my findings. While 
I argue that a 23-fold increase in any drug is significant and denotes an actual increase in 
drug prescribing, I also wish to address the potential problem of “listing bias,” or the 
likelihood that sleep drugs are more likely to be listed as space for more drug listings become 
available.  
As seen in the unweighted counts of the number of medications prescribed in Table 
11, the mode for each year is “0.”  
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Table 11. Number of Medications prescribed, unweighted counts (1993-2006). 
 1993 1994 1995 1996 1997 1998 1999 
0 14,180 13,103 15,057 12,379 9,713 8,996 7,573 
1 10,527 10,126 10,110 8,054 7,117 6,369 5,745 
2 5,483 5,158 5,717 4,848 3,792 3,609 3,348 
3 2,718 2,489 2,828 2,130 1,857 1,996 1,787 
4 1,435 1,233 1,407 1,060 921 990 904 
5 1,635 1,489 710 549 550 547 558 
6 0 0 1,046 785 765 832 845 
7 0 0 0 0 0 0 0 
8 0 0 0 0 0 0 0 
TOTAL 35,978 33,598 36,875 29,805 24,715 23,339 20,760 
 
 2000 2001 2002 2003 2004 2005 2006 TOTAL 
all years 
0 10,765 10,236 11,023 9,061 10,180 8,431 8,585 149282 
1 7,573 6,204 7,461 6,588 6,248 6,326 6,826 105274 
2 3,996 3,391 4,421 3,844 3,421 3,743 4,544 59315 
3 2,128 1,732 2,270 2,033 1,909 2,258 2,714 30849 
4 1,087 935 1,189 1,192 1,020 1,366 1,821 16560 
5 667 517 735 757 658 965 1,307 11644 
6 1,153 1,266 1,639 573 477 722 966 11069 
7 0 0 0 345 388 598 762 2093 
8 0 0 0 895 985 1,256 1,867 5003 
TOTAL 27,369 24,281 28,738 25,288 25,286  25,665 29,392 391,089 
 
As seen in Table 12, the mean number of drugs actually listed as a percent of the 
allowable listed never exceeded 27%. In addition,  the mean number of drugs increased by 
only 1 drug on average over a 14 year period of time, even though the allowable drug listings 
went up by 3.  
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Table 12. Average number of prescriptions per office visit, by year (1993-2006).  
Year Total 
observations 
Mean Std. Dev Max 
allowed 
Mean # of drugs as 
percent of allowable 
listed 
(mean/max*100) 
1993 35,978 1.21 1.37 5 24% 
1994 33,598 1.20 1.36 5 24% 
1995 36,875 1.23 1.48 6 21% 
1996 29,805 1.20 1.45 6 20% 
1997 24,715 1.27 1.50 6 21% 
1998 23,339 1.34 1.55 6 22% 
1999 20,760 1.41 1.59 6 24% 
2000 27,369 1.34 1.59 6 22% 
2001 24,281 1.32 1.65 6 22% 
2002 28,738 1.44 1.69 6 24% 
2003 25,288 1.66 2.02 8 21% 
2004 25,286 1.57 2.06 8 20% 
2005 25,665 1.93 2.23 8 24% 
2006 29,392 2.18 2.36 8 27% 
 
In ‘transition years’ (1994-1995; 2002-2003) there is no substantive change, and over 
time, the upward trend appears to be a primarily smooth, slow-growing curve. 
Figure 15. Average number of medications in NAMCS (1993-2006). 
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I argue that, while the increase in allowable categories may have had some impact on the 
significant increase in sedative hypnotics over this time period, it cannot fully explain the 
increase and does not negate or substantially diminish my findings. 
In sum, in this chapter I have systematically described, in text and in figures, trends 
over time in complaint, diagnosis and treatment of insomnia. I discovered some interesting 
disparities in insomnia-related outcomes, particularly when comparing the prescription of 
NBSHs to the complaint and diagnosis of insomnia. Analyses of independent variables were 
also conducted. Further discussion of these, and the qualitative results, is available in Chapter 
6. 
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Table 10. (Panels A-E) Bivariate Relationships between dependent variables and 
independent variables (weighted numbers). 
 
A. Insomnia as reason for office visit 
 Regime 1 (1993-1997) Regime 2 (1998-2001) Regime 3 (2002-2006) 
 N 
(millions) 
Proportion  N 
(millions) 
Proportion  N 
(millions) 
Proportion 
  
Total 18.7  20.7   28.9 
Age       
<55 12.1 0.0051 13.0 0.0063 19.2 0.0069* 
55+ 6.6 0.0052 7.6 0.0063 9.7 0.0055 
Sex       
Female 10.2 0.0047 13.8 0.0071** 16.3 0.0060 
Male 7.3 0.0059* 6.9 0.0051 12.6 0.0067 
Race       
White 14.2 0.0050 15.9 0.0061 22.9 0.0066*B 
Black 1.7 0.0051 1.8 0.0060 1.8 0.0044 
Hispanic 2.1 0.0072 1.7 0.0061 2.8 0.0059 
Asian 0.7 0.0058 1.3 0.0118*W, 
B 
1.1 0.0072 
All other 0.01 0.0015 0.02 0.0013 0.2 0.0057 
Insurance       
Private 11.6 0.0048    11.6 
 
0.0057    17.0 0.0063    
Govt. 7.6 0.0067**O, 
P 
6.8 0.0072  9.5 0.0064   
Other 3.2 0.0051     3.2 0.0075    3.6 0.0064   
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B. Insomnia Diagnoses 
 Regime 1 (1993-1997) Regime 2 (1998-2001) Regime 3 (2002-2006) 
 N 
(millions) 
Proportion  N 
(millions) 
Proportion  N 
(millions) 
Proportion  
TOTAL 7.7  11.4  20.7  
Age       
<54 4.4 0.0019 6.4 0.0031 13.4 0.0041 
55+ 3.3 0.0026* 5 0.0041 7.3 0.0048 
Sex       
Female 5.0 0.0023 7.5 0.0038 12.3 0.0046 
Male 2.7 0.0019 3.8 0.0029 8.4 0.0045 
Race       
White 5.6 0.0019 9.2 0.0036* H 15.9 0.0046 
Black 1.2 0.0037 1.1 0.0039* H 1.2 0.0029 
Hispanic 0.6 0.0019 0.4 0.0015 2.1 0.0044 
Asian 0.4 0.0031 0.6 0.0050 1.0 0.0066 
All other 0 0 0.06 0.0032 0.3 0.0087 
Insurance        
Private 5 0.0021 7.1 0.0035 12.8 0.0047   
Govt. 3.2 0.0028*P  3.7 0.0040 5.9 0.0040  
Other 1.3 0.0021 1.0 0.0024  2.7 0.0048  
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C. Office visit resulting in a prescription of a Benzodiazepine 
 Regime 1 (1993-1997) Regime 2 (1998-2001) Regime 3 (2002-2006) 
 N 
(millions) 
Proportion  N 
(millions) 
Proportion  N 
(millions) 
Proportion  
Total 10.4  10.2  14.9  
Age       
<55 4.1 0.0017 4.7 0.0022 6.6 0.0024 
55+ 6.2 0.0050** 5.5 0.0046** 8.3 0.0047** 
Sex       
Female 6.4 0.0030 5.9 0.0030 8.8 0.0033 
Male 3.9 0.0027 4.3 0.0032 6.0 0.0032 
Race       
White 7.3 0.0027 8.5 0.0033** 
B 
11.1 0.0032 
Black 1.0 0.0031 0.4 0.0012 1.3 0.0031 
Hispanic 1.3 0.0045 0.8 0.0031 1.7 0.0036 
Asian 0.2 0.0018 0.3 0.0027 0.3 0.0019 
All other 0.009 0.0008 0.05 0.0028 0.2 0.0043 
Insurance        
Private 5.2 0.0022   4.5 0.0022 *O   7.2 0.0027  
Govt. 
6.1 
0.0054 
**O,P 4.5 
0.0048**P   
7.3 
0.0049**O,
P  
Other 1.8 .0029**P    1.5 0.0036 1.9 0.0034 
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D. Office visit resulting in a prescription of a Non-benzodiazepine sedative hypnotic 
 Regime 1 (1993-1997) Regime 2 (1998-2001) Regime 3 (2002-2006) 
 N 
(millions) 
Proportion  N 
(millions) 
Proportion  N 
(millions) 
Proportion  
Total 5.4  12.8  44.4  
Age       
<55 2.8 0.0012 6.6 0.0032 21.9 0.0078 
55+ 2.6** 0.0021** 6.2 0.0051** 22.4 0.0126** 
Sex       
Female 3.6 0.0017 8.1 0.0041 30.0 0.0110** 
Male 1.8 0.0013 4.7 0.0035 14.4 0.0080 
Race       
White 4.7 0.0016*B, 
**H 
10.7 0.0041**H 35.5 0.0103**B 
Black 0.3 0.0008 1.0 0.0033 2.9 0.0069 
Hispanic 0.3 0.0009 0.5 0.0017 4.2 0.0089 
Asian 0.2 0.0013 0.5 0.0047 1.2 0.0077 
All other 0 0 0.02 0.0013 0.4 0.0099 
Insurance        
Private 3.3 0.0014   7.4 0.0037    25.9 0.0096  
Govt. 
2.4 
0.0021*O,
P    4.3 
0.0046  
16.8 
0.0113**O,
P     
Other 0.8 0.0013 1.2 0.0030 5.2 0.0092  
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E. Office visit resulting in a prescription of Trazodone 
 
Regime 1 (1993-1997) Regime 2 (1998-2001) Regime 3 (2002-2006) 
 
N 
(millions) 
Proportion  N 
(millions) 
Proportion  N 
(millions) 
Proportion  
Total 13.9  14.7  26.0  
Age       
<55 8.9 0.0038 9.0 0.0043 15.0 0.0054 
55+ 5.0 0.0040 5.7 0.0047 11.0 0.0062 
Sex       
Female 10.0 0.0046** 9.7 0.0050* 17.3 0.0064** 
Male 3.9 0.0027 5.0 0.0037 8.7 0.0046 
Race       
White 11.6 0.0040**A 13.0 0.0050**B
, H 
21.2 0.0061**A
*H 
Black 0.961 0.0030 1.0 0.0032**H 1.9 0.0046 
Hispanic 1.0 0.0035 0.3 0.0011 1.9 0.0040 
Asian 0.2 0.0018  0.4 0.0033 0.4 0.0026 
All other 0.07 0.0062 0.05 0.0031 0.5 0.0128 
Insurance        
Private 8.7 0.0036    7.5 0.0037    14.2 0.0053  
Govt. 
5.4 
0.0048**O
,P  5.2 
0.0056*P 
9.6 
0.0065*P 
Other 2.5 0.0041   2.3 0.0056 *P    3.6 0.0063  
Note: Individual totals may not add to expected total, due to rounding.  
Note: Insurance categories will equal >100%, as more than one insurance category could be 
checked, per office visit. 
* P-value < 0.05   
**P-value < 0.01 
A=significant and positive, compared to Asian 
B= significant and positive, compared to Black 
H= significant and positive, compared to Hispanic 
P=significant and positive, compared to Private 
G=significant and positive compared to Government 
O=significant and positive, compared to Other 
  
CHAPTER 4 
PHYSICIAN PERSPECTIVES ON SLEEPLESSNESS 
 
The objective of this and the following chapter is to provide insight into the patient-
physician interaction surrounding sleeplessness by providing qualitative analysis of 
interviews with both patients treated for sleeplessness and their physicians. The current 
chapter provides detailed methodology, qualitative findings and a brief discussion of my 
physician interviews. I focus on the evidence of the medicalization of sleeplessness and the 
factors present in the patient-physician dyad that may be fueling the medicalization process.  
 
Methods 
Sample 
My sample consisted of physicians practicing in an Internal Medicine Clinic (IMC) 
affiliated with a large Southeastern University. In addition to their clinic responsibilities they 
also, to varying degrees, engage in research, teaching and mentoring of interns and residents. 
 
Recruitment 
An email was sent by the head of the Internal Medicine Clinic to all 24 of the clinic 
physicians describing the project and asking doctors to contact me if they had any interest in 
participation. See Appendix 2 for a copy of the email. All recruitment materials and 
physician interview questions were approved by the UNC Institutional Review Board (Study 
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#: 08-0593, IRB approval received 6/6/08). In addition to gaining UNC-IRB approval, this 
project was approved by the IMC in-house research committee. 
 
Interviews 
Interviews lasted approximately 30 to 60 minutes and were semi-structured in nature. 
Interviews were carried out in a private office space or conference room within the hospital 
and were recorded with consent. 
I asked participating physicians to fill out a short demographic form that included 
questions about their race, age and years in practice. In addition, I asked them to estimate the 
frequency with which they heard insomnia complaints, whether complaint of insomnia was 
typically primary or secondary  (to another complaint) and if they thought patient complaint 
of insomnia has increased, decreased, or stayed about the same during their time in practice.  
I used an IRB-approved interview protocol to guide the conversation and provide 
continuity across interviews. However, physicians often brought up topics of interest that 
were not covered in the interview guide. Insights that seemed interesting or relevant were 
discussed further and often informed the topical structure of subsequent interviews.  As a 
“thank you” for the physician’s valuable time, a small donation was made to the Clinic’s 
Education Fund. 
Please see Appendix 3 for a copy of the physician interview questions. 
 
Coding and Analysis 
Data were transcribed from the interview recordings. All transcripts were given an in-
depth initial read-through. Next, I performed a “first pass” coding on three of the transcripts. 
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I chose an early interview, an interview performed mid-way through the process, and the 
final interview. These transcripts reflected the evolution of conversations and relevant themes 
that emerged over time and allowed me to construct a comprehensive “first pass” code list.  
First pass codes were then added to a list of “housekeeping codes.” Housekeeping 
codes represented themes that were expected to emerge, based on the theoretical framework 
of medicalization and some of my key interview questions. Housekeeping codes included: 
medicalization, age, gender, race, SES, insomnia context, insomnia definition, physician 
compliance, rhetorical authority, physician education and training, practice type, and role of 
drug company. 
Many of the housekeeping codes became “Free nodes” in NVivo. Free nodes in 
NVivo are “stand alone” codes. NVIvo also contains a coding or “node” system referred to as 
tree nodes. Tree nodes are helpful because they allow for multiple, related codes, or 
“families,” to cluster together. For instance, rhetorical authority, originally a free-standing 
concept was turned into a tree node when I realized I wanted to make distinctions between 
the origins of rhetorical authority (e.g. internet vs. friends and family).  
Other emerging codes were created as tree nodes. One example is the concept of 
attitude. During the coding process it became evident that attitude toward diagnosis and 
treatments was a critical part of this qualitative analysis. In addition, the contrast between 
patient and physician attitudes seemed important to the medicalization process. Separate, but 
related, tree nodes were created to capture these attitudes.  
Using the first-pass code list, I read and coded all of the transcripts. During the 
coding process, a few new themes emerged and codes were consequently revised, deleted, 
added or expanded. A final code list is available in Appendix 4. 
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During the coding process, I wrote memos about emergent themes, and themes I 
thought might be conceptually connected; illustrative quotes were added. A memo example 
is available in an appendix. [Please see Appendix 5] 
After using the revised code list to do a second coding pass on all of the transcripts, I 
uploaded the transcripts into NVivo and coded them a final time. In this coding pass, I was 
working from hard copies that had been coded using the “final” code list, but it was also 
another opportunity to assess codes and their use within an interview.  
Using NVivo, I was able to print coding reports of particular nodes, as well as 
visually assess the way selected portions of text were double-coded or triple-coded, and so 
on. Co-occuring codes were common and codes that frequently appeared together offered 
insight and a framework for my analyses. 
 
Limitations 
There are several limitations to my design. As previously noted, I was not able to 
carry out direct observation of office visits centered on a complaint of insomnia or resulting 
in the prescription of a sedative hypnotic. In asking patients and physicians to talk about their 
past encounters, I introduce an element of recall bias.  
I must also allow that the day-to-day practice of the physicians differs significantly 
from the office-based physicians surveyed in NAMCS. IMC physicians interviewed carry out 
research and/or teach in addition to their clinic responsibilities. These additional 
responsibilities could theoretically heighten their investment in the medicalization process.  
Another distinction of this clinic is that residents and interns have far more limited 
interaction with drug representatives than most of their peers. A few years prior to this study, 
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the Chairman of the Department of Medicine decided to no longer allow the infamous “drug 
lunches” (lavish, free lunches provided by representatives from pharmaceutical companies) 
that have been a hallmark (and, at times, highlight) of being a practicing physician. To that 
end, this IMC is spending an extra $40,000 per year to provide lunches (personal 
communication Drs. C. and M22, November 2007).  While this impacts my ability to assess 
one of the fueling factors in my conceptual model – the influence of the drug companies on 
physician compliance - it did not impact the physicians’ ability to express their opinion of the 
relationship between drug companies and patient and physician attitudes toward prescription 
sleep aids.  
Finally, the small size and narrow demographic profile of this convenience sample 
preclude it from being generalizable to a larger population. 
 
Findings 
Twenty-four physicians received the clinic director’s email; eight agreed to 
participate in this study. Two of the physicians were women,23 and all were Caucasian. They 
ranged in age from 32 to 63 and their years in practice reflected this range (1 to 38 years, 
mean = 14). On average, they saw 36 patients a week, but the range was broad (8-80). The 
mean number of patients seen in a month was 144. For further demographic detail, please see 
Table 13. 
 
 
 
 
                                                          
22
 For purposes of confidentiality, I cannot identify these physicians by name. 
23
 Due to the small number of female participants, in cases where a gendered pronoun is used I will use the 
masculine. This is intended to provide an extra measure of confidentiality. 
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Table 13. Physician Descriptives. 
 Mean or %, range 
Age 45 
(32, 63) 
Male 75% 
25% 
Caucasian 100% 
Years in Practice 14 
(1, 38) 
Years in this clinic 11 
(1, 33) 
Patients seen in a week 36 
(8, 80) 
Patients seen in a month 144 
Patients who complain of insomnia in a month 12 
(2, 40) 
Patients complain: 
  In context of other problems 
  As a primary complaint 
100% 
0% 
(Over time) Patient complaints have 
Increased 
Decreased 
Stayed about the same 
50% 
0 
50% 
 
Physicians in this sample reported that an average of 12 patients per month 
complained to them of insomnia (range= 2 to 40). When asked if patients complained of 
insomnia in the context of another problem or if it was a primary complaint, all eight said 
that it was presented in the context of another problem. The sample was evenly split on 
whether patient complaint of insomnia has increased or stayed about the same during their 
time in practice. No-one reported that it had decreased.   
Is there evidence of the medicalization of sleeplessness? If so, what forces might be 
fueling the process?  
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To best answer these questions, I focus on three components of the physician 
interviews: their language, attitude and reported behavior. Specifically, I highlight the 
language that they use to discuss medicalization, their attitudes toward insomnia diagnosis 
and treatment and their prescribing behaviors.  
I expand upon and give examples of the meso-level theoretical constructs that may be 
moderating the patient-physician interaction: consumerist attitudes, rhetorical authority, 
physician compliance, patient compliance and knowledge alignment. I address the concepts 
of patient compliance and knowledge alignment on a very limited level, as physicians have 
little knowledge of patient’s behavior once they exit the office visit, and the physicians in this 
sample have restricted or no contact with pharmaceutical representatives.  
 
Language of medicalization 
Physicians in this sample used sociological language, discussed facets of the 
medicalization process and were able to offer another example of a medicalized disorder. 
To varying degrees, all of the physicians in this sample appeared cognizant of the 
medicalization process, and a few even used sociological language when discussing it. One 
physician used the term “disease mongering,”24 another discussed “case findingness.” Two 
physicians asked me if I had read the work of Norman Hadler (a physician who writes on the 
expansion of disease categories and the over-use of medications in American society). A 
couple of physicians used the specific term “medicalize” and other examples of 
medicalization were discussed. 
Yeah…I think we tend to medicalize insomnia to a large degree….I think the majority 
of cases of insomnia are due to stressors in life and normal variance and I think they 
                                                          
24
 (see Moynihan, Heath and Henry 2002) 
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are usually not psychiatric diagnoses but I think to gain the diagnosis of insomnia it 
ought to be that.   (Doc 4) 
 
I think sometimes these direct to consumer commercials or advertising makes people 
think they have a problem when they don’t. And then medicalizes it and makes them 
want medicine when they don’t necessarily need it. (Doc 2) 
 
Another physician discussed the medicalization process in terms of awareness and its 
relationship to “case-findingness.” 
You know, there are lots of ways to raise the awareness and case-findingness out 
there. And then all of a sudden you get, just like with any condition. If you start doing 
more case-finding you start calling things that we used to call normal, disease. 
Right? And so, all of a sudden you’re treating people who are on the more mild 
spectrum. And you’re kind of left in this quandary well what’s disease and what’s 
not? What should be treated and what shouldn’t? (Doc 3) 
 
When asked if he thought there was an epidemic of sleeplessness, one physician described, 
eloquently and at length, the process of disease “creation” using the examples of high blood 
pressure and post-traumatic stress disorder. He also employs the term “disease mongering.”  
I would say it’s two things, it’s ascertainment bias and also disease mongering. 
Where we search. And we can create. Well, disease mongering is the most cynical 
way to put it. But there are a lot of conditions that we do not define statistically. 
Diseases, that we define them epidemiologically. For example, a 50 year old man 
with a blood pressure systolic of 145 has statistically a normal blood pressure. 
Statistically well within the 95% of the normal people. But we’ve decided that since 
strokes and heart attacks go up in the population starting at about 140 that we’re 
going to define 145 as abnormal. So it depends on whether or not you want to make 
your disease criteria-based or normative-based. And so if you change the definition 
of an illness then you will ascertain more cases. So it’s not just an ascertainment bias 
which is a measurement phenomenon it would also be, and more sophisticated 
epidemiologists will have the term for me, for this. But when you can create a disease, 
you can define a disease into existence, if you relax the criteria or you make them 
broad enough so that you’ll encompass a lot more people. And that’s been done all 
the time. I mean, for example in the psychiatric literature there’s some controversial 
examples about how post-traumatic stress disorder, it used to be considered that you 
had to have some terrible experience like being on the Bataan death march or being 
raped or something like that. Some extraordinary experience, negative experience is 
the trigger. But now that’s been relaxed. And so obviously the number of people who 
will have the disease is greater. Or who will be diagnosed with it. It also does serve 
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commercial interests though to expand the diagnosis of a disease if there is a 
treatment. (Doc 5) 
 
Two physicians departed from the topic of insomnia to parallel it with another, arguably 
medicalized, disorder – toenail fungus. 
Seeing commercials about insomnia makes people more inclined to think of it as a 
disease process. I mean it’s the same thing as the toenails, you know? I mean those 
fungal nails. Fungal nails did not necessarily. I mean some people came in and 
complained about their fungal nails but now a lot of people come in and complain 
about fungal nails ‘cause it’s all over the TV. And they say, well I think I have fungal 
nails and I need a prescription for this. And there’s a bit of that with respect to 
insomnia, that being bombarded with it makes people start thinking about their sleep 
pattern more and it’s not always clear that is what has generated the visit or the 
inquiry, but I think it is bound to, to some extent. And then, and so that’s the one half 
of it, is just making people start thinking about, Oh, do I have a sleep problem. Maybe 
I should talk to my doctor about it. And the other one is then, a specific pill that they 
could request when they came in. (Doc 7) 
 
And think about, I remember when Lunesta was all over and it’s like the butterfly 
waking up all happy. You know, they will come in, Oh, I want to try that one. And it 
kind of made me giggle because I was like, well ‘cause you watched it last night with 
the butterfly waking up….I mean, I’m trying to think of another, you’re doing this in 
terms of insomnia but like toe fungus is another one that they were really pushing. I 
mean, I have people who are really ill, dialysis and diabetes and they want their toe 
fungus and they want the pill for that. And that’s just, I don’t know what would make 
them think of that unless they’ve, you know, why would they ask me for a pill for their 
toe fungus unless they saw an advertisement? And that would be certainly never 
something that I would ever bring up. So it does affect, I mean it affects what you end 
up [doing], it affects the agenda you have with them. (Doc 2) 
 
Although none of the physicians were enthusiastic about the medicalization of sleeplessness, 
a couple of physicians pointed out that the complaint of insomnia could aid in the discovery 
of a mood disorder.  
The only other positive might be if people are really talking about their insomnia and 
it does cover a mood disturbance you may actually get a little more, you know, 
insight into their mood that you might not. You know, sometimes men are less, they 
don’t want to talk about depression as much, so they might talk about their insomnia. 
It gets you to be able to open the door and talk more about mood disturbance. And I 
guess that’s probably the case for a few of my patients. So that might be a positive of 
it, I don’t know. (Doc 2) 
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In sum, several of the physicians in this sample used targeted terminology – including 
“medicalize”, “disease mongering” and “case-findingness” -  to describe the medicalization 
process. They seemed keenly aware of factors that aided in the medicalization process, such 
as the expansion of a disease category and the influence of advertisements (discussed later in 
more detail), and were able to relate the medicalization of sleeplessness to other medicalized 
disorders such as toe fungus. 
 
Attitudes toward diagnosis 
By definition, a medicalized disorder is a symptom or set of symptoms formerly 
considered a “normal” biological or behavioral process (Conrad 2007). Physicians in this 
sample were reluctant to categorize insomnia as a disease process. Insomnia was typically 
described as either a) a symptom of another disease process (typically a mood disorder) or b) 
a normative process – particularly when viewed in the context of aging. 
 
Insomnia as symptom 
The following quote highlights physician views on insomnia as a symptom. 
 Well, to me insomnia is to mood as fever is to pneumonia. It’s not a disease, it’s a 
symptom. So I don’t treat insomnia. You know, it’s very rare that I find someone who 
has insomnia for which it’s not related to a mood disorder. Depression or something 
like that. And I do not use benzodiazepines or sleep tablets or things like that because 
I feel that it would be like treating pneumonia with an aspirin to remove the fever. So 
typically I’m looking for a mood disorder, anxiety disorder, panic disorder, or some 
other reason which is underlying the sleep disorder. That may be even something as 
simple as chronic pain. It may be something that has to do with other things keeping 
them awake. Maybe they’re having reflux at night. There are lots of different reasons. 
But I don’t view insomnia typically as a disease. (Doc 1) 
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There are rarely patients who have, you know, you screen them for everything and all 
they have is trouble sleeping and have insomnia but everything else is fine. I mean I 
think you can almost always find something else to address. But…the portrayals are 
that this person is a beautifully healthy person who just can’t sleep and now they take 
this drug and they’re happy. (Doc 2) 
 
One of the physicians who used the term “medicalize” (began on page 86) continued the 
quote to address what he felt were the root causes of insomnia. 
It is getting ahead of myself, for the majority of patients I see I feel like are normal 
life variance of that and there is relatively few cases that I see where I would say this 
is a medical diagnosis of insomnia. (Doc 4) 
 
In the following quote, Physician 5 goes beyond the symptom versus disease distinction by 
emphasizing the clinical impact. Further he states, “we are being led to believe” certain 
things about insomnia, which, in his judgment are inaccuracies.  
In most people insomnia is a symptom, it’s like sneezing. In my, that’s my judgment, 
not my opinion. You have to understand the clinical impact. If everyone stopped their 
Ambien for a week in this country, it wouldn’t even register on a public health level. 
If everyone stopped their insulin or aspirin for a week, who needed to be on those 
medicines, it would register as a big public health problem. Or, let’s say a month. It 
would register as a huge public health problem. But we’re being led to believe that 
the clinical impact of this is as important, is on par with things like being on insulin 
for diabetes or aspirin if you have heart disease, or certain blood pressure medicines 
if you have heart failure. Certainly if you have someone with advanced heart failure 
and you told them to stop their after-load reducing medicines, which is a fancy term 
for kind of a blood pressure medicine that takes stress off the heart. There wouldn’t 
be enough, and you told them to do it for two weeks, there wouldn’t be enough 
hospital beds in the country to accommodate all those people. (Doc 5) 
 
Later, he notes: 
You know, we have made some important advances in sleep disturbances like 
obstructive sleep apnea. We know, but that’s, I don’t think that’s what we’re talking 
about. We’re talking about this generic symptom which is basically a subjective 
symptom which does not involve any measurable disturbance in the physiology. You 
know, like a sleep study you can actually see some bad things happening. (Doc 5) 
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Insomnia as normative process 
Some doctors commented that the larger problem may be in patient expectations 
about what constitutes “normal” sleep and how this may or may not relate to their daytime 
function.  
So insomnia is a great example because probably just about everyone has had a 
sleepless night. And a whole lot of people may have a few of those together. And is 
that pathological that needs treatment or not? And that’s a values question of how 
bad that is to that individual and how, what the relative risks and benefits of the 
medication are, if you’re going to use medication. (Doc 3) 
 
Physician 6 talked specifically about changing patients “norms” regarding sleep. 
There’s a whole thing about what should be the expectation about sleep and how we 
make the expectation you’re supposed to sleep 8 hours in this perfectly blissful state 
and that that’s not [what we’re] really evolutionarily programmed to do. I was 
reading this thing in the New York Times magazine or maybe it was in the New 
Yorker about really people have this thing where they’re supposed to wake up at 3 in 
the morning and be kind of semi-alert for an hour and then go back to sleep and that 
was well recognized and considered to be normal. And then we kind of said, no, no, 
no you’re supposed to have your suspended animation state for 8 hours. And that may 
be too high of a bar…. So I try to talk about well, so you’re not sleeping well, so what 
does that mean. If it just means that you’re not getting 8 hours sleep and you think 
that’s the norm then we’re not likely to intervene. You just try to then change your 
norm. (Doc 6) 
 
Physician 2 clarified that daytime function was a key indicator in whether and how he chose 
to treat sleeplessness. 
Sometimes another, I didn’t say this earlier, but another question I ask patients now 
is, how do you function during the day? Many people may not sleep well, you know, 
or may not sleep straight through for 8 hours, but they are getting, accomplishing 
everything they need to do. They have energy, they’re fine, they’re not sleepy during 
the day. So does that person really have a sleep problem? Right? I mean if you’re 
functioning the next day, probably not. So that’s where I struggle a little bit. (Doc 2) 
 
Related to the idea of sleep “norms” is the issue of aging. As noted in the background 
section, many believe that reduced sleep time may be a normal part of the aging process.  
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 “I’ve come to think that it’s really rare for some, for people over 40 to sleep through 
the night….Yeah, more and more I try to normalize fractured sleep. And maybe that’s 
from my, just from my own experience and from talking to so many patients. And 
that’s another way I divert this and don’t prescribe. It’s getting up, you know, waking 
up once or twice a night. Sometimes staying awake for an hour seems really normal 
by the time you get to a certain age.  And not something to be treated with a pill. And 
so then it’s a matter of resetting expectations. That, ok, well you don’t need as much 
sleep. You don’t need to spend as much time in bed.” (Doc 7) 
 
And we know for example that the elderly tend to have more sleep fragmentation. And 
they may not stay sleep as long, and that may be physiologic. Although I’m not an 
expert in this. You know, we tend to think of that sleep fragmentation or sleeping for 
shorter periods as being a common phenomenon in the elderly. Although they do 
catch up in the day by taking naps and such. Yeah, but those are, that’s how I would 
conceptualize it. (Doc 5) 
 
Another physician alluded to the fact that older patients are more likely to have multiple 
comorbidities. 
The other context is in older folks who are not doing well, who are tired, who just 
don’t seem to feel well. And it’s a combination of a number of symptoms. They 
haven’t been eating well, or you know don’t have much energy, not much enthusiasm. 
They’re tired, they don’t feel well, they don’t sleep well. They can’t stay asleep they 
wake up early, can’t go back to sleep. They have racing thoughts through their heads 
at night when they’re trying to lie down. So there are many contexts which it would 
come up in, but it’s not usually, not ever just a single isolated event. I rarely, I don’t 
think I can recall very many people ever coming in and saying you know, I’m 
perfectly fine, everything is great, I just can’t sleep. (Doc 1) 
 
None of the physicians in this sample stated that they thought insomnia was a biologically-
based disease process. It was either considered a symptom of another disease process – 
typically a mood disorder - or described as a normative, if unpleasant, part of life for most 
people, especially as we age.  
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Attitudes toward Insomnia Treatment 
An integral part of the medicalization process is the use of prescription drugs to treat 
a disorder. Physicians are still considered the gatekeepers to the prescription pad (Conrad 
2007) and it seems logical that their expressed attitudes toward sleep aids may have some 
impact on their prescribing practices. Physicians in this sample discussed both behavioral and 
prescription treatments. Prescription treatments mirrored the categories analyzed in the 
NAMCS dataset: Trazodone, non-benzodiazepine sedative hypnotics (NBSHs) and 
benzodiazepines.  
 The physicians in this sample emphasized that they try to utilize behavioral 
techniques or “sleep hygiene” prior to, or in lieu of getting out the prescription pad. The 
following quotes are representative of their attitudes towards different sleep therapies. 
 
Non-prescription sleep treatments 
The concept of sleep hygiene arose in the first interview I conducted and was a topic 
of discussion – to varying degrees – in all of the physician interviews. The practice of sleep 
hygiene offers guidelines on health practices (diet, exercise, substance use) and 
environmental factors (light, temperature, noise control) (IOM 2006). Discussion of sleep 
hygiene was both a diagnostic technique and a suggested treatment for sleeplessness. 
The first thing we’ll do is we’ll try to figure out how much coffee they’re drinking or 
how much soda they’re drinking or, what they’re eating before they go to bed, what 
they do before they go to bed. You know, do they relax, have they just been doing a 
whole lot of work. I mean, there are a lot of reasons that people can increase or 
decrease their levels of stress. And those are the more common things. Sometimes I 
tell them, ok just have a warm glass of milk and sit down and relax.  So sleep hygiene 
is critical. And many times people, you’ll find, are doing things you just couldn’t 
imagine doing before sleep. [Like] maybe having a couple of cups of coffee at 3 or 4 
in the afternoon. Not realizing the caffeine has a long half-life and will keep them 
awake at night. (Doc 1) 
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When asked if he ever talked to his patients about lifestyle or behavioral changes, this 
physician told me: 
I do, and that is where I will start.  I will tend to talk to them about regular bedtimes, 
regular awakenings, not watching television in their bed, trying to use their bed 
mostly just for sleep, caffeine intake, reducing caffeine intake, alcohol intake, any 
other drugs they may be using around bedtime.  And that is always where I start and 
try to see if that will help someone before medication. (Doc 4) 
 
Physician 6 talked about sleep hygiene and its use as a first line treatment before prescription 
therapy. 
For the people who don’t have obvious depression then the next thing is to ask them 
about sleep hygiene. So, then I’ll usually start with ok, so tell me about your sleeping. 
…. When you get to the people that are like, I just wake up and I’m awake and I can’t 
get back to sleep, then you do a little bit of probing about caffeine and what have they 
tried previously. And usually my first intervention is a sleep hygiene recommendation, 
so no caffeine at all if possible or at least after noon. And then I focus on, try an 
exercise intervention, so getting exercise, aerobic exercise during the day not close to 
bedtime. As a way of helping people to relax and go to sleep, I usually do that first. 
And then if that’s not effective then we talk about pharmacologic therapy if it’s 
bothering them enough that they want to do something. (Doc 6) 
 
 
Prescription sleep treatments 
Despite their stated preferences for the use of non-pharmaceutical solutions, for a 
variety of reasons (discussed in more detail in the section on “prescribing behaviors”) most 
of the physicians in this sample routinely wrote prescriptions for sleep aids. The three types 
of sleep aids they mentioned were (in order of physician preference) Trazodone, NBSHs and 
benzodiazepines. 
Trazodone 
Trazodone was the first-line prescription of choice for many of these physicians. 
Most preferred it because of its non-addictive properties. 
But I also tend to use Trazodone a fair bit, not necessarily for its anti-depressive 
actions but as a sleep agent. So if they really want a pharmacologic therapy and 
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aren’t fixated on one I typically will suggest Trazodone at 50 mgs to start with and 
then 100 and I’ll go up to 200. And a fair number of people have gotten good success 
with that. But some people it doesn’t work, so I won’t say that it’s always effective. 
(Doc 6) 
 
Physician 5, while acknowledging it is not habit-forming, opined that Trazodone was 
primarily effective in patients also being treated for depression. 
There’s another class of medicine that’s used for sleep aid and depression. That’s 
called Trazodone. Now, Trazodone has never been shown to really help with 
insomnia outside of treating people, if you are treating them concomitantly with other 
medicines for depression. I tend not to believe it. And in order to minimize the amount 
of polypharmacy I just don’t use Trazodone. But it is not known to cause physical or 
psychological dependence. It’s not a controlled substance.  (Doc 5) 
 
The only negative side effect mentioned for Trazodone was the possibility of hangover.  
If someone for example, let’s say we’re treating them for depression and their sleep 
hasn’t quite gotten as better as I would like, I’ll often add Trazodone which is an 
antidepressant, which is very effective. The only problem is it gives them a hangover 
in the morning. So, to some extent you’re limited in how well you can use it, you 
know. (Doc 1) 
 
NBSHs 
The non-benzodiazepine sedative hypnotics are by far the most oft-prescribed sleep 
aids, both at a national level and in this practice.  
Mostly I prescribe zolpidem in either 5 or 10 milligrams. And very occasionally 
temezepam. And I guess rarely triazolam….Occasionally patients will come in and 
they’ve seen advertisements for Lunesta and think that, well that might have some 
advantage for them. (Doc 7) 
 
NBSHs are preferred to the older generation sleep aids because they are typically thought to 
have fewer negative side effects or addictive potential. (Although, in a later quote, this 
physician questions whether there is good clinical evidence to support some of these ideas).  
You know, for example the sleep aids are controlled substances. You know, I think it’s 
a relatively minor transgression to keep prescribing them, compared to let’s say 
benzodiazepines chronically or opiods chronically for pain, other controlled 
substances. Where I can have objective evidence that if I’m prescribing them 
inappropriately, these other controlled substances, that I’m doing this person harm. 
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They’re no longer as productive as they used to be. They’re exhibiting certain kind of, 
we call them drug-seeking behaviors. In all honesty I don’t see, I won’t see that 
degree of misbehavior as I would maybe with certain narcotics, certain opiods, pain 
relieves. Another reason I’m willing to put up with it, with what I consider is 
suboptimal prescribing on my part. (Doc 5) 
 
When asked why Ambien was his prescription sleep aid of choice, this physician told me: 
It’s just what I’ve gotten used to prescribing. If someone came to me and said that 
they wanted to try Sonata I would be happy to prescribe it for them. But I think it’s 
generally true about physicians that we kind of figure out the medicines that we’re 
most comfortable with within a given class. And I haven’t found, I’m not aware of any 
other medications that have been proven to be far superior to Ambien. (Doc 3) 
 
Benzodiazepines 
Benzodiazepines, an older generation of sleep aids, are still commonly used. These 
physicians noted that benzodiazepines can be quite useful in situations were sleeplessness is 
fueled by anxiety. 
Certainly sedative hypnotics and benzodiazepines, they certainly have a role in lots of 
different areas, but I do not routinely prescribe them for sleep unless, and there 
again, the caveat here is that I just saw a woman yesterday actually who is a 78-year-
old woman, very nice older lady with diabetes and her daughter-in-law is dying of 
ovarian cancer so she is under a lot of stress right now and that is understandable.  
She is having trouble falling asleep so I gave her a prescription for clonazepam, a 
very small dosage, like 0.125 mg, I think, very small; but again talked to her about 
how that would be used for, we would use this over a few weeks. So that is an 
example of that but, overall I do not prescribe benzodiazepines for sleep unless it is 
an acute cause like that….Zolpidem or Ambien, that will be the one that I will 
prescribe if I decide to initiate therapy by myself.  (Doc 4) 
 
However these physicians were cautious in their prescribing practices because of the known 
potential for addiction. 
Benzodiazepines which are sometimes used for sleep but also a lot for anxiety, I tend 
to not use a lot of those. So maybe it’s more for these controlled medications or 
schedule 2 medication that I feel like I try not to prescribe. So there may be certain 
classes that I’m more averse to prescribe. (Doc 3) 
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Prescribing behaviors 
Nationally representative data (described in Chapter 3) indicate that, particularly in 
relation to NBSHs, physicians are increasingly likely to prescribe a sleep aid. What forces 
influence this critical office visit outcome? I posit that the forces of consumerism, physician 
compliance, rhetorical authority, knowledge alignment and the influence of insurance 
companies directly influence the outcome of a hypnotic prescription. These interviews offer 
valuable insight into these elements and how they may present in physician office visits.  
Physicians noted the presence of consumerist attitudes among patients, as patients 
request specific drugs and bring pharmaceutically-sponsored coupons into the office visit.  
Physician compliance seems to be motivated by various factors, including the 
aforementioned consumerist attitudes. The influences discussed most frequently in these 
interviews include the presence of time constraints; a “soft” bias toward sleep aids that rarely 
precluded the writing of a prescription; the propensity for patients to enter the encounter with 
pre-existing prescriptions; and, to some degree, the physician motivation to achieve patient 
compliance.  
According to these physicians, rhetorical authority [RA] is commonly seen in their 
office visit interactions and patients acquire their medical information from a variety of non-
medical sources.  DTCA, or direct-to-consumer-advertising is a catch-all phrase for various 
forms of media that advertise directly to patients, and was mentioned by most of the 
physicians. More specific sources of RA, the internet and social networks, were also 
mentioned.  
I touch on the concept of knowledge alignment. Although my original conceptual 
model included the influence of pharmaceutical companies on physicians, this particular 
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sample, as previously noted, does not see drug reps. Despite this fact, some of the physicians 
expressed their opinions on the pharmaceutical industry, and I have included their quotes. 
Finally, I briefly note an unexpected finding - the influence of the insurance 
companies on physician prescribing behaviors. 
 
Consumerism among patients 
Patients increasingly act like the physician office visit is one more service industry, to 
the extent that they engage in doctor-shopping and other consumerist behaviors. 
Consumerism was evidenced by the use of coupons for prescription drugs, patient instigation 
of a diagnosis or prescription, and awareness of “doctor-shopping” (the practice of finding a 
physician who will give you your desired prescription). 
Two of the physicians mentioned that patients had entered the office visit with coupons for a 
free trial of a specific sleep drug. 
At some point he said he wanted to try, it was pretty early on, he wanted to try 
Ambien. In fact, he brought in a coupon, said, you know I can get these free with this 
coupon. I’d just like to try it and see if it helps because sometimes I have trouble 
sleeping. And you know, so I thought sure you know you‘ve got a coupon you want to 
try sometimes, that’s fine. (Doc 3) 
 
Physician 1 noted quizzes in addition to coupons.  
KI: Oh yeah, I see coupons. But it’s not new to Ambien I mean they do it for Viagra 
for all those things, you know…. And somebody will say I took the Pfizer quiz and I 
need the medicine 
I: And how do you respond? 
KI: I just simply tell them. I say, well, think about it for a moment, if I were your car 
salesman I could give you a quiz to make you want to buy my car. (Doc 1) 
 
Physician 3 also noted how patients are more likely to bring up the issues of sleep, and in his 
estimation, they “bring it up all the time.” 
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Um, patients in my experience patients almost always bring it up. I don’t ask about it 
as a general routine thing. It’s such a, it’s so common to have occasional insomnia, 
that, I just have never found it useful to ask about it. But people bring it up all the 
time….Most have seen commercials or talked to friends that take medicine for the 
insomnia and have an impression that medicine would help them. (Doc 3) 
 
When I asked Physician 1 to give me an example of an instance where he had refused to 
prescribe a requested medication, his answer hinted at the concept of “doctor-shopping.” 
KI: Oh well I’ve had people, matter of fact, who stopped coming. 
I: What do you think their next course of action is? 
KI: They’ll find a doctor who will give it to them. And that’s not too hard. (Doc 1) 
 
Physician 5 also referred to the healthcare system as a “marketplace.” 
So this is why direct to consumer advertising is insidious because patients hear one 
thing from the TV and then their friends and then the physician’s put into a position 
of contradicting a belief that the patient has already established. And it’s not a 
therapeutic situation for a generalist physician who’s expected to kind of monitor a 
variety of problems. You know the rheumatologist for this person can always decide 
that this sleeping aid, and appropriately, is not what they have to deal with. “Go ask 
your primary care doctor.” So that’s what makes it difficult for primary care. 
Because I know the patients, it’s a marketplace, a lot of them could go out and find a 
doctor and also get samples. (Doc 5) 
 
He also gave a specific example of a patient who had “doctor-shopped.” 
But you know, interestingly, people will get what they want. So I have a patient who’s 
very loyal to me because I diagnosed her with a very unusual disease, well not so 
much an unusual disease but a serious disease at a young age. And she comes to me 
and she’s on Lunesta and something else, so I know she’s seeing another doctor. And 
I never prescribe Lunesta but I know she’s seeing another doctor who’s prescribing 
this. And it probably started out of the sample cabinet, but I don’t refill it for her.  
(Doc 5) 
 
 
Physician compliance 
The following paragraphs outline some potential contributions to physician 
compliance : time constraints, “soft bias”, pre-existing prescriptions, and patient compliance. 
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Time constraints 
One physician mentioned the issue of sleep three times during the interview. It 
initially came up about midway through the interview. 
Are you spending more time talking about their insomnia than you could be talking 
about, because you only have 20 minutes with them, than their preventive medicine or 
other things that might be more of an impact on their health. But it does. (Doc 2) 
 
Once the recorder was turned off, this physician became somewhat more relaxed and candid 
and the issue of time was re-introduced. With his permission, I restarted the recorder: 
Sometimes if a patient has a lot of complaints and other health problems and they 
mention their insomnia and they’re interested in a medication sometimes it’s easier to 
write the prescription than it is to take a lot of time talking about behavioral 
modification. I always do try to talk about it, but sometimes there are just I think 
there are days that you write it, without. And you, well, you readdress it, but you do 
write it without much more discussion than that. (And a moment later) 
And sometimes you feel bad for people who are just trying to be informed about their 
health and then their sources are getting them more and more confused. And then it’s 
for us, confusing because it’s taking us time we could be taking care of our patients 
with what we have perceived as being,  not meaningful but really will help them. So, 
cardiovascular prevention, or cancer prevention, but we’re spending all this time 
talking about sleep. And that’s, to them what they’re focused on. But really what I’m 
focused on is your blood pressure is really high or this other issue, so it can be hard. 
(Doc 2) 
 
Physicians also spoke of conflicts that may occur during time negotiation. 
And you know, we negotiate….and it’s an unspoken negotiation at times and even 
negotiation itself the very act sometimes involves conflict and resolving conflict as 
you go. And first of all, there’s not necessarily time to resolve all these little conflicts 
or these latent conflicts. And second of all you have to balance that kind of 
negotiation against the really important business, the really important business of the 
clinic visit. (Doc 5) 
 
Physician 8 echoed these sentiments. 
And also, I mean I think the other thing that would be interesting to explore is what 
are the other competing issues that are in the visit. So, if this is all I was dealing with 
then I might in certain people take more time than otherwise I might not if I’m also 
dealing with their diabetes, their hypertension and all their social issues that may be 
impeding their ability to take care of themselves. (Doc 8) 
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Related to time is when during the office visit the complaint of insomnia arises.  
It’s never the center of the visit and most likely it’s at the tail end, when you’ve 
already finished evaluating things. In your mind you’re done with the visit and ready 
to go on to see the next patient and you know, maybe the last thing you do is the 
paperwork and write prescriptions and they say “And will you refill my Ambien?” 
And you so sort of, you know, maybe you’ve forgotten they’re on it. But now are not 
prepared to address it in any detail. And you sort of assume “I guess I’ve already 
been through this before because I’ve prescribed it before.” And so you say “Oh 
yeah, what dose are you taking? And how many nights a week do you use it?” (Doc 
7) 
 
“Soft bias” 
In this section I discuss what I have termed “soft bias”25 against sleep aids. In cases 
where they did not feel it posed a danger to the patient’s health or was counter-indicated by 
some other condition or medication interaction, the majority of physicians in this sample 
were comfortable with, if not enthusiastic about, prescribing sedative hypnotics for sleep. 
However, these physicians also noted the habit-forming nature of most sleep aids, as well as 
the negative side effects they are likely to engender in older populations. 
Only two physicians indicated that they routinely refused to prescribe sleep aids.  One 
physician discussed his preference not to use sedatives for sleeplessness, instead urging 
patients to try sleep hygiene practices,  but called it a “soft bias”  against medication. 
Oftentimes people will say they’re doing all of those things. Or they’ll say, yeah, I 
have a TV in my room but that’s not what’s keeping me awake. So, I talk about [sleep 
hygiene] every time because I have this bias against prescribing a lot of the sleep 
medicine. But on the flip side of that, it’s a very soft bias. The flip side of that bias is 
that I know for some people it really makes their lives better and so I don’t mind 
prescribing it that much. But I have this, I don’t know if it has to do with my values or 
my own biases in life but I feel like I need to try and get them to manage their sleep 
without medications. And you know, I’ll tell them you can get hooked on these 
medications and things like that. And a lot of patients actually when you start talking 
about it they’ll say, yeah I’d rather not try medicine yet. Let me see if I can do ok. 
And then a lot of patients just want something for the hard nights. (Doc 3) 
 
                                                          
25
 Derived from Physician 3’s quote. 
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Another viewpoint expressed is that while these drugs may not be particularly helpful, they 
are not particularly harmful either. 
But I do, people will often bring up sleep problems and we’ll talk about it, and I’ll 
make recommendations for behavioral changes and lifestyle changes and I won’t 
offer the medication even though I can sense that they might like on. And if they don’t 
push me on it then we’ll just say you know, let’s see how this goes and we’ll 
reevaluate next month when you come in and we’ll see if this takes care of it. If they 
push back and they say I really want a medicine for this then I’ll let them try a 
medicine. I don’t feel like I have to engage in that sort of, I don’t know, it feels very 
parental to me and it’s not something that’s going to hurt them, then I’m ok….And at 
the end of the day it’s really a values question because some of these things are not 
that helpful. They cost money. And is it, you know are they, is it really bad for 
patients to take an Ambien every night? It may not be the end of the world. Might cost 
our healthcare system a lot of money and that may be bad if we thought about things 
that way, but we don’t think about things that way in our country. (Doc 3) 
 
Near the end of the interview, Physician 5 mentioned some rare but bizarre side effects of 
prescription sleep aids. 
Someone told me a funny story recently about of friend of theirs who was, you know it 
was like a doctor who ended up taking some Ambien. Next thing you know he was out 
in the road naked or something like that. [laughs] No seriously. Fortunately the 
people who picked him up realized that he was probably completely psychologically 
deranged at that time. And you know I’ve seen like a Baptist minister try to take off a 
nurse’s clothes in the hospital once when he was given a dose of Ambien. He became 
disinhibited. It was really. But I’ve seen that with the Benzodiazepines, people have 
these paradoxical reactions to sedative hypnotics. And you certainly see that with 
alcohol. There are some people who are meek and mild and you give them a few 
drinks and the next thing you know, they’re a raging bull. So, you know, and the 
alcohol works on a similar set of receptors in the brain. (Doc 5) 
 
In addition, he discussed their potential for addiction. 
And they’ve [NBSHs] never even been shown to be safer, cause less dependence than 
the benzodiazepines. You know there’s a lot. The Benzodiazepines were certainly 
overused for a while. Not mainly for insomnia but for anxiety and other psychiatric 
disorders. They certainly can cause physiologic and psychologic dependence, the 
latter which we call addiction. But you would be hard pressed to find a clinical trial 
that compares the addictive potential of the new drugs, Lunesta, Sonata, Ambien to 
the Benzodiazepines. Its been suggested that they’re less addictive and it’s perplexing 
to me that some of the commercials can say that they’re not habit forming, when 
indeed they’re scheduled, they’re controlled substances. You have to have a special 
license to prescribe them. A DEA license. And certainly we see clinically that people 
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become psychologically and physically dependent on them. And I don’t think there’s 
any proof that they’re less apt to cause that. It’s been suggested, but there’s not a 
clinical trial that I know of, that shows it. (Doc 5) 
 
In fact, when other physicians mentioned concern about sleep aids, their most common issue 
was the issue of dependence.  
I struggle a lot with the medicines. You know, I think that um, you know, I worry that 
patients will rely on them and that their sleep cycles will become disrupted. So I um, I 
try to focus on the behavioral. (Doc 2) 
 
Well, I think Ambien is certainly habit-forming.  Um, the others probably too. I don’t 
know with the dependency. I’m not sure you could say they’re addicting, to take it 
once a day a short acting, you know, you don’t crave it. They’re habit forming 
because, and I think you get a rebound. Maybe just from my own experience, taking 
them for jetlag for a few days and then leaving it off and staying up a lot. And um, 
and I think. So um, I think again there’s sort of, there is a bit of a dependency. (Doc 
7) 
 
Ironically, this physician also mentioned that a pre-existing dependence may in fact lead him 
to just refill the prescription. 
And then I may, you know, if somebody’s using [Ambien] every night I may try to 
address that. Or if they’re, actually if they’re using it every night I feel like it’s 
already a lost cause. If they’re using it three or four nights a week I may say, you 
know that’s sounding like you’re really getting dependent upon it and maybe we 
ought to try to cut back a little bit. And you know, give them quantities to reflect that. 
Maybe some effort to cut back. If they say they’re taking it every night, and I do have 
some patients that are doing that and I think have probably just gotten there by 
gradually over the years, then I just am likely to have given up on it, and I say OK, 
here it is. With refills. (Doc 7) 
 
Another concern about sleep aids, even those that are sold over the counter, is their use in 
older populations. 
I mean you kind of get into when somebody gets frail and elderly you begin to worry 
that they’re going to fall on the way to the bathroom in the middle of the night. But or 
that maybe when they start having their mild cognitive impairment that they’re 
having some drug effect left over the next day that is impairing their cognitive 
function….The harms are more in the frail elderly.  (Doc 7) 
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Like elderly folks, you really shouldn’t prescribe antihistamines because they can 
have delirium and things like that. So there are some side effects, but Benadryl 
generally is pretty innocuous. I don’t think it’s really hurting anyone but I guess I’ve 
just been taught in my years of education that it wasn’t a  great sleeping medication. 
(Doc 3) 
 
Pre-existing prescription 
Two of the eight physicians denied prescribing sedative hypnotics to their patients 
with sleep problems. There was one exception to their refusal stance, borne out by both their 
own admission and the hospital database-generated records from the prior 6 months. These 
physicians allowed that they would continue a prescription for sedative hypnotic that had 
been originally prescribed by another physician, even if they would not necessarily prescribe 
it themselves.  
Yeah, I’ve had a couple of older folks who come in who were living over at some of 
the higher-rent, you know, assisted living, who had been taking medicines for years. 
The doctor’s given them Ambien or Lorazepam for years so they think since maybe 
their spouse died and they were a little excited, just kept on it. And I say to them, you 
know, well I’m not going to, I really don’t think you should take it. We’ll give you a 
schedule for tapering a dose down to remove it. And most of them when they do it feel 
better, but it impairs their memory, it does a lot of things. I just don’t see any reason 
for them to be on it. (Doc 1) 
 
One physician noted that a certain set of older female patients were quite interested in 
maintaining their prescription for Valium and would request it specifically. 
It’s much more likely to be benzos that they’ve been on forever. So in our practice 
there’s older women who’ve been on valium for 100 million years. And it’s like 
(shrugs) yes, you can have your valium. They’re not escalating but they were put on it 
as mother’s little helper and they’ve been on it. And so unfortunately they’re going to 
continue that. And I’ve had people especially ask for that. Valium. I want my valium. 
70 year old women. 80 year old women….I’ll say, don’t we want to start something 
longer acting like this clonazepman. NO! I want my valium! [Laughs] (Doc 8) 
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This physician admitted he was willing to prescribe outside of his comfort zone, in order to 
continue a patient’s prescription from a previous physician. 
And um, with Ambien at least, which is the one that I prescribe. I haven’t gotten used 
to prescribing Sonata or any of the others, I don’t even know if they’re still out. 
[laughs] and I don’t prescribe benzos for sleep, unless someone comes to me and 
they’ve been taking it for 20 years, and then I’ll just continue prescribing it. (Doc 3) 
 
Patient Compliance 
While all of the doctors in this sample said they discussed sleep hygiene with their patients, 
they were cognizant that some patients “just want the medicine.”  
Every time this comes up I give them the sleep hygiene talk. And I get these looks 
back at me like I just want a medicine. Is kind of how I feel at least, maybe they’re not 
thinking that way, but. (Doc 3) 
 
Some physicians indicated that offering a treatment based on patient request was one way to 
gain compliance. In response to the question “How much influence on your ultimate decision 
does patient request play?” one physician answered: 
 
A lot. Since there’s not, since I don’t feel like there’s a whole lot of difference 
between them. And if they have an idea what’s going to be beneficial, then there 
doesn’t seem to be any advantage to contradicting them and saying, well why don’t 
you take this instead. It sort of sets me up for failure. Like for them to say, oh, well I 
tried this that you suggested and it didn’t work. [laughs] so, since I don’t have a 
whole lot invested in which one they use then I might, then there’s no point in being 
contradictory about it. (Doc 7) 
 
When asked if he ever designed a treatment plan, based on how well he thought a patient 
would comply with it, one candid physician said, “Yeah, that’s a hard question. I mean I 
think we probably always do, but we wouldn’t admit that we do. Yeah.” (Doc 8) 
One physician talked about physician compliance could extend well beyond the sleep 
drug. In certain cases, he felt that allowing a sleep drug enabled him to keep the patient 
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compliant with the more serious health issues he was dealing with. This quote is quite 
layered and also encompasses themes such as: role of insurance company, doctor shopping, 
and DTCA. 
I have a patient who is a PhD researcher, semi-retired here in his 8th decade of life. 
Who is absolutely insistent that these make his quality of life so much better. He takes 
them every night. We’ve had some struggles about prior authorization. I’ve had to set 
some limits because he assumes that I’m going to fill out all this paperwork. And I’ve 
told him that I don’t fill out the paperwork, my staff will and they’ll do it when they 
get around to it. But I do not call 800 numbers as a physician to get prior 
authorization for sleeping meds. And I think we’ve come to some equilibrium. And he 
can always find another doctor if he doesn’t like the way I approach his sleeping 
medicine issue. But for something that’s not, as I see, a compelling public health 
[issue]. And he came to me on these medicines, so this was not a conversation that I 
initiated. So it’s very hard to take someone off that. Especially when they have several 
other needs like diabetes and high blood pressure and that you need to keep that 
person in your clinic because you realize that you can give them. You know, you’re 
negotiating with them, so I think that’s a relatively small price to pay to keep them, to 
let this person stay on a medicine that he takes every night. Which I know he doesn’t, 
he shouldn’t probably be taking every night because it’s probably no longer effective. 
But at the same time I’m balancing that against the fact that I realize that there’s 
quite a bit of good that I can do, and that this clinic can do in making sure that his 
diabetes and hypertension are well-controlled. So it’s kind of like the real politique of 
medicine. You’re going to ignore a few, ignore a few, put up with a few sub-optimal 
practices because you know that the impact on the other ones can so outweigh that. 
And that’s what I’m often dealing with in my very complex population is that I’m not 
making an issue of it and of course this works very much to the advantage of industry. 
They realize if physicians feel committed to their patients and I can’t, conflict is 
definitely counter-therapeutic in clinical medicine. So this is why direct to consumer 
advertising is insidious because patients hear one thing from the TV and then their 
friends and then the physician’s put into a position of contradicting a belief that the 
patient has already established. (Doc 5) 
 
Rhetorical authority 
As noted in the background section, the concept of rhetorical authority describes the 
phenomena wherein patients seek and receive medical knowledge from non-medical sources 
(Kroll-Smith 2003). These sources vary, but physicians in this sample noted several, 
including direct-to-consumer advertising (DTCA), social networks and the internet). 
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Direct-To-Consumer Advertising (DTCA) 
By far, the most commonly discussed source of rhetorical authority was that of 
DTCA. 
Whereas it’s possible that in the past it was something that, well, yeah I had some 
sleepless nights but I’m not going to bring that up, that’s not going to be the major 
issue that I discuss with my doctor. But all of a sudden this is something that we can 
treat with medications that are appealing. So, I don’t know exactly, I suspect DTCA 
has some effect but it may not be directly through, you know, telling the patient, the 
patient coming in and asking me. It may be that we’ve just raised the awareness and 
comfort level with talking about it across society and DTCA is one factor in 
increasing that awareness….So I don’t know, that’s kind of how I think about it. I 
can’t, I’m not willing to lay all the blame on DTC but I’m sure it plays a role. (Doc 3) 
 
Some of the physicians in this sample had fairly negative feelings toward DTCA and the 
effect it had on the patient’s knowledge and/or the patient-physician interaction. This 
physician describes his negative feelings, as well as noting the propensity to self-diagnose. 
I: Would you say that it’s common for patients to come in and request a specific drug 
for sleep? 
KI: Ask for a specific one? [Yeah] Yeah, I mean I think people will come for what 
they‘ve seen on TV or in the magazines and say Oh, I want Ambien CR instead of 
Ambien. You know and they’ll ask, what do you think of that? So yes, people very 
often specifically ask for medications by name.  
I:  And what do you think of that?  
KI: I struggle with that. I think it’s terrible. I actually really hate it. I think that, you 
know, if the patient has a particular idea of what they want before they see you, it can 
be hard. It can be hard to make sure you’re doing the right thing for them and, and if 
that’s they’re expectation is that they’re going to leave with that medicine. You know, 
are they relying on what your expertise is? And are they going to be unhappy unless 
they get this medicine. And sometimes they’ll come in with cards that they’ve ripped 
out from the magazines that say get your 10 day free trial of this one. So, you know, I 
struggle with it. But sometimes if they’re, you know, I will, I’ll say fine, this is the way 
I approach it and I try to go through it with them. But if this is what you’re very 
interested in, ok, I’ll write you for it….It makes me sort of laugh in some senses. It’s 
like, they come in with the treatment, you know, without even going through the 
diagnostic process. (Doc 2) 
 
Physician 4 talked extensively about rhetorical authority, and its pros and cons. 
The way our medical system is established and they way it works is you know we live 
in a capitalist system so the pharmaceutical company is there to make a profit, 
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understandably, so what they do is they will do direct marketing.  What they want to 
do and I guess you can understand this from a business-end perspective is that they 
want to sell their product to people so they will put that, sort of make that very known 
to someone so they will go in and ask physicians about that so, that is across all 
different medications I think that that happens. (Doc 4) 
 
When asked how he felt about these outside sources of information, he clarified his stance. 
So first of all I think that is a good thing and the way I have been trained is to have a 
lot of that push and pull and that is again, so my philosophy in medicine is that is 
what I like to do with patients, I like to talk with patients. So, I like people to be 
informed and I welcome people reading on the outside.  I think that is a great thing.  
The medical system we are in right now is not such that it is practical to have the all-
knowing and it was never even a reality, you know, the all-knowing physician being a 
paternalistic, for lack of a better word, person guiding the patient.  So what we have 
now is a lot more interaction and push and pull.  Now the problem I have there is I 
think that push and pull, or a lot of that information is not the best. So when the drug 
companies give that information I think people are skewed in lots of different 
directions. So you know the challenge with that is finding a clear source of 
information for patients to use to advocate for themselves and you have 
pharmaceutical companies who are, they have some hopes to advocate for a patient 
but they are trying to make a profit also, so that is clear.  It is sort of a double edged 
sword, you know. (Doc 4) 
 
Other doctors took issue with the tactics of drug companies. 
I try to be very clear with my patients that they um, that there’s no evidence that any 
one of them are better than the other. And that obviously the advertising can’t suggest 
that. It doesn’t, it’s illegal for them to state that one sleep aid works better than the 
other. You’ll never see that. And in fact, the classic example is the one you see for 
pain medicines. “Nothing works better than Advil.” That’s how it’s phrased. But it’s 
absolutely illegal the company will get fined if the company says Advil works better 
than Aleve. But nothing works better is an interesting semantic subterfuge…..well 
nothing else works better because they’re all equally….But they can’t say their 
products are any better than the older ones. They can’t even say, interesting, 
although they say they’re not habit-forming. I don’t even think they’re allowed to, 
they’re not allowed to say they’re less habit forming than older sleep medicines. But 
to the non-sophisticated public, or less sophisticated about the laws and regulation 
regarding detailing of drugs, don’t recognize that distinction. That semantic 
distinction. You know, you can’t get away with submitting a peer reviewed paper by 
initiating a comparison and not completing it. And if you had a high school English 
teacher who was paying attention, they would take 3 points off your essay because 
you did not complete your comparison. But that’s marketing. So they can’t say that 
they’re better, and they can’t say that they’re safer, explicitly. But it’s strongly 
implied in the presentations of their ads. (Doc 5) 
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Social Networks 
Other sources of RA include friends or family. 
Or it’s something their friends took. And, I even had a patient one day who started 
talking a little bit about sleep. And we had a very candid discussion about it. And you 
know, she was wanting to get something for travel. Which I’m fine with. You know, 
people are traveling. But she said, you know I went on a weekend away with, I think 
she’s about 60 this woman, with a bunch of my female friends and every single one of 
them was on Ambien. And she laughed at that. She actually thought it was, you know. 
Do all of us really have all these problems and need to be on this medicine? So, I 
think they also hear what they’re friends are taking and so it kind of explodes the 
number of people who are taking these medications.  And it’s hard to argue. It’s often 
hard to argue with patients. You know, if they perceive that they have a problem with 
sleep, it’s sometimes hard to talk them into that, after talking and taking the history 
and seeing that they’re able to accomplish the things during the day, it’s still hard to 
make them believe that they don’t have a problem with it. (Doc 2) 
 
One physician discussed the interplay between commercials and social networks.  
I suspect that direct to consumer advertising probably makes the conversation about 
that much more common. So a lot of my patients aren’t coming in saying that they 
saw a commercial. Although, I guess everyone’s seen a commercial by now, because 
these medicines are always advertised. But a lot of them have talked to their friends 
how have been on medication. And so, you kind of, you know, it’s like the diffusion of 
innovation curve, I don’t know if you’re familiar with that, or if you’ve read the 
tipping point. This notion that as soon as something becomes prevalent in society it 
spreads really fast like a wildfire. So if you start doing direct to consumer advertising 
and you get a few more people on these medications and you get people starting to 
talk about it. Somebody mentions at a cocktail party oh yeah, I take Ambien. (Doc 3) 
 
Internet 
Although he specifically cites the dangers of the internet, this physician makes it clear 
that it is not so much the vehicle, but the message that is troubling. 
I: Do you think that you’ve seen any effects of direct to consumer advertising in terms 
of the way that patients talk to you about specific drugs? 
 
KI: Yeah. Not so much sleep, sleep pills. I think because there’s so much already out 
about sleep pills, but and I would say, not so much television. Although I think it does 
have an effect and the drug companies control it, but the Internet is your biggest 
enemy. There’s so much garbage on the Internet. Ah, that’s where we find our biggest 
enemy. 
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I: Tell me more about that. 
 
KI: Well, someone will look up and say gee, you know, I have this, I have this disease 
and I need this medicine for it because somebody said so on the Internet…. And so, 
the point here is that the capacity to distinguish between good and bad information, 
whether it be on the television or on the Internet just isn’t reachable by most folks. 
They don’t know how to evaluate critically. So, ah and they almost always will begin 
with the following “What your doctor doesn’t know…” is the introduction. “What 
your doctor hasn’t told you…” or “What your doctor is keeping from you…” to make 
it seem like, you know, if you’re not espousing, because you’ve got some sort of secret 
vendetta against their product. (Doc 1) 
 
One physician mentioned another sleep disorder that he has had patients self-diagnose with, 
based on internet information. 
A few people have been on the internet for restless leg. Like, this has got to be what I 
have. Because I’ve read on the internet and this is my diagnosis and I’ve got to be on 
something for it. (Doc 8) 
 
It is worth noting that one physician actually encouraged the use of the internet to promote 
sleep hygiene. 
I used to go through the whole rigmarole about sleep hygiene and now it’s 
convenient, particularly if my patient has internet access, I write down “sleep 
hygiene” and say Google this and you’re going to find a whole bunch of information 
about behaviors that can help you overcome insomnia. (Doc 7) 
 
Knowledge Alignment 
As previously noted, the fact that this particular group of physicians does not 
currently have regular interaction with drug company representatives , making this sample 
less than ideal in terms of ascertaining the influence of the drug companies on the knowledge 
about sleep disorders. However, this lack of regular interaction did not preclude them from 
having thoughts on the matter.  
I certainly get patients coming in lobbying for a particular medicine…. you know, 
they’ve gotten samples of it. Our clinic, you know, samples, we can just end that part 
of the discussion now. We don’t keep samples in our clinics so.  But you know, having 
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samples available to physicians is a powerful tool in the hands of the pharmaceutical 
companies to popularize a new product. I don’t know what the literature is on 
detailing physicians in terms of whether it improves patient care, or physician 
education. The pharmacy companies would argue that it does. I do know the 
literature because I’m an educator of residents that there’s not a single study ever 
that shows that pharmaceutical influence on resident physicians improves how care is 
delivered. They almost all show that it promotes bad decision making. That the 
literature on detailing residents, taking them to dinner and giving them pens, that 
they’re more likely to make non-guideline based, non-evidence based decisions when 
treating physicians. There may be a separate, parallel literature looking at physicians 
already out of residency and practice. So there’s no reason to believe that this will 
have a beneficial effect on physician practice. And from at least the resident 
physician literature, there’s every reason to believe that this kind of promotion to 
patients and physicians by the commercial interests alone will have a negative 
impact.  (Doc 5) 
 
One physician compared the motives of sleep aid makers to those of the cigarette companies. 
Yes, I mean it’s, does it concern me, yeah. Well it’s sort of a commercial thing isn’t 
it? I mean, it’s all about making money. And I think, that the drug companies, it’s like 
the cigarette companies have de-emphasized that these drugs are habit forming. But 
there’s not near enough information about that out that so that people understand 
that that’s the case. I mean it’s so self-serving to be able to market something that’s 
habit-forming isn’t it. (Doc 7) 
 
Physician 1 had been in the department for many years and had seen drugs reps come and go. 
He emphatically told me the following: 
My policy has been from Day 1, I do not see drug reps. I don’t talk to them. I don’t 
take any of their pills, I don’t take pens, I don’t take anything. And some years ago 
when I was assistant chair of the department what we did is we got rid of all the 
lunches that they supplied for the house staff. Because I felt that it was not ethical. 
For many reasons. And then for a while after I left they started having them back. But 
now I think the policy is not having them. But, I just simply think that it’s not a good 
way to get information. Information is biased, it can be. And I don’t think it’s a good 
way to, to show young people about the best way to get information. I have never 
talked to drug reps. Never. (Doc 1) 
 
Influence of insurance companies 
An unexpected addition to my set of theorized influences was that of insurance 
companies. Recently, insurance companies have limited the amount of sleep aids that can be 
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prescribed in a month. This increased bureaucracy was viewed in both negative and positive 
ways. 
No, you know the principle issue that we have to confront is what insurances will pay 
for. So, I mean that’s where it gets to be problematic because getting multiple forms 
to fill out and send back in. A lot of times patients don’t want to have another patient 
encounter in order to get their prescription refilled. We don’t make people come in to 
get refills. So that’s work being done for free in time that I’m supposed to be doing 
something else. So every time you get 2 or 3 forms for the prior authorization, for this 
and that, that becomes the onerous part. So trying to avoid that is kind of important. 
(Doc 6) 
 
One physician saw the limitations enacted by the insurance companies as potentially helpful 
to the physician. 
You know I think I generally when it comes to prescriptions I really try to have 
exhausted is there anything else underlying like sleep apnea or a problem. Are you 
really following behavior modification and then, I’ll try the medications for sleep. 
And generally if I’m the first person to meet, you know, to discuss this with a patient I 
will try to say, OK, something like Ambien, I don’t want you to take it every night. But 
if you kind of need it for two or three nights and then go back to not taking it. So try 
to use it kind of re-set. The idea is like re-setting. And actually the insurance 
companies are helping us with that because they’re not covering, they’re not all 
covering patients for every night taking Ambien. They’re only giving them 15  a 
month or something like that. So, I wouldn’t say, helping, but they’re trying to limit it. 
(Doc2) 
 
Another physician emphatically felt that getting involved in prior authorization for sleep aids 
was a waste of his time. 
I’ve had them come in and ask for Ambien CR and I frankly just tell them. I mean, if 
they have insurance, yeah I’ll write you the Rx but if your insurance company balks, 
I’m not going to fill out the extra paperwork, I mean that’s, just so you can this drug. 
And interestingly I’m not tormented with too much extra paperwork for the sleep aids. 
Because I think in this case the insurers have drawn a line. They don’t really even 
want to pay for them at all in general. They either pay for them or they don’t and I 
don’t get too involved in having to do what are called prior authorizations for sleep 
aids. (Doc 5) 
 
He even gave a specific example of refusing to do the extra paperwork for a patient, and the 
patient’s reaction.  
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I had a patient who was already on Ambien and he wanted Lunesta and I said I don’t 
think it’s going to work any better. And I think at one point I did prescribe it, but then 
his insurer came back and wanted all this proof that he’d failed other trials and I said 
bluntly, I don’t have the time to do this. And it’s not a good use of my time and I’m 
not going to do it. And he wasn’t happy about it. But I let him know. (Doc 5) 
 
In sum, physicians in this sample offered insight into the medicalization process 
through the language they used to discuss medicalization, their attitudes toward insomnia 
diagnosis and treatment and their prescribing behaviors. A confluence of factors including 
consumerism, physician compliance, rhetorical authority, knowledge alignment and the 
influence of insurance companies seem to be contributing to the medicalization of insomnia 
via the patient-physician interaction. 
I end this section with the following lengthy, but interesting, physician quote. I ask 
the reader to consider two things: a) Does this quote reflect a reality that some of us are all 
too familiar with? and b) Is this patient using Ambien to treat a sleep disorder, or something 
else? 
But you know, because I’m like this myself, I know that when he lies down to go to 
sleep his mind is spinning on 3 different grants he has to write and it’s hard to shut 
one’s mind off. And he’s gotten in this cycle, I think, where he’s not able to separate 
himself from his work very well and it’s interfering with his sleep. And we’ve talked 
about that and you know, should he cut back, how should he deal with this. And kind 
of when push came to shove when he takes the Ambien he does fine. He sleeps wel. 
He wakes up refreshed. He’s able to be productive at work and he can do all the 
things he likes to do, so he’d like to stay on the Ambien. And you know, I’d 
offered[psychological] therapy to him, I recall and he really wasn’t interested in 
pursuing that….I actually have a few professors [laughs] that are kind of in that 
category. And it’s interesting because I, I think in those cases I sort of relate because 
I have had times when I’ve been really busy and I’ve woken up early with work on my 
mind…..I guess I feel like I sense what they’re describing as going on in their mind 
and why they have trouble turning things off.  But I’ve found that they, I’m thinking of 
another professor in my mind right now whose also really kind of high-powered 
successful person who would rather keep going at his pace than trying to slow down 
and maybe have a little more work like that. Now this is my hypothesis that they’re 
driving themselves too hard and they can’t turn off because they’re working right up 
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until the time when they hop into bed and they’re working as soon as they wake up. 
(Doc 3) 
 
Discussion 
In the following section, I provide an overview of my findings. More in-depth 
discussion, linking these findings to the patient interviews and the quantitative findings, is 
available in Chapter 6. 
In order to gain insight into the patient-physician interaction surrounding 
sleeplessness and explore the forces that might be fueling the medicalization process, I 
conducted in-person, semi-structured interviews with 8 physicians who practice in an Internal 
Medicine Clinic. Focusing on the language they use to describe medicalization, their attitudes 
toward insomnia and their reported prescribing behaviors, I gained insight into several 
factors that influence the patient-physician interaction. These factors include consumerism 
among patients, physician compliance, rhetorical authority, knowledge alignment, and to 
some degree, the influence of insurance and drug companies. Evidence from these interviews 
seems to indicate that the medicalization of insomnia is occurring. 
Physicians in this sample seemed keenly aware of the medicalization process and 
used sociological language  - including the terms “medicalize,” “disease mongering” and 
“case-findingness” to describe it. Use of such ‘sociological’ language begs the question – do 
these physicians think about medicalization in the same way that Conrad and others have 
conceptualized it? I argue that their understanding of the concept is very sociological. 
Physicians in this sample not only use sociological terminology, but are also able to describe 
parts of the medicalization process (e.g. expansion of disease criteria), link it conceptually to 
fueling factors (e.g. DTCA), and give other examples (e.g. toenail fungus).  While their 
115 
proximity to and employment in an academic research center may facilitate this awareness, 
their academic insight is not necessarily a limitation of the study. However, it does lend itself 
to a follow-up study with physicians in the community. I suspect that non-academic 
physicians may not use precisely the same language, but they may have similar conceptions 
of the process and its prevalence. 
My respondents typically characterized insomnia as a normal process, often related to 
aging, or the symptom of another disorder, typically a mood disorder. They noted that 
individual or cultural norms seemed to be influencing their patients’ perceptions of sleep, 
their ideas of what was abnormal and thus treatable. Regardless of the root of the problem, 
however, these physicians indicated that their patients were not shy about asking for 
something to help them sleep. 
Physicians in this sample had mixed feelings about insomnia treatments. Despite the 
arsenal of sleep drugs at their disposal, every doctor I interviewed broached the topic of sleep 
hygiene; most asserted that it was their first line, or preferred, treatment. It is important to 
note that there are no consistent definitions of sleep hygiene and even these physicians, who 
all mentioned some sort of behavioral or lifestyle intervention were not necessarily consistent 
across the board. Nevertheless, I was told that some patients were not open to the idea of 
sleep hygiene or they just ‘wanted the medicine.’  
Trazodone was the preferred prescription treatment for most of these physicians, as it 
has few side effects and does not cause dependence. Benzodiazepines, despite their potential 
for addiction, were used by many of these doctors, particularly for older patients who had 
been on them for many years and were not escalating in their use of the drug. However, as 
seen in the NAMCS data, the most popular sleep drugs nationally and in this practice are the 
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newer-generation non-benzodiazepine sedative hypnotics. They are also, not coincidentally, 
the most heavily advertised, as will be explored in Chapter 6. 
 Physicians admitted that their prescribing behaviors were influence by a plethora of 
factors, including consumerism among patients. My respondents reported that patients asked 
for drugs by name and sometimes brought in pharmaceutical-company-produced coupons. 
While shifts in the patient physician relationship have eroded physician power, and rhetorical 
authority ensures that they are no longer the sole holders of an esoteric body of knowledge, 
physicians are still seen as the gatekeepers to prescription medications. However they are, to 
some degree, at the whim of the patient consumer, and they are not naïve to this fact. Some 
of these doctors showed great candor and admitted that patient preference did influence their 
prescribing choices, and that it could be used as a means of gaining patient compliance.  
The physicians I spoke with seemed cognizant that if patients were not given what 
they wanted they could, and would, take their business elsewhere. My respondents did not 
seem overly bothered by this, it was noted with little more than a shrug or a laugh – but given 
the intense commitment and dedication that each and every one of these physicians 
demonstrated towards their patients and practice, I do wonder if further probing would have 
revealed more frustration or dissatisfaction with this facet of consumerism. 
One interesting phenomenon I noted: all of the physicians in this sample had at least 
some degree of bias against the prescription sleep medications – ranging from flat-out refusal 
to prescribe them to patients not already taking them, to fears about dependence, to biases 
against their cost or lack of effectiveness. Most exhibited an attitude that one doctor called a 
“soft bias” – essentially, a mixture of concern about dependence or side effects, mitigated by 
mostly positive or neutral experience with the drugs leading them to conclude that they are 
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‘doing no harm.’ Regardless of their self-proclaimed ‘soft’ or ‘hard’ biases, every physician 
in this sample prescribed these medications, even if only in restricted quantities or in 
exceptional situations. This lack of parallel between attitude and behavior intrigued me and 
prompted me to recognize my vast over-simplification26 of the concept of physician 
compliance.  
As evidenced by these practitioners,  physician compliance is not merely the 
expectation or action of physicians accepting patient expertise regarding diagnosis or 
treatment (Freidson 1988), but a complex decision making process where physicians must, in 
a matter of minutes or even seconds, weigh a myriad of pros and cons and emerge with the 
best decision possible for an individual patient. 
In this study many things, including time constraints, influenced physician 
compliance. While these doctors may actually be able to spend more time with patients than 
the national average of 10 minutes (Stange 2007), they nevertheless discussed their limited 
time and how it affected their ability to listen to patients, prioritize health issues, and make 
decisions about withholding or prescribing medications.  
Another influence on physician compliance was the existence of a pre-existing 
prescription. Physicians in this sample indicated repeatedly that, even though they engage in 
primary care, their patients often come in with prescriptions written by other doctors, with 
the expectation of renewal or refill.  Even the two physicians who stated that they did not 
prescribe sleeping pills, did not necessarily refuse patients in the case of a pre-existing 
prescription. This apparently common scenario raises another issue - continuity of care. In 
                                                          
26
 In fairness,the bureaucratic pressures, psychological nuances and biological possibilities a physician must 
navigate in any given patient interaction are well beyond the scope of most of our experience and thus my lay 
understanding of physician compliance, even with these insights, is bound to be somewhat naïve. 
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sharp contrast to the ‘Golden Age of Doctoring’, patients, particularly older patients, may see 
multiple physicians concurrently. Doctors may or may not be aware of what these other 
physicians are prescribing –  and this fragmentation of care could be potentially dangerous. 
According to these physicians, patients commonly exhibited medical knowledge from 
non-medical sources. Rhetorical authority came from many sources including social 
networks and the Internet, but most commonly these physicians mentioned the influence of 
DTCA. These physicians noted a relationship between DTCA and patient request. While 
some had moderate feelings about it (“I’m not willing to lay all the blame on direct to 
consumer advertising, but I’m sure it plays a role”) others were more vehement in their 
feelings (“I think it’s terrible. I actually really hate it”). One physician made a connection 
between DTCA and the social networks that influenced their patients (“So if you start doing 
direct to consumer advertising and you get a few more people on these medications and you 
get people starting to talk about it. Somebody mentions it at a cocktail party. ‘Oh yeah, I take 
Ambien’.”). Although physicians in this sample do not have direct contact with drug 
company representatives, that did not dissuade them from having opinions on the drug 
companies and their means of pushing their products. One participant compared the motives 
of sleep aid makers to those of tobacco companies (“I mean it’s so self-serving to be able to 
market something that’s habit-forming, isn’t it?”). 
An unexpected finding was the influence of insurance companies. Increasingly, it 
seems, insurance companies are limiting the number of sleep aids that can be prescribed in a 
month. Perhaps it is the increasing awareness that, though promoted otherwise, these drugs 
can be quite habit forming and are in fact controlled substances. It may also be related to the 
2007 FDA warnings about the strange side effects that, though uncommon, can be quite 
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serious – or at the very least, embarrassing (as seen in the anecdote about the dis-inhibited 
Baptist Minister). One physician intimated that the drug companies might be, in fact, 
“helping” them by limiting the amount of drugs that patients can receive. 
In sum, multiple factors emerged that influence the patient-physician interaction 
surrounding insomnia including: consumerist attitudes on the part of the patient, 
predispositions to physician compliance, the prevalence of rhetorical authority, and the 
unexpected influence of the insurance companies in limiting sleep aids. Data from these 
interviews seems to indicate that physicians are aware of the medicalization of insomnia, and 
that it is in fact occurring through a confluence of factors – many of which seem outside of 
their control. The next chapter will explore insights from the patient interviews, and in 
Chapter 6, I will compare and contrast patient and physician attitudes toward insomnia and 
its treatments.  
 
 
  
CHAPTER 5 
PATIENT PERSPECTIVES ON SLEEPLESSNESS 
 
The objective of this chapter is to provide insight into the patient-physician 
interaction surrounding insomnia by exploring the patient perspective. In the following 
pages, I provide detailed methodology, qualitative findings from 27 patient interviews and a 
brief discussion. I focus on patient’s experience with insomnia, interactions with physicians, 
patient attitude toward insomnia treatment and sources of medical information from non-
medical sources. 
 
Methods 
Sample 
Recruitment 
I consulted the head physician in the Internal Medicine Clinic (IMC) to compile a list 
of prescription sleep drugs commonly used in the clinic. In order to collect a sample of 
patient participants, a list of National Drug Codes (NDCs) of these sedative hypnotics were 
submitted to the clinic database group on June 19, 2008. A query was run and I received a list 
of IMC patients who had been seen in the clinic and prescribed one or more of the following 
drugs within the previous 6 months: Ambien, (generic zolpidem), Ambien CR, trazadone, 
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triazolam, temazepam,Lunesta, Rozerem, or Sonata. In addition to patient names, I was given 
their address, telephone number and prescribing physician.27 
Physician participants were asked, prior to the initial interview, if they would be 
willing to help identify appropriate patient subjects. Physicians were given the query-
generated list of patients for whom they had prescribed a sedative hypnotic within the last 6 
months and asked to rule out patients who had been prescribed a sedative hypnotic for less 
than a four week period of time, patients who were prescribed a sedative hypnotic for travel 
purposes only, and patients who were not fluent in English.28 
Once identified, potential patient participants received a lead letter signed by their 
IMC primary care physician explaining the nature of my research project. The lead letter 
requested the patient’s permission to be contacted by a researcher (Mairead Eastin Moloney). 
Enclosed in the letter was a postage-paid, ‘opt-out’ postcard. Subjects were informed that 
they could either return the postcard in the mail if they do not wish to be contacted or simply 
refuse to participate when contacted by the interviewer via telephone. If I did not receive an 
opt-out postcard from a patient, I called them using an IRB-approved phone script and asked 
if they would like to participate in a research project on insomnia. Subjects were assured that 
their participation, or lack thereof, in no way affected their access to care at the IMC or its 
affiliated hospital. For examples of the follow-up letter to physicians, IRB-approved lead 
letter to patients, opt-out postcard and phone script, please see Appendices 6-9. 
 
 
 
                                                          
27
 This method did not capture patients who had received a paper prescription, nor those whose prescriptions 
had been called in to a pharmacy. 
28
 This criterion was necessary, due to my lack of fluency in a language other than English. 
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Interviews 
Patients were asked to participate in a face-to-face interview that would be conducted 
in a private office; patients unwilling or unable to conduct face-to-face interviews were given 
the option of participating in a phone interview. Interviews were semi-structured and lasted 
approximately 25 to 75 minutes. Patients were asked to sign an IRB-approved consent form. 
Both phone and in-person interviews, with the express consent of the participant, were taped 
and transcribed. Patients were asked to describe their experience of sleeplessness, their 
interaction(s) with physicians29 regarding their sleeplessness, other (non-medical) sources of 
information they may have consulted about their sleeplessness and any treatments they may 
have tried. Patients also filled out (in-person interviews), or responded to a short list of 
demographic questions, available in Appendix 10.  Strict measures were taken to protect 
confidentiality. Patients received a $25 gift card to Target department store for their 
participation.30 A copy of the IRB-approved interview questions is available in Appendix 11. 
 
Coding and Analysis 
The procedures for coding and analyses of the patient interviews were identical to 
those of the physician interviews. Please refer to pages 81-83. The code list, however, was 
somewhat different, and a copy is available in Appendix 12. 
 
 
 
                                                          
29
 Due to the small number of female physicians, in cases where a gendered pronoun is used by the patient, I 
have chanted it to the masculine. This is intended to provide an extra measure of confidentiality. 
30
 Two patients requested that the $25 instead be donated to the charity of their choice. These requests were 
honored.  
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Limitations 
These patients were sampled on the basis of a prescription for a sedative hypnotic. 
While useful in identifying patients who had seen their doctor with, and been treated for, a 
complaint of sleeplessness, it excludes patients who had successfully tried other methods of 
managing their sleeplessness.  
In addition, although I asked physicians to eliminate patient interview candidates 
based on the limited criteria noted above, it is possible (though unlikely, given their 
exclusion of very few patients) that physicians selected only patients from the list whom they 
thought would discuss their interactions in a positive light.  
The use of the IMC-affiliated hospital database to generate patient names and 
prescriptions for sedative hypnotics does not accurately represent all prescriptions written for 
sedative hypnotics in the IMC during the time period of interest. By using the database I 
potentially exclude paper prescriptions written, and those called in to a local pharmacy. 
Nevertheless, it was the most systematic option of data collection available and avoided 
creating extra work for the physicians, as well as the bias that would have resulted from 
asking physicians to ‘nominate’ patients for interview. 
Patients in this study, having received a lead letter from their primary care physician, 
may have feared that their interview responses would be reported back to their physician. 
Participants were assured that this was not the case, however, it is a valid possibility that the 
study’s connection to their physician altered their level of candor.  
Patients in this sample were asked if they thought they were influenced by direct-to-
consumer advertising. A follow-up question was “Do you think others might be influenced?” 
This may seem ‘leading’, but in fact has a related precedent in the literature. Studies have 
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been done in which health care professionals are asked if they think they are influenced by 
drug representatives and detailing. Most say no, but believe their colleagues are much more 
likely to be influenced. (For a recent example, see Wiley-Blackwell 2009.)  
Like the physician sample, the total number of participants interviewed is small, and 
patient level of education was higher than one would expect from a random sample. Thus, 
these results are not necessarily generalizable to other patient populations.   
 
Findings 
Of the 53 patients I contacted, 27 agreed to participate in this study. The majority of 
patients preferred to be interviewed over the phone; I conducted six in-person interviews. 
Ten of the participants were male. Three participants were African American; two refused to 
identify their race, and the remainder were Caucasian. Ages ranged from 31 to 78 and the 
average age was 50. This was an extremely well-educated sample. Ten participants had some 
form of advanced degrees (advanced degrees included: MA/MS, JD, RN, PhD, MD, 
PharmD). Eight held bachelor’s degrees and 6 had either some college, or an associate’s or 
technical degree. Two participants had high school diplomas and one participant had some 
high school education. Eighteen participants had private insurance. Ten had Medicare, and 
none had Medicaid. Five participants said they had no insurance and three of them mentioned 
that they received “charity care” at the IMC. For further detail of patient demographics, 
please see Table 14. 
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Table 14. Patient Demographics (N=27) 
#  of 
patients 
Patient 
Number DOB Sex Education Race 
Private 
Insurance Medicare Medicaid 
1 1 1940 M BA/BS Caucasian Y Y N 
2 2 1938 M JD Caucasian Y Y N 
3 3 1960 F some 
college 
Caucasian Y N N 
4 4 1961 F MA/MS Caucasian N Y N 
5 6 1947 F AA/tech Caucasian Y N N 
6 9 1957 M PhD/MD Caucasian Y N N 
7 12 1951 M BA/BS Caucasian Y N N 
8 14 1976 M BA/BS Caucasian Y N N 
9 16 1946 F some 
college 
Caucasian N N N 
10 17 1956 F some HS African 
American 
N N N 
11 19 1926 F RN Caucasian Y Y N 
12 21 1957 F some 
college 
African 
American 
N Y N 
13 22 1954 M MA/MS Caucasian Y N N 
14 23 1941 F PhD/MD Caucasian Y Y N 
15 25 1946 M HS African 
American 
N N N 
16 26 1925 M PhD/MD Caucasian Y Y N 
17 28 1955 F some 
college 
Caucasian N N N 
18 30 1956 M AA/tech Caucasian Y N N 
19 31 1978 F BA/BS NA N N N 
20 33 1940 F HS Caucasian N Y N 
21 34 1953 F BA/BS Caucasian Y N N 
22 37 1962 F BA/BS Caucasian Y N N 
23 38 1947 F BA/BS Caucasian Y N N 
24 39 1944 M MA/MS Caucasian Y N N 
25 42 1955 F PharmD Caucasian Y N N 
26 43 1931 F Some grad NA N Y N 
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school 
27 46 1937 F MA/MS Caucasian Y Y N 
Is there evidence of the medicalization of sleeplessness? If so, what forces might be 
fueling the process? To best answer these questions, I focus on the individual experience of 
insomnia, the interaction with the physician, patient attitudes toward insomnia treatments and 
sources of knowledge. Some of the themes that arose in these discussions paralleled themes 
from the physician interviews, including consumerism, physician compliance, time 
constraints of physicians, pre-existing prescriptions, rhetorical authority and the influence of 
insurance companies. Patient participants were unaware that I was doing a dissertation on 
medicalization and lacked the meta-awareness of the process possessed by physicians. Thus, 
explicit discussion of medicalization is limited. Unique to this chapter is the individual’s 
perspective of the causes and impacts of insomnia. An unexpected finding was the amount of 
unprompted discussion about fears of sleep drug dependence. 
 
The individual experience of insomnia 
Individuals spoke candidly about their experiences with insomnia. Symptoms 
typically entailed difficulty falling asleep and/or difficulty staying asleep. Most did not report 
early morning awakening. All reported experiencing insomnia symptoms for at least two 
years. One patient reported battling insomnia for the past 20 years and a couple of patients 
said that they had had trouble sleeping for as long as they “could remember.”  
KI: But I do have a lot of difficulty sleeping. I, going to sleep initially is not the big 
problem for me. But staying asleep through the night is. I usually wake up after 3, 4 
hours. Use the bathroom and then I have a LOT of difficulty getting back to sleep, 
way too often. Sometimes I read. And that gets my  mind off whatever it is I’m focused 
on that was causing concern for me. You know that’s the kind of thing that I, I think I 
dwell on at night and can forget about during the day. So reading, whatever I’m 
interested in reading, sometimes helps, sometimes I read in bed. Sometimes I go out 
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to the living room and read on the couch. But I am often awake for a couple of hours 
during the night. And um, that’s the story of my difficulty with sleeping. 
MM: Ok. So about how long have you been having these issues with your sleep. 
KI: I was thinking about that this morning because I figured that would be one of 
your questions.[laughing] I think about 20 years. (PT 46, emphasis, their own) 
 
This patient’s ‘normal’ bedtime is currently when most are waking up for the day. 
KI: I have trouble falling asleep. 
MM: Ok. Once you get to sleep you’re able to stay asleep? 
KI: Sometimes I am. Sometimes I’m not. 
MM: Ok, and what’s your regular bedtime. 
KI: Right now, it’s 6, 7 o’clock in the morning. (PT 31) 
 
This patient told her physician: 
Well, I said to him, you know, I just cannot keep going on. I’m so tired, I wake up at 
night. I can’t keep functioning because I’m absolutely exhausted. And I just have to, 
you know you’ve got to give me something so that I can sleep and stay asleep. I mean 
sometimes it’s not a problem going to sleep. It’s the waking up where I just cannot 
get back to sleep. (PT 3) 
 
A couple of patients told me that they dreaded trying to sleep at night. 
I told my daughter about 3 weeks ago I said, you know I dread to see bedtime come. 
Because it’s twisting, turning. I wake up some mornings ‘til my neck literally sore and 
hurting from twisting and turning. I get up; I sometimes get up three times a night. I 
come in here sit in a chair. Or go back, think I can lay back down. And I did the same 
thing last night. I got back up at 2 o'clock and come in here and read a little while 
and thought if I get out of the bedroom and do it, you know, I might get sleepy and 
could go back, go back to sleep. But it didn’t work. I was still awake at daylight this 
morning. And I don’t have anything on my mind, that, that’s what bothers me. That I, 
that it could keep me awake. And, I, I just, I don’t know what it is. (PT 33) 
 
Although an extreme example, this woman was simultaneously exhausted from lack of sleep 
and yet terrified of sleep.  
But you know what the deep sleep is what I’m afraid of. If I fall in a deep sleep when I 
wake up my body is traumatized. Like something’s happened in my sleep. I don’t 
know. Deep sleep. As long as I can be asleep and I can hear stuff going on around me 
then I’m fine. But if I go into a deep sleep, when I wake up it’s like, you know. Awful. 
Like I went somewhere that I didn’t want to be. (PT 12) 
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While patients communicated the discomforts of insomnia, when asked directly, few reported 
significant daytime impairments. This patient noted that it didn’t seem to have any ill effects. 
KI:  It’s mostly thinking about things that have happened. Well, actually I’m not even 
thinking half the time. I’m just lying there with my eyes wide open not really thinking 
about anything and just can’t simply go to sleep. I keep saying ‘this is stupid, go to 
sleep lady.’ 
MM: Tell me how, tell me a little bit about how not sleeping affects you during the 
daytime. 
KI: It actually doesn’t seem to affect me at all. (PT 19) 
 
The most commonly reported impairments were fatigue and irritability.  For instance, Patient 
21 told me, “If I haven’t slept for a couple of days I’m irritable. Extremely tired and 
fatigued.”  Another patient noted a feeling of depression, in addition to fatigue. 
Just a general feeling of tiredness. Feeling like I haven’t been to bed. [PAUSE] some 
general vague feelings of just, depression, you know, feeling like I’m just dragging 
through the day. And nothing to look forward to in the evening! [Like] a good night’s 
sleep, you know. (PT6) 
 
Patients, rarely, if ever, discussed their insomnia as a medical diagnosis. When asked, 
patients either denied receiving a formal insomnia diagnosis or talked about their diagnoses 
of mood disorders; a few mentioned that they had diagnoses of obstructive sleep apnea 
[OSA]. Some patients “normalized” their insomnia – similar to the way that physicians did in 
the previous chapter – by linking it to aging or hormonal changes. 
 One patient, out of the 27, seemed to accept and even embrace her unusual sleep 
pattern. She had learned to ‘manage’ it by re-arranging her schedule. 
 It has always been difficult for me to get up in the morning. It’s just, you know, kind 
of a painful experience to get up in the morning. And um, I’m, I had a roommate in 
college who JUMPED out of bed and [happy noises] started the day and I thought 
ahhh. [Sighs] how can she do that? And then, but as the day goes….And as the day 
goes along I wake up more and more and I hardly ever take a nap because it takes me 
so long to get to sleep. And then finally by evening I’m wide awake and ah![happy 
noise] You know everything is bright and I get my work done and then it gets to be 
midnight and then one, and two and everybody else is in bed, and I, and I can’t go to 
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sleep. And this is, I have been this way as long as I can remember. But I would try all 
sorts of different things. And I tried over the counter sleep things and, and I just. And 
the thing I found was that if I could get a job where I didn’t  have to be at work in the 
morning, and I could go to work at noon and work until midnight, I was great, you 
know I was fine. And so that’s essentially what I’ve done, most of my life. Except that 
I had a boss who insisted on having meetings at 9:30 at the morning. And I, I would 
get to those meetings not having slept because my experience is that the earlier I 
know I’m going to have to get up the harder it is to go to sleep. (PT 23) 
 
When asked what she thought the cause of her sleeplessness was, she answered: 
Well my guess is that some people are born night owls and some people are born 
larks and I’m definitely not a lark. Being a night owl, I’m, I feel like I’m always 
fighting. When I do go to bed, I’m not sleepy. I’m maybe sleepier earlier in the day 
but by the time it’s time to go to bed, I’m not sleepy. And so I’m fighting that, my body 
clock. And then if I know that I have to do something particular the next day I start to 
worry about how I’m going to do it if I don’t have enough sleep and that makes it 
worse. And I think that’s the [laughing] the core of the problem. (PT 23) 
 
Another, more common attitude of normalization was connecting one’s sleep issue to the 
aging process. 
But the sleeping is a problem. But it could be related to getting older. Who knows? I 
don’t know. But anyhow. It bothers you when you can’t go to sleep at night. So I don’t 
know what to do or how to fix it. (PT 33) 
 
In conjunction with age, some women  mentioned menopause or hormonal changes as 
probable causes. Said one patient, “So I have trouble falling asleep….And I’ve been 
experiencing that for about. It seemed to have started when I hit peri-menopause. So geeze, 
probably 5, 6 years now at least” (PT 42). Another woman told me: 
I have had problems with sleep for a really long time. And I could never tell if it was 
because I’m getting older, you know, I’m getting closer to menopause. And I couldn’t, 
I didn’t know if that was what it was, or if it’s heredity, because my mom has terrible 
problems with sleep too. So I’ve had problems for probably the last 5, 6 years. (PT3) 
 
Some of the male patients mentioned having an enlarged prostate that had them up several 
times a night to urinate. 
MM: Hmm. OK. So when you say sleep issue, is it trouble falling asleep, staying 
asleep, do you wake up multiple times? 
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KI: It’s waking up. And part of that is probably a growing and large prostate and 
taking Hytrin for that to relax that muscle. Because I get up, on a good night twice in 
the evening to urinate and it could be 4 or 5 times if I’m concerned about, you know if 
I’m just worrying about something. (PT2) 
Even now I, I, usually don’t get to sleep until 1:30, 2 o'clock. And that’s when and 
I’m still on Xanax. Aand ah, melatonin, take that too. [Sighs] So, I just, just and then 
also I have a BPH prostate. So, since I’ve had that which has been five or six years I 
guess since it started. I have frequent urination at night a lot. (PT 39) 
 
This particular quote underscores how framing it in this normative fashion means they are 
not ‘sick’ and could be described as ‘anti-medicalization.’ 
I know that increasing age and menopause does bring on insomnia and it’s just, I just 
look on it as part of the aging process. Because so many people that I know that are 
in my age group has those same, they have the same issues. So I said, well, you know, 
we can’t all be sick! [LAUGHS] So it’s pretty much how I look at it. (PT6) 
 
 Patients in this sample had a myriad of health issues ranging from cancer to 
fibromyalgia, heart disease to mood disorders. The most commonly disclosed comorbidity 
was mood disorder. Several patients told me that they had received a diagnosis of depression. 
Anxiety or stress were issues for many and in fact, when asked to a) describe their insomnia 
experience or b) estimate the cause of their insomnia, most patients in this sample cited 
anxiety or stress. 
A lot of times I just feel like my mind is racing. And I can’t quiet that down and I 
can’t, you know, make it blank so that I won’t think anything. A lot of times songs are 
running through my head and I’ll never be able to get that song out of my head. It’ll 
just keep me up and keep me up. (PT3) 
 
This patient attributed his sleeplessness to both his chronic health condition and worrying. 
Well, I guess first of all, I’m a known worrier so. I have great problems falling asleep. 
And up until I was diagnosed with COPD back in the fall I thought it was a panic 
disorder….But prior to the COPD and all that, as I said I was a chronic worrier and 
I always worried about my youngest son and his children and everything so. It’s just 
chronic. (PT 1) 
 
Another patient’s sleep pattern was disturbed by obsessive thoughts.  
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I don’t sleep very good at night unless I do take something. It’s hard for me to fall 
asleep because I think about the whole day. I can’t just fall asleep. It takes me hours 
to fall asleep. Because I will have to think about every minute of that day. Up until the 
time that I got ready to lay down. And ah, it just goes on and on and on and on. And 
so that’s why, that’s my sleep pattern. And then when I wake up I’m tired because I 
didn’t get enough sleep. I didn’t go to sleep you know early because I went to bed 
early but I didn’t go to sleep and then I wake up every hour. (PT 12) 
 
Several of the patients told me that they had very stressful jobs, or jobs they disliked. When 
asked if she could name one or two primary causes for her issues with sleep, one patient shot 
back: “I can tell one right off the bat. I hate my job” (PT 34). 
This patient noted a confluence of factors: his age, “worrier” personality and his 
stressful job. 
I think it’s a function, in part, of age. I think it’s also a function of my own 
personality. Of being a basic worrier about whatever….I’m different than most 
people and probably worry more. And have enough responsibility. I’m running a 
program here that doesn’t get the support I think it should and so I’m always kind of 
tilting with it. (PT2) 
 
Others had very stressful life situations that seemed to have sparked their sleeplessness. This 
patient in her early sixties had multiple stressors and care-giving responsibilities that she 
directly linked to her issues with sleep.  
MM: What do you think the cause might be with your sleep issues. Would you say 
maybe it comes from a life circumstance, or maybe… 
KI: [interrupts] Now I have a lot of stress in my life. My husband he’s, he has kidney 
failure. And I help look after my parents, they’re in their 80’s. You know I go clean 
for them once a week. And you know I’m busy helping everybody else a lot.  
MM: So it sounds like you’re a caregiver to multiple family members. 
KI: Right. I am. And then I watch my grandchildren in the afternoons when they come 
home from school. So. I you know, I have a busy life which is good and I’m thankful 
for, but um. I don’t have a lot of time for myself. (PT16) 
 
For some patients, it went beyond stress or worrying. One patient, when asked what she 
thought caused her issues with sleep replied: “I think early, um, a childhood trauma.” (PT 21)  
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 Other patients had experienced deaths in the family that coincided with the onset of 
their sleep problems. Said one patient “Really kind of started having my [sleep] problem 
after, seems like after my husband passed away” (PT 33). And another told me “The catalyst 
of getting an actual prescription for sleeping started 8 years ago with the death of my 
grandson” (PT 6). 
It seems that some may have always been predisposed to anxiety and this was 
exacerbated by stressful events. 
KI: Anxiety. Anxiety. That will do it. My husband worries about nothing. And his head 
hits the pillow and he rarely gets, wakes up at all during the night. He sleeps until the 
alarm goes off in the morning. I just, I just tend to worry about whatever. And um, so 
yeah, I think it’s anxiety.  
MM: Ok. And is that anxiety something that you’ve experienced just in the last 20 
years or has it been something you experienced longer.  
KI: I think it’s my nature to, to  focus on things in my life and decide that I can worry 
about them and I need to worry about them. I think it’s just part of my personality. 
(PT 43) 
 
Later, when discussing her treatments for sleeplessness (Ambien and Valium) she mentioned. 
“Now I use valium much more freely. Perhaps five years ago my husband at that time was ill, 
was dying, it was a terribly tense time” (PT 43). 
In sum, patients in this sample typically had trouble falling or staying asleep at night. 
Some woke up several times per night. Like their doctors, these patients related many of their 
sleep problems to the aging process. Most of the sample had comorbidities in the form of a 
physical or mental illness.  
Many of the patients in this sample described themselves as “worriers” and discussed 
the inability to “turn off” their brains when lying in bed. Others disclosed traumas or 
intensely stressful times that had triggered their bouts with sleeplessness. A few individuals 
had multiple care-giving roles and many in this sample had diagnoses of mood disorders. 
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These insights prompt the following questions – is their sleeplessness a symptom of mood 
disorder? A personality trait? A normal reaction to stress? What is really being treated here?  
 
Interactions with physicians  
Most patients in this sample reported positive interactions with their IMC physicians 
about sleeplessness. A few patients described interactions with physicians outside the IMC. 
Factors that seemed to shape these interactions and their outcomes included time constraints, 
consumerism, pre-existing prescriptions and physician attitudes toward treatment. I will 
address each in turn, in the following pages. Though the perspective is different, it is 
noteworthy that these were also factors mentioned in physician interviews. 
 
Time constraints 
Echoing the previously interviewed physicians, patients in this sample discussed the 
impact of the physician’s limited time on their interaction. This patient, who may have had 
special insight because her daughter was a physician, noted both the constraint of time and its 
relationship to managed care.   
But then there’s so many things that a doctor needs to remember to ask about in 
their[visit]. You’ve got 15 minutes and you have to diagnose, figure out, what, you 
know who this person is, what’s wrong with them. Get the diagnosis. Get their 
prescriptions written and write up your paper work. And you’ve got 15 minutes to do 
it! And then you’ve got the next person. And I don’t think that’s fair. And I don’t think 
it’s right. And I don’t think any of us are going to get all of our needs taken care of. 
How’s the doctor going to have time to ask about sleep when, when those are the 
circumstances? [Incredulous laughter] We’ve got to do something about our health 
care system. It’s, it really, really needs to ah, get some work done on it. And I don’t 
know who came up with the idea this middle, this middle layer of the [system]. You 
know that you have to call and get permission before you can have the doctor. [Oh, 
managed care] Of managed care yes. The managed care system seems to me that 
that’s just taking money that could be, being funneled into actual care. Instead of the 
managed part. [Laughing] (PT 23) 
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Patient 9 was in a unique position to discuss challenges to today’s physician, as he was one. 
In addition, his perspective echoes that of some of the IMC physicians.  
 [Sighs] Well, number one as doctors, as physicians have less time to spend with their 
patients and there’s a you know growing physician shortage and there’s a growing 
aging population. My guess is the tendency is, the simple thing to do is just give the 
patient a pill, you know and not to delve into the you know, the why about, why the 
patient’s not sleeping. But just to, like I said, you have a limited amount of time to 
deal with each of these issues. So if the patient complains that they’re having trouble 
sleeping, first thing that most doctors would do, especially if it’s a first time 
complaint would be, simply get their prescription pad out, write a prescription. And 
as a patient made a, mentioned a drug by name, that would be even easier because 
usually you wouldn’t argue with the patient you would just write them a 
prescription….you know we’re expected to crank the patients through, to see patients 
every 15 minutes and fill our schedules up. And so the doctors are under more 
pressure to see more patients and generate more revenue so you don’t have the time 
to sit and explore some of these issues. (PT9) 
 
When I asked her if her doctor had ever talked to her about sleep hygiene, this patient noted 
time constraints and how she had ultimately sought information from other sources.  
Well, actually, I have read a lot about it. I don’t think any physician has actually 
taken the time to tell me that. They don’t usually have time to sit and tell me much of 
that sort of thing. However, I’ve done a fair amount of reading about it. And I’ve read 
all those things and I try and practice those things. (PT 43) 
 
This patient recognized the challenges doctors face, but asserted that her doctor would be 
willing to take time for her.  
I think that Dr. X would be very willing to take the time. I think the time is the 
primary issue for physicians who are you know, practicing medicine. Um, but I think 
if I let him know that this was a concern of mine, it affects my, you know my living 
and therefore eventually my health, he would take the time to discuss it with me, 
share his knowledge, become more knowledgeable if he felt he didn’t have knowledge 
at hand, it was appropriate for me. So yeah, I think that he, I think he’s a very 
unusual physician. But I think yes, he would, he would take time and do whatever he 
could do to um, help me.  (PT 46) 
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In sum, some of the patients in this sample recognized the time constraints that 
doctors operated under and how it could influence their interactions about sleep. The 
physician-patient of the sample echoed sentiments seen in the previous chapter; specifically, 
that the limitations of time might make a physician more likely to just “simply get their 
prescription pad out, write the prescription.” 
 
Consumerism 
Even though physicians are still technically in charge of the prescription pad, several 
of the participants in this study admitted to me that their first experience with a particular 
sleep drug (typically Ambien) was by trying someone else’s. In a way, this is almost like 
hyper-consumerism – the determined ‘customer’ bypasses the normal route for prescriptions, 
heading first to a source where they are essentially guaranteed to get what they want. This 
could also be viewed as a way to ‘try before you buy.’ 
At first [my doctor] prescribed valium and I think I took a half a valium but that was 
just Whoa, my gosh. That just made me feel too crappy the next day. And um, so I 
took that for, aaah I don’t know. Like I said, it’s not like I do it every single night. But 
when I took that I took it for maybe 6 months to a year, maybe once a week a so, and 
like I said, I just felt really, really crappy. So, um, my mom. [Laughs] My mom you 
know, whose got sleep problems too, had Ambien. So she gave me some Ambien and I 
tried Ambien and oh my gosh, greatest drug ever invented…. It worked for her and so 
I talked to her about this and I said, you know, you gave me a lot of great things, but 
you also gave me your insomnia. And, you know, so I knew she was taking Ambien. 
And she said, well let me give you one of these. (PT3) 
 
This patient was candid and unapologetic about using his wife’s Ambien. 
MM: When did you begin taking Ambien? 
KI: I really began taking my wife’s prescription because I don’t use it very often. I 
usually take about a quarter of a 10 mg. And, or half. So, what she got took care of 
my needs, because I don’t use it very often. You know, I’m using it more now because 
I would much rather develop some dependency on Ambien than lose sleep at this 
point. But, perspectives change when you get a little older, post-heart attack, which I 
had back in ‘98. So you see the world a little differently.  
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MM: Right, right. So you started occasionally using your wife’s and then um, at what 
point did you ask your previous physician for a prescription? Do you recall?  
KI: A couple of years ago, I don’t remember. (PT2) 
 
Another patient who admitting trying someone else’s prescription told me: 
 Well, initially yes. Because when he first prescribed the Ambien to me, because my 
wife takes Ambien as well. And um. [PAUSE] She talked about how good it, you know 
how it relaxed her and helped her to sleep and so I thought I’d give it a try and it 
does seem to help considerably….so yes, I have taken my wife’s Ambien before and 
that’s what prompted me to ask Dr. X for it as well. (PT 30) 
 
I correctly assumed that most patients would not admit to doctor shopping, even if they had 
engaged in it. One patient did tell me that she had considered it when seeking to continue a 
benzodiazepine prescription from another physician. 
KI: Um. Well, when I started working down at NAME I switched my doctors down 
there. And I’ll be honest with you, that was the main concern of mine that I would get, 
I would not have switched doctors if I felt like I could not get the sleeping medication. 
And you know, he keeps a close check on it. And I do not abuse it or use more of it 
than I should. So he has continued to prescribe it for me. 
MM: Ok, and so, what you were saying a second ago is that that is a major concern 
for you. 
KI: Uh-huh 
MM:  and that in fact if he was not willing to prescribe that, that you would, you 
would then want to find someone who would, is that correct? 
KI: Probably so, yes, in all honesty.(PT 28) 
 
This patient spoke of an interaction he had had with an IMC-affiliated psychiatrist. 
But I went to the psychiatrist that was in the same office for medications. And at some 
point I had been getting prescriptions from him for a couple of years at least he said 
he had read this article that Xanax you know could be really addictive and he um, he 
um, wanted to stop giving me the medication. And not give me anything else. And I 
was ah, and I said what am I supposed to do. And he said you know, try ah, herbs. 
Try going to bed earlier, whatever, you know, and it, and ah, none of that worked. I 
mean I really, it’s a problem. And at that point I was still working so um, that was the 
only time I had an issue with this doctor. And I ended up going to, eventually going to 
a different psychiatrist.  (PT 39) 
 
The following quote not only exemplifies consumerism but touches on how the insurance 
companies and the Internet moderate the patient-physician relationship. 
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MM: Apparently some insurance companies have said you can only have 15 pills a 
month. Is that something you’ve run into? 
KI: You know, I have not, but Dr. X mentioned that to me at the last visit where I 
asked for some Ambien…I got the generic and I have not had a problem with that but 
it wouldn’t surprise me, which I think is really kind of unfortunate, but it wouldn’t 
surprise me. I think, I think if that were the case I would probably go to Canada and 
buy the generic. 
MM: Well that’s a bonus of you traveling internationally a lot. 
KI: No, no, no. You can do that over. You can do that actually over the internet to 
Canada. Drugs.com, which is pretty reputable so I don’t feel too bad about that. 
[Laughing] (PT 42) 
 
Consumerist attitudes were evident among some of the patients. Some engaged in 
hyper-consumerist behavior by seeking sleep drugs from a friend or family member, 
allowing them to try the drug before buying it. A handful of patients also alluded to doctor 
shopping. However, many of these patients entered their office visits with pre-existing 
prescriptions. 
 
Pre-existing prescriptions 
Just as in the physician interviews, I found there were several reasons why docs 
tended to comply with patient request. A familiar one is the presence of pre-existing 
prescription. These interactions were apparently cut and dry and not particularly memorable. 
When pressed, most patients could not recall the ‘exact’ conversation. 
MM: And if you can recall the interaction where you first left your doctor’s office 
with a prescription for Ambien, I’d be interested in hearing about how that 
interaction went. Who brought up the sleeplessness? Was it you, or was it your 
doctor. And how you decided upon a course of treatment together. 
KI: You know, I think it, I can’t, I cannot remember all that much. I know though that 
a couple of years ago I was in a time in my job where it was very, very, very high 
stress. And I really couldn’t sleep a lot at all. And I was working all, probably 10 to 
12 hours a day, 7 days a week. And it was high enough stress where I said you know, 
I’ve go to be able to sleep at nigh and I walked in and I asked for a couple of months 
of Ambien and it was from the nurse at work.  Or the PA at work. And, and so she 
gave me some. Because I knew it was going to be pretty much short term where it was 
pretty impactful. So and then because it was, it works pretty well actually and so now 
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when I. And I’ve asked my, my regular physician [at the IMC], I’ve asked him, you 
know and he’s given me a few months here. You know like a month’s supply with the 
one or two refills and I just have some on hand.  (PT 42) 
 
This patient got quite defensive when asked about his interaction with an IMC doctor about 
sleep (an assumption I had made based on his recent prescription). 
You know, your assumption that he’s treated me for sleep is incorrect. The only thing, 
I’ve seen him one time for a physical. Because the internist I had for many years, 
NAME retired at [the] IMC. And I asked my good friend and former neighbor NAME 
for someone he would recommend. And that’s how I got Dr. X.  And I had my first 
and only physical, annual physical with him last February. And I wanted a um, a um, 
Ambien prescription renewed. And that’s about the extent of my conversation with 
him about anything related to sleep. So, he gave me a prescription.  (PT2) 
 
The following quote exemplifies how most patients recalled their interactions with doctors in 
instances where they were had a pre-existing prescription for a sleep aid. 
MM: Ok. And so, um, if you can remember how it came up with Dr. X, did you 
present it as hey I’ve tried this before, I need it again or. 
KI: Yes, basically that was all. I just told him I was having problems sleeping and you 
know, that was all. I didn’t go into any detail or anything. I mean he had known I had 
been on the ah. In fact, I don’t even know. At the beginning when he first become my 
doctor I might have been on the paxil and Buspar, I don’t remember. But I had lost 
my, I had lost a job. 
MM: Oh. 
KI: I remember he prescribed, what did he prescribe Klonipin for me which I never 
took. But, I don’t know if I, like I said, it’s hard for me to remember but I might have 
been on those other medications and he would ask me about sleep and I would say I 
have trouble sleeping so. I don’t know. I just can’t remember the exact conversation. 
MM: Sure. Do you recall if you felt like he was receptive or not to your, to your 
needs. 
KI: Yeah, he was receptive, definitely. (PT 34) 
 
To summarize, many of the patients in this sample had prescriptions for sleep aids 
written by physicians other than their IMC doctor. It was not uncommon for them to seek a 
renewed or refilled prescription from their IMC doctors and it seems that most complied 
without much hesitation. Patients did not often recall these simple interactions in great detail.  
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Physicians’ attitude toward treatment 
Patients confirmed that IMC physicians routinely suggested lifestyle/behavioral 
changes or touted the tenets of sleep hygiene; patient response to these suggestions was more 
indicative of their own attitudes toward treatment than that of their physicians. Thus, 
discussion of sleep hygiene practices are reported in the section “patient attitudes toward 
treatment.” In the end, however, all of these patients received a prescription for a sleep aid. In 
this section, I focus on physicians’ attitudes toward prescription medications. 
When patients discussed interactions related to acquiring a prescription treatment, 
different prescribing ‘personalities’ emerged. Doctors were described as alternately 
‘cautious’ or ‘free-wheeling.’ 
 
The cautious prescriber 
Most of the patients in this sample indicated that their physicians were ‘middle of the 
road’ in terms of prescribing practices. There was a tendency to use words like “cautious,” 
“conservative” and “careful.” 
He was more cautious. He  wasn’t like, Uh-huh, take this here and you go to sleep. 
You know. He explained some things. ‘ I can prescribe, but it would be best not to, 
but, I can prescribe something to help you sleep.’ But, you know he didn’t want 
nothing for me to get addicted to now.  (PT 25) 
 
I would be more than willing to try different medications that ah, might be helpful. 
The doctors tend to not want to make changes very frequently though. So they have 
been probably more conservative than I would like. (PT22) 
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I think Dr. X is careful. Yeah, he’s not sitting there going ’Ooooh, yeah, here, just 
take this.’ And he’s not, he’s not saying ‘no, I never prescribe these.’(PT 42) 
 
I don’t feel that there was reluctancy [sic], but they also wanted to follow [up] and 
make sure. You know. I mean I felt that it wasn’t like an open prescription pad, you 
know, that they wanted to know if it was helping and that sort of thing. (PT 38) 
 
Yes, initially it was Ambien and then the zolpidem. Ah, and he’s very ah, 
conservative. And he asked me a LOT of questions. I could tell that, you know, he was 
concerned about giving it to me, and he would make sure which day I needed it. (PT 
30 – emphasis his) 
 
An attitude of resistance led one patient to question the physician’s knowledge of sleep aids. 
He said “I don’t know whether his hesitancy to prescribe anything is due to he doesn’t know 
that much about it or either his hesitancy is about what sleeping aids help people sleep” (PT 
33). However, others seemed to appreciate the physician’s point of view, even as they felt 
frustrated with their options. 
Yeah, and I think that’s when he give me the Trazodone. And he talked with me in-
depth about it, you know, and he, he just don’t like to prescribe something that. He 
told me though, he said I have a hesitance about prescribing anything to my patients 
that, like sleeping pills and things. And I think well, you know, I understand where’s 
he’s coming from too and I don’t want to get hooked on anything. But do I do this 
[not sleep] forever? You know what I’m saying? (PT 33) 
 
The free-wheeling prescriber 
This was an uncommon characterization.  However, in these characterizations it is the 
physician who is eager, or at least extremely open, to prescribing the drug. 
MM: How do you feel like the physicians that you’ve encountered, what is sort of 
their openness to prescribing medications for your sleep issues. 
KI: I think very open. I’d say like a 9 [out of 10]. I mean, even Dr. X who wants to put 
me on something else he’s like “Ambien’s great!”. …I mean all the feedback I’ve 
gotten. I feel like I could go in there, a stranger off the street, and they’d just write up 
a medication. So, I feel like that. They just use it as like a tool for them to  not have to 
deal with it. Like ‘Oh, I’ll just prescribe them Ambien because it’s working and we 
haven’t heard anything.’ You know? Instead of you know, doing other measures, 
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psychotherapy. You know what I mean? When it comes to the sleep I think that 
they’re just very open to it. And even my wife…she’s like, they’re like what do you 
want to be on? Is there anything that you’ve heard of that you want to be on? I think 
her doctor asked her that. You know. So, and Dr. X [previous physician] was like that 
too. He was like do you see any other[drugs]? Because I joked about all these sleep 
drugs. I’m like gosh, everywhere I go I see sleep commercials in newspaper and in 
print and media. It’s like this whole country is sleepless! And he’s like yeah, if there’s 
anything else you want to try just bring it in. You know he was just really like kind of 
like freewheeling, you know. (PT14) 
 
This individual was suspect of not only physicians, but the FDA. 
Physicians are really [sighs] apparently quite interested in um, prescribing 
medication that may or may not be [safe] because they are, they have been 
approached by a drug company….I wouldn’t hazard a guess on that one, but 
certainly it seems kind of obvious to me since they always. Since many of them and 
I’m not including my own physician here necessarily but, um, many of them have 
copious samples of recent, brand new drug medications, you know, drug things. And 
um, I think the system in this country is completely screwed up. …And one of the 
things that’s going on in the world is corruption of the Food and Drug 
Administration.  (PT 43) 
 
I asked the following patient how willing her physician was to prescribing sleep medication. 
MM: Uh-huh. And how open, if you could again think of a scale of 1 to 10, how open 
to prescribing sleep medication did you feel like Dr. X was. 
KI: A 10. (PT 34) 
 
In sum, most physicians in this sample seemed cautious or conservative in their 
approach to the prescription of sleep aids. This attitude toward sedative hypnotics verifies 
what physicians told me in their interviews. However, patients indicated that a few doctors 
were more liberal in their prescription policies. 
 
Patient attitude toward insomnia treatments 
Patients in this sample preferred prescription medication to sleep hygiene practices, 
although a handful did report strange side effects from Ambien. A surprising finding was the 
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number of patients who discussed fears of becoming dependent on sleep aids, particularly as 
I did not raise this topic in the interviews.  
Patients confirmed that their physicians had spoken to them about sleep hygiene or 
making changes in their lifestyle and behaviors. However, few found theses suggestions 
helpful in practice. 
Well, some nights it’s very hard. I’ll lie in bed and I’ll be sleepy when I go to bed, but 
when I lie down I can’t go to sleep. So I lay there about 30 minutes and I try to do 
what all I read in these books and little pamphlets that tell you to get up and stay up a 
little bit and then come back to sleep. Well some nights I do that 3 times or 4 [laughs] 
and some nights I’m up 1 o’clock, 2 o’clock or 3 o’clock in the morning before I ever 
get situated enough to fall asleep. And maybe once in a while I’ll get up and take a 
hot bath, because that’s supposed to relax you. I try to do the things that I’ve been 
told that might help. And it might [help] some but I, I’ll fall asleep and then I’ll wake 
back up. I just you know, hadn’t had a, don’t have a good night’s rest and I’ll wake 
up as tired as if I’d just gone to bed.  (PT 16) 
 
One patient was frustrated with his inability to get a prescription for daily use and 
complained of being “lectured” on sleep practices he found “impractical.” 
Also know that, that at least my doctors have been unwilling to give people just a 
prescription for daily use….I think that they need to be more aggressive with their 
approach. And they need to put a greater sense of reality into treating their patients. 
You know having; you know having a doctor tell me that um, I should get more sleep 
or allow myself more time to sleep is sometimes not practical. To tell a, you know, to 
tell someone not to do something, which they know is not normal is not a practical 
approach. So, you know, a lot of, remember I told you about all the lectures. A lot of, 
a lot of the content of those lectures ok, is great from you know, being in the ivory 
tower and being academic about it….Taking or helping the patient with an action that 
can be actually implemented and yield a result is probably a better approach to take. 
And I’ve found that a lot of the things that I’ve heard out of this experience have been 
a little too impractical in nature.  (PT 22) 
 
Similarly, this patient found the suggestions impractical. 
And like I said my doctors never brushed it off at all. But I think, I don’t know that 
some of them realized how it really affects your whole being. You know. I mean, just 
are not sleeping then, most of the night. Just laying there. And they’d say get up and 
go read a book or something. Well, that’s hard to do. I mean, I feel like that would 
disturb my husband if I get up. Although he’s told me it never would, if I wanted to 
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get up. But, that didn’t help me either. To go get up and do something and then I’d 
lay back down and I’m actually more wide awake after I’ve done that. (PT 38) 
 
This patient found neither behavioral suggestions, over the counter remedies, nor a 
Trazodone prescription helpful. 
KI: That’s what I don’t understand why I can’t get to sleep. Why, and I, like I’ve said 
I’ve drank milk. Dr. X told me to drink some more milk. I said I don’t. Take warm 
milk…..And but anyhow I’m just, I’m just not sleeping. I have took the Tylenol PM 
and stuff like that. Well that makes my legs cramp, seems like. Dr. X has gave me a, I 
forgot the name of it, it was kind of like ah, take it at night but it was kind of like an 
antidepressant too, I think, or something to that effect. And it didn’t help. 
MM: Was that Trazodone. Do you remember? 
KI: I think it was. Yes, that’s what it was. That’s the name, yep. So, um, but nothing 
I’m doing seems to be helping. I mean I just stay awake all night long. (PT 33) 
 
It was clear, however, that in certain instances patients were actually incorporating ‘bad’ 
behaviors into their sleep-inducing attempts. For instance, the artificial light and stimulation 
from television and/or a computer monitor are to be avoided at least an hour prior to bedtime 
(IOM 2006). 
And I lie there and I keep, try not to be thinking about things but unfortunately, they 
keep, things keep rolling around in my head. And I just can lie  there 2 and 3 hours 
without falling asleep. And then sometimes I try not to do that. I’ve read that 20 
minutes is all you should do [in the bed]. But I still try longer than that because we 
share a king size bed which doesn’t bother my husband too much. But if I’m gone 
from there too long he worries about whether something’s happened. Anyway I 
usually give up and go upstairs to a room that’s away from everybody else and I can 
play stupid games on the computer like solitaire and FreeCell and things. And 
anything to be monotonous enough to put me asleep. And after I do that for an hour 
or two I usually go down and go right to sleep. (PT 19) 
 
This patient may have realized in describing his home versus vacation sleep routines, that 
one appeared to be much more conducive to sleep. 
And, at home, what I generally do is, my wife goes to sleep about 11, 11:30, 
sometimes midnight. And if I’m not tired, which is often the case, then I’ll go in the 
living room and mess with the computer or watch TV until I’m tired. Which is like 
1:30 or 2. But when we’re together like in a hotel room I guess I can’t do that. And so 
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I just, I just lay in bed 'til I go to sleep and I seem to get to sleep without staying 
awake. (PT 39) 
 
On the whole, patients in this sample reported that their prescription sleep aids were 
generally effective, although a few reported that every night use diminished or eradicated the 
effectiveness. Although side effects were uncommon, a couple of patients did report sleep 
walking and possible sleep-eating. This particular patient had had several episodes of sleep-
activity. 
Ah, it ah, like I said [the Ambien is] not always real effective. Sometimes it just 
knocks me right out and other times you know. And of course one of the side effects of 
it is that I do things. I occasionally will do things that I have no memory of. My son 
called me one night and we talked on the phone for 30 minutes. And the next day he 
said mom have you made a decision about what we talked about last night. And I 
said, WHAT?? [LAUGHS] I had no idea that I had carried on a perfectly lucid 
conversation with him in the [night]. You know. I had no idea. I got up one night and 
ate a piece of pizza out of the refrigerator. I had no memory of doing that. My twin 
sister was visiting with me and ah, I had one of my granddaughters, she was a baby 
at the time. And she said, NAME started crying and you got up and you came down 
the hall and you picked her up and you, and you come out of the bedroom with her. 
And you staggered back down the hall. That’s another thing, it makes you walk like 
you’re drunk. She said you staggered back down to the hall to your bed and put her in 
the bed with you. And [LAUGHING] I had no, absolutely no idea how that child got 
in bed with me the next morning. But my sister was there to witness it so she could tell 
me. So that is one side effect about it that I don’t like. (PT 6) 
 
Despite physician discussions related to the habit-forming nature of these drugs, an 
unexpected finding in these data is the frequency with which patients mentioned the topic of 
addiction or dependence. One candid patient said: 
So I do…use Ambien. Not every night but quite a bit. Well, gee. If I could take it every 
night and I felt like I wouldn’t become dependent on it, I would. (PT 42) 
 
Many in this sample expressed a reluctance to take sleeping pills, or even pills in general. 
And I tried it, you know, a lot of people that they have pills to get up by, pills to go to 
sleep by and I myself wanted to not be that person. Occasional, which is not bad, I 
don’t think. Occasionally when you really can’t go to sleep or you need a good 
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night’s rest, I may take a pill. But overall I try to stay away from them, but I do have 
them in case I do, you know. It’s a great help that a-way. (PT 25) 
 
Another patient went so far as to deem regular medicine taking not “normal,” saying “I don’t 
want to really use any medicine if I can help it because I don’t want to get used to doing 
things like that. I don’t think that’s a normal thing for people” (PT 19). Even the physician in 
the sample expressed concerns about the habit-forming nature of Ambien. 
I’ve been reluctant to use [Ambien] on a regular basis. You know, even though I’m a 
physician, and even though truthfully that proba-, that may be less habit forming than 
Tylenol PM, I don’t know. But I’m still reluctant to use the prescription sleep 
medication because I don’t want to get, get addicted. But yet, my perception is that 
since Tylenol PM is not, is over the counter, I’ll use that with you know, I’m more 
comfortable using that. (PT9) 
 
Another patient was very stressed about getting dependent on Ambien. 
I told [my doctor] I didn’t want to take it every night. I had took it a lot to begin with 
so I got rested and then I told him I said it was helping but I hate to take it every day. 
Because I didn’t want to get addicted to it. So now what I do, he lets me keep some 
but I don’t take it over a couple times a week. And then I’ve cut back to one. I want, 
even if I have to stay up until 1 o’clock in the morning I’ve tried not to take but one 
because I don’t want to make myself totally depend on something like that. (PT 16) 
 
She later elaborated on her fear.  
I tell you I’ve had drug addiction in my husband’s family and it’s made me. I guess 
I’m. They sent me to a psychologist one time because I wouldn’t take my medicine. 
[laughs]….I feel sometimes I feel like I don’t want all that medicine in me, to take all 
that medicine. When you’ve seen what it would do to people it’s sort of scary. And I 
just want to make sure that I don’t ever over-use anything.  (PT 16) 
 
This patient makes an interesting point about his prescription drug use. 
And ah, you know, the issues of addiction um, you know, I’ve been on Xanax for most 
of the last 16 years….I don’t feel like I have the need to take more, you know. But it 
really helps me get to sleep. You know, if that’s an addiction, I’m addicted. But I 
mean I’ve been on antidepressants for that time and, I guess I’m addicted to that to. 
Or not. (PT 39) 
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In sum, most patients allowed that they had tried some variation of sleep hygiene 
practice but, for the most part, they found it to be ineffective or impractical. In these 
discussions, however, it became clear that some patients were engaging in poor sleep hygiene 
as part of their bedtime routine.  
In terms of prescription drug use, most patients found their sedative hypnotics to be 
helpful, particularly if they were prescribed Ambien or zolpidem. However, a few patients 
reported that these drugs lost effect when used on a routine basis and a very small number of 
patients reported strange side effects including sleep-walking and sleep-eating. As I did not 
ask about issues of addiction, it was particularly striking to me that many of these patients 
initiated discussions about their fears of dependence.  
 
Sources of rhetorical authority 
Patients in this sample discussed multiple sources of rhetorical authority, although 
some patients did tell me that they only information they had gotten about sleep was from 
their physicians. Like the physician sample, direct to consumer advertising [DTCA] was the 
most commonly mentioned source of rhetorical authority. Other sources mentioned were 
social networks and print media. 
 
 DTCA 
All of the patients in this sample were aware of DTCA for sleep aids but most viewed 
them (and other drug ads) negatively. Only a few patients admitted that the ads might have 
influenced their interactions with physicians. The most common response from participants 
was that they were not influenced by DTCA, but that other people probably were. 
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This patient openly admitted that his knowledge of Ambien came from an ad and that 
that was his prompt to ask his doctor about it.  
My, my knowledge of Ambien came from the commercial and I did ask the doctor 
about that and you know, and he thought that, sure, it might be good to switch from 
the Xanax and see how this worked. (PT 39) 
 
One patient admitting to seeing and requesting not one, but two drugs from advertisements. 
She had tried the drug Lyrica after seeing it advertised. Unfortunately, it did not provide her 
any relief from fibromyalgia.  
MM: Ok. Ok. Any other, any other times when you can think of. You mentioned the 
Ambien CR; I know that’s being really, ah, it’s advertised a lot on TV.  
KI: Yeah, that’s where I saw that. And my doctor, I asked him if the CR would be any 
different. And I don’t really think they knew how it would affect me differently, or if it 
would. So we tried that, but that, I just couldn’t function the next day. I was so 
groggy. Still. So, I went back to the plain Ambien. (PT 37) 
 
These patients, though they said they were not influenced by DTCA, did think that drug 
companies were effective in getting people to think about their products.  
I think, and not just sleep aid medicine. I think all medicine that is advertised on the 
TV for all the different things, like being able to go to the bathroom, or stuff with your 
eyes. I think it cues people to say, well hey, maybe that would work for me.  
(PT 30) 
 
MM: Yeah. So I’m curious if people feel like seeing those advertisements on television 
influence them to ask their doctor for a specific name brand. What do you think? 
KI: I think it does. I think people just notice that, hey, these commercials are on and 
I’m still awake. Maybe I should talk to my doctor about this. It leads them to ask for a 
specific medication. (PT 31) 
 
In the following quote, the patient made a distinction between the ads for the sleep drugs and 
other types of drugs.  
KI: No, and I see advertised all the time Ambien CR or something, which is the 
sustained release or something. But it hasn’t made me want to try it. As a matter of 
fact a lot of the ads just turn me off.  
MM:  What is it about them? 
KI: I guess I don’t like commercials. And they’re ongoing. I mean you can’t watch the 
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evening news or anything now, or a ballgame or anything else without being 
bombarded left and right with Viagra and Cialis and everything else. And this is 
during prime time. And I think there’s a time and place for everything. And I think the 
pharmaceutical companies, although my daughter-in-law is with one of them, are just 
[PAUSE] spending a fortune on advertising and the price of medication keeps going 
up and I think that’s part of it. I don’t think it’s all research and development. I mean, 
that may be their development, by advertising, but…Spireva and the Advair 
commercials are, they’re toned down. And they’re realistic and they don’t bother me. 
As a matter of fact they’re encouraging to know that they are helping people. I just 
think more and more ads are going to the drug companies and I just don’t like it, 
because I think that’s part of the cost.  And they’re not going to convince me to use 
any of them. So. Maybe some people it would, but it just doesn’t turn me on. (PT1) 
 
Another interesting perspective emerged from the physician-patient.  
You know it’s interesting my brother in law is a pharmacist and he was, we were 
chatting and he was telling me that the ah, the butter-, the Lunesta butter fly is, has 
been extremely popular and very recognizable. And um, it’s interesting. Now I’ve 
never asked for Lunesta, but ah, I can specially remember their ads on TV. And so, I 
would imagine that that does  have an influence on patients asking their doctors for 
sleep aid prescriptions. And they you know they advertise Ambien quite a bit as well. 
The ads now you know focus on Ambien CR, which is you know a controlled release 
and I can picture the ad on TV where they have, ah, you know it has two different 
types. There’s a white part of the pill and a yellow part of the pill and it looks like 
spark, you know they show the pill coming together with little sparkly ingredients and 
things. And I don’t know if other people pay that close attention, but I can picture the 
sleep aid ads from TV….The good news/bad news is these medicines do help. The 
only thing is I think sometime the direct-to-consumer-advertising might increase the 
dependency on some of these drugs. But I don’t know that for a fact. It just seems like 
it’s going to make more patients request sleep aids. (PT9) 
 
This patient felt like ads were being ‘pushed down his throat’ and doctors seemed in on the 
game. 
I think with all the new medications out there that they’ve just been so free to kind of 
um, promote and kind of want to fill. It seems they just want to fill a prescription for 
these sleep medications. Like I said, I feel like it’s just like a new tool that they have, 
now. And, you know I see a lot of the advertising and all of the, you know like going 
into all the doctor’s offices now it just seems like it’s everywhere. It’s like, you know, 
they’re just really pushing. It seems like that whole part of the pharmaceutical 
whatever, industry just pushing that down your throat. Like basically everybody 
needs to be on sleep medication. And I think that the doctors are kind of in a sense 
like, I don’t know if their, what their incentive is, but they’re just really eager to push 
it. (PT14) 
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The following quotes exemplify what most patients told me – that they were not influenced 
by DTCA . But ,when asked if they thought others were influenced by DTCA, they 
invariably said yes. 
KI: I view those advertisements as purely a way for the pharmaceutical companies to 
get more revenue for the medications. I have listened to my doctors and their 
warnings about becoming dependent on these medications. And you know basically 
weighing the different information I’ve chosen to take a conservative approach to 
dealing with these medications. So you know the advertising has very little influence 
on my approach.  
MM: So your approach has been to really take a conservative approach to these 
medications and to view the advertisements as a revenue making endeavor on the 
part of the drug companies. If you had to guess would you say that they are largely 
influential on other people however? 
KI: Yes. I believe that they are very influential on a lot of people. (PT 22) 
 
Though lengthy, the following exchanges exemplify the attitude that ads may be effective on 
other people, but not the speaker. 
MM:. So the knowledge that you’ve gained through you know internet, TV shows, 
what have you. Do you feel like that information influenced your interactions with 
your physicians at all? 
KI: No, I actually I don’t. Uh-huh. 
MM: OK, how about advertisements for prescription drugs. Do you ever find yourself 
asking your doctor about drugs for, that you’ve seen advertisements for? 
KI: You know I never, I never do I. For sleep or for anything.  
MM: For anything. 
KI: Aaah, not too much because I’m not. The, the, no, no. Uh-huh. No. 
MM: Ok. 
KI: No. Even, even the Ambien I didn’t. That came about through my colleagues from 
work, so that wasn’t….it wasn’t something I saw on TV and said oh I must have. It 
was, oh really this works really well for traveling to the UK. Yeah. 
MM: Right, right. Ok, just in doing this research I’ve become extremely aware of the 
amount of advertisements for sleep aids that are on television.  
KI: yes. 
MM: and particularly in the evening obviously. [Yep] But so I was curious if you 
thought that those ads might have influence on other people. 
KI: Oh yes I, I am sure they do. I’m sure they do. (PT 42) 
 
Another example goes further. 
MM: And some people see those and they, they in turn do ask their doctors for 
specific brand names of medications. Is that something that you’ve ever done? 
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KI: No, I don’t believe in it. 
MM: More generally though in terms of the advertisements for sleep aids do you 
think that even though they’re not something that might influence you, do you think 
they might play a role in other people asking for prescription medications. 
KI: Oh yes, I definitely think that kind of advertising has influenced people. 
MM: Why do you think that they might be convincing for other people. 
KI: Because [pause] I hate to say it, but if you look at the voting population. 
[Laughing] You will discover that most people are completely gullible, quite 
uneducated and just parrot what they hear. (PT 43) 
 
A different patient thought that advertisements could be potentially positive for the patient-
physician interaction.  
MM: And one place I’m curious if people get their information is from the drug 
advertisements that are on television or in magazines for sleep aids. Have you, have 
you noticed those advertisements. 
KI: I haven’t been aware of noticing but I, I certainly flip through magazines, see ads 
for prescriptions and I know I saw Ambien advertised. So that may, that may be 
something that has encouraged me to feel like that would be helpful. 
MM: OK, ah, so you think that in fact might influence you in thinking it’s helpful. 
KI: Yeah. 
MM: In general, there are so many advertisements, direct to consumer 
advertisements for so many pharmaceuticals these days. 
KI: Yes. 
MM: Are there other advertisements that you may have seen that you’ve then actually 
taken action and gone to your doctor and said, you know, I saw this ad for so and so 
and I’d like to try that.  
KI: Um, no, I don’t think so. 
MM: No. Ok. Do you think that advertisements might encourage people who maybe 
hadn’t thought about their sleep issues to, to go and talk to their doctor about sleep 
aids. I mean this is obviously a hypothetical. 
KI: Yes. I would think so. You know. Just knowing that are other people out there who 
have enough difficulty so that they would discuss it with their doctor would make one 
feel like, you know, he’s not going to feel like I’m really strange or unusual if I. Yeah, 
I think that that probably would have a freeing effect. (PT 46) 
 
DTCA was the most commonly discussed form of rhetorical authority. Many patients seemed 
to view it negatively and only a few admitted to being influenced by it. However, patients 
invariably believed that they were less vulnerable to these messages, compared to others. 
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Other sources of rhetorical authority 
While DTCA was by far the most discussed source of rhetorical authority, some 
patients mentioned friends and family as sources of knowledge. One patient said that in 
addition to the internet, she had sought information from friends with sleep issues.  
KI: Yeah, and friends. I guess I’ve had a couple of friends who struggled with sleep 
too. And just talking to them and hearing what they did and what they do. And that 
sort of thing.  
MM: Are their issues with sleep similar to yours, different from yours, or. In other 
words, do they have sleep apnea or are they struggling with.  
KI: No, Uh-huh. One of them ended up having restless leg syndrome. But I think she’s 
doing better now. But she was one of. And one is a new friend that I have, that does 
have sleep apnea. Which is kind of interesting. Because we didn’t realize it and we 
started talking one day and, but you know, I think it’s good to have a support group. 
(PT 38) 
 
Patient 14 gained information about sleeping pills from family and friends.  
MM: What were some of the other sources that you felt like you gained knowledge 
about sleep and sleep treatments from? Like people talk about Internet, TV, book, 
magazines, newspapers, friends or family. Which of those sources, if any? 
KI: Oh, I mean I would definitely say just interactions between my family and friends. 
I mean it’s just like. You know in the last 10 years like you know, I’m very open with 
medications that I’m on and everything and they’ve just been like, Oh you take 
Ambien too, you take Ambien too. So um, you know I think it’s not like this taboo that 
you’re like you know. It’s like you’re on a sleeping pill. You know. Versus like you’re 
on like lithium or something. (PT 14) 
 
Part of the ease of these conversations, he thought, was due to the fact that Ambien didn’t 
carry some of the negative stereotypes, or stigma, associated with other drugs. 
It’s like, I mean I feel that with my like colleagues and then people, I’m a manager 
and I openly talk about people that can’t sleep I’m like you know you should go see a 
doctor and maybe get some help. I’m like, I’m on Ambien, but I’m also on other stuff 
that I don’t tell them about. And people just say how wonderful these sleep 
medications are and they help them and yeah, so I don’t think there’s a stigma at all 
associated with it. (PT14) 
 
This quote is noteworthy because, even though it references an over the counter treatment, 
the patient said she had not considered sleep “a problem that a doctor might help me with.” 
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Yeah, I’ve tried [over the counter medications]. I don’t think I discussed that with a 
physician but a friend with whom I taught for a long time took Tylenol PM every 
night for years and years and years before she went to bed. And that was the only way 
she could sleep and it worked like a charm and she always did it. And she said NAME 
if you’re having trouble sleeping try Tylenol PM. Well, I felt that it made me. It felt 
too strong to me. It felt like I. I felt in the morning like I was on knock-out drops. I 
didn’t like that. But I didn’t discuss with a doctor. I just asked my friend and used my 
friend’s advice.  Because it  just seems like sleeping. I didn’t really think of it in terms 
of a problem that a doctor might help me with. (PT 46) 
 
Print media and the Internet were mentioned with some frequency, and though most deemed 
the information not that helpful, this patient had found one ‘trick’ to be helpful. 
And then we read up on the internet about, you know all the tricks of the sleeping. 
You know, have a dark room, go to bed at the same time very night. [Laughing] Etc, 
etc, etc. none of which [helped]. But one, one of those tricks I have been using and it 
has helped a lot, and that is a sleep mask. (PT 23) 
 
This patient said she had gained information from many sources.  
MM: Other than the doctors at [the IMC], are there other sources that you’ve used to 
gain knowledge about sleep issues, such as the internet, watching TV, reading books 
or magazines or talking to friends and family? 
KI: Oh, yeah. All.  
MM: all of the above. 
KI: Yeah. Newspaper, did you say that one too? Whenever something is on about 
sleep or insomnia I always read it or look it up or whatever, but at this point I always 
know everything they have to say. (PT 4) 
 
Another patient told me that she had sought information at a library. 
I was desperate so I did it, that’s why I did. I went to the library. [Uh-huh] Because I 
was trying to do everything else I could before medication. (PT 21) 
 
In sum, people in this sample used a variety of sources of rhetorical authority. 
Patients mentioned friends, family, the internet, TV, and print media as sources they had 
turned to in order to learn more about sleep. 
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The influence of insurance companies 
Like physicians, several patients noted that insurance had limited the amount of pills 
they could get in a month. 
This patient went into great depth about how he perceived the role of the insurance 
company to influence the doctors. This quote provides an interesting parallel to the physician 
interviews as a couple of the doctors discussed how much they didn’t like dealing with the 
insurance companies on certain issues and would warn their patients to that effect. 
I think that the doctors and assistants, medical assistants is, again too tied into what 
the insurance companies will allow versus pushing back on the insurance companies. 
I think that they just tend to be compliant with the insurance companies. I don’t think 
they are willing or able to fight the insurance companies. Because I believe that it’s 
just a battle that they’re not willing to invest the time and effort in. Because it is such 
a big battle….I think our insurance system is very, very much financially driven and 
for certain things. You know for example if you have a catastrophic issue they’re 
very, very good, ok. But when you have something like this where there is no direct 
correlation to a life and death situation or they don’t see themselves in a liability or a 
legal implication immediately I think that they are going to take every step possible to 
minimize their expense versus you know solving the problem. (PT 22) 
 
This patient was prescribed Paxil for her obsessive-compulsive disorder. 
That other doctor that I was telling you about, the older fellow, one day he gave me, 
he upped the strength of the Paxil. Well Dr. X had already gave me, I take like 40 
milligrams a day. But then my insurance company didn’t want to pay for two pills. 
They wanted to pay for one. So then a lot of the times I was only taking one anyway. 
So they just, they cut it down. So he had to cut it down so that they would pay for it. 
(PT 12) 
 
Although the role of insurance arose more frequently in the physician interviews, a few 
patients in this sample mentioned that insurance played a role in their ability to receive 
certain medications. 
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Discussion 
In this discussion, I summarize my findings from the patient interviews. In Chapter 6, I 
create further linkages between these data and the previously discussed quantitative and 
qualitative findings. 
To gain further insight into the patient-physicians interaction surrounding sleeplessness 
and explore evidence of the medicalization process, I interviewed 27 patients. All of the 
participants in this sample were patients of the IMC physicians I had previously interviewed. 
Patient interviews were semi-structured, lasted between 25 and 75 minutes and were 
conducted in-person or over the phone.   
Interviews focused on patient’s reported experience of insomnia, their interactions with 
physicians, attitudes toward insomnia treatment and sources of rhetorical authority. A few 
patients mentioned the role of insurance, but it was not nearly as prevalent a theme, 
compared to physician interviews. An unexpected theme was patient fears of dependence on 
sleep aids.  
Patient interviews allowed me to put faces, voices and personal history to bear on the 
national level trend statistics discussed in Chapter 3. Patients’ descriptions of their insomnia 
experience were consistently unpleasant. Individuals in this sample reported difficulty falling 
and/or staying asleep. Some woke up multiple times during the night. Commonly reported 
next-day impairments were fatigue and irritability; however, some reported little or no 
impairment.  
Like physicians, some of the patients in this sample ‘normalized’ their insomnia 
experiences by placing them in either the context of their individual circadian rhythm (being 
a “night owl” versus a “lark”) or in relation to the aging process. Women sometimes 
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associated the onset of their insomnia with mid-life hormonal changes and men mentioned 
prostate issues that woke them up multiple times a night to urinate, exacerbating their 
insomnia. 
In general, this was a sample with high levels of physical and psychological 
comorbidities. Patients self-disclosed a variety of health issues including heart disease, 
obsessive-compulsive disorder, fibromyalgia, arthritis, obstructive sleep apnea and 
depression. Most striking was the amount of participants who, when asked to cite a probable 
cause for their sleeplessness or describe their sleeplessness, noted life stress and symptoms of 
anxiety. Patients talked about “racing thoughts,” being unable to turn off their minds, lying 
awake and ruminating about the day, etc. They also revealed hating their jobs or having very 
stressful jobs, surviving dying spouses or grandchildren, and taking on multiple care-giving 
roles.  In short, despite the level of comorbidity, this group had plenty of life issues to lose 
sleep over. 
When describing interactions with physicians, patients were generally positive. Like their 
doctors, they noted several factors that potentially mediate the office visit outcome. These 
factors include: time constraints, consumerism, pre-existing prescriptions and physician 
attitudes toward treatment.  A couple of the patients seemed to have special insight into the 
issues of time that face physicians today. One of these patients was a physician and the other, 
a mother of a physician (neither of whom is affiliated with the clinic in question). They were 
not the only participants who discussed time; but they both discussed how the typical 15 
minute visit was insufficient to address all health issues, and may lead to hasty decisions 
regarding the treatment of sleeplessness. 
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Consumerism among these patients was evident in mentions of trying other people’s 
sleep medications before seeking a prescription, switching physicians if their drug choice 
was refused and buying drug on the internet. Trying the prescription of a friend or family 
member is not legal, but does provide a convenient and cost-free way of ‘trying before you 
buy.’ Admissions of doctor-shopping or buying drugs from alternate sources were 
uncommon, but I suspect this may be related to a previously addressed limitation of the study 
– patients may have feared that their physicians would have access to these interviews. 
Many of the patients in this study had pre-existing prescriptions for sleep aids from other 
doctors. This parallels what physicians told me in their interviews. Pre-existing prescriptions 
are not only a motivator for physician compliance, but because the interactions were 
described as brief and straightforward, I did not receive detailed accounts of these 
interactions. 
When describing the physician interaction surrounding prescription insomnia treatment, 
different prescribing ‘personalities’ emerged. By far, most patients used words like 
“cautious,” “careful” and “conservative” to describe their physicians prescribing preferences. 
Interestingly, a small number of patients described their physicians as far more liberal with 
prescription medications; one went so far as to describe one of his physicians as 
“freewheeling.” Another patient extrapolated from physicians being “interested” in 
prescribing certain drugs, to the corruption of the FDA. 
Patients in this sample confirmed physician assertions that lifestyle and behavioral 
changes were high on their list of first-line insomnia treatments. A few patients had read 
about sleep hygiene practices on the Internet. Regardless of their source of information, 
patients typically found their efforts to engage in these practices ineffectual or impractical. 
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However, in describing their sleep routines a few patients revealed to me that they 
maintained such sleep-hygiene “don’ts” as watching television or being on the computer late 
at night or right before bed. 
Generally, these patients were satisfied with their prescriptions sleep aids – particularly if 
they had a prescription for Ambien or its generic, zolpidem. However, some chronic users 
found that it lost effectiveness over time, and a couple of patients experienced side effects 
including sleep-walking and sleep-eating. Others experienced next-day hangovers from using 
Trazodone or over the counter medications.  
Concerns about drug dependence or addiction were raised in physician interviews, but I 
did not expect it to be a common theme in the patient interviews. Nevertheless, the topic 
arose frequently and quite a few patients told me of their reluctance to depend on these drugs 
to get them to sleep. A couple of people opined that drug taking was unnatural or too 
prevalent in our society. In a more extreme example, one woman told me that she had been 
sent to see a psychiatrist for not taking her medications; her rationale was that she had seen 
drug addiction in her husband’s family. But as one patient points out “I’ve been on Xanax for 
most of the last 16 years….if that’s an addiction, I’m addicted. But, I mean I’ve been on 
antidepressants for that time and, I guess I’m addicted to that too. Or not” (PT 39).  
Once more paralleling physician interviews, patients were most likely to discuss DTCA 
as compared to other forms of rhetorical authority. Drug advertisements – not just for sleep 
aids - were generally viewed negatively. When asked explicitly if they were influenced by 
DTCA, only a few patients admitted to seeing drug ads and subsequently asking their doctors 
for prescriptions. The rest asserted that they were immune, but that ads were probably 
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effective on others. One patient did note that they could be useful for making patients feel 
they were not “strange” or “unusual” and could be “freeing” in the doctor-patient interaction. 
Other forms of rhetorical authority mentioned were social networks, the Internet, and 
print media. One patient noted that her friends with sleep issues had served as an informal 
“support group.” Another noted that she had not thought sleep was something one talked to a 
doctor about, but she had taken advice from a friend on an over-the-counter sleep medication. 
A different patient noted that there seemed to be a lack of “taboo” surrounding Ambien that 
made it more acceptable to talk about with family and friends, as opposed to certain 
psychiatric medications.  
 A small number of patients discussed the impact of the insurance companies on their 
access to, or cost of, prescriptions. One patient in particular seemed miffed that his doctors 
were not “willing to invest the time and effort in” battling insurance companies. Another 
patient described how her insurance company refused to pay for her prescribed dose of Paxil; 
the physician’s solution was to lower the dosage.   
A major difference between these and the physician interviews was the lack of explicit 
discussion around the medicalization of sleeplessness. Unlike the physicians, patients were 
initially unaware that I was interested in exploring medicalization. Not surprisingly, patients 
lacked the meta-awareness about the process that was so striking in the physician interviews. 
A few patients made indirect references to medicalization. Several patients suggested that 
DTCA might make people believe they are sick or at least in need of a certain medication. 
One patient told me “I’m like, gosh, everywhere I go I see sleep commercials in newspaper 
and in print and media. It’s like this whole country is sleepless!” (PT 14). But some of the 
patient observations were more in line with de-medicalization, such as the woman who 
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proclaimed, when referring to all her friends who had sleep issues “We can’t all be sick!”  
And, as previously referenced, one patient said “I didn’t really think of [sleep] in terms of a 
problem that a doctor might help me with” (PT 46). Finally, perceptions of sleeping pills as 
unnatural or even dangerous may be antithetical to their popularity. 
In sum, patients described their experiences with insomnia, interactions with physicians, 
attitudes toward insomnia treatment and sources of rhetorical authority. Multiple subjects, 
including consumerism, rhetorical authority, physician time constraints, pre-existing 
prescriptions, and the influence of insurance companies offered parallels and contrasts to 
physicians thoughts on the same topics. An unexpected finding was the number of patients 
who, unprompted, described their concerns about dependence on, or addiction to, sleep aids. 
Data from these interviews indicates that patients are aware of some of the fueling factors of 
the medicalization process, particularly DTCA, but do not necessarily place their individual 
experiences in the context of these larger forces. Further discussion of these, and related 
findings from previous chapters, is considered in Chapter 6. 
  
CHAPTER 6 
INTEGRATED DISCUSSION AND CONCLUSIONS 
 
Overview of Research Intent and Methodology   
The goals of this dissertation are to provide quantitative and qualitative evidence of 
the medicalization of sleeplessness at the level of patient-physician interaction and elucidate 
how gaining a greater understanding of the forces influencing this interaction and its 
outcomes are vital to understanding the medicalization process. Medicalization, as previously 
noted, is typically conceptualized as the way in which social problems or formerly normative 
biological processes are re-conceptualized as having a medical definition and a medical 
treatment (Conrad 2007). 
 In an effort to answer my research question, “Is there evidence of the 
medicalization of sleeplessness at the level of doctor-patient interaction?” I carried out a 
mixed methods research agenda that offered evidence at both the macro and micro levels.  
I believe that the use of a mixed methodology was particularly apt for gaining insight 
into my research question. As noted by Creswell “the problems addressed by social and 
health science researchers are complex, and the use of either quantitative or qualitative 
approaches by themselves is inadequate to address the complexity” (2009: 203). In addition, 
this work is intended to appeal to an interdisciplinary audience who may have diverse 
methodological approaches (Creswell 2009). 
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Collectively these data indicate that the medicalization of sleeplessness is occurring at 
the level of patient-physician interaction. The quantitative data describe trends over time at 
the national level and highlight the disparities between complaint, diagnosis and treatment. 
The qualitative data help elucidate some of the forces that may be influencing these 
insomnia-related outcomes and fueling the medicalization process. 
In this chapter, I briefly summarize my quantitative and qualitative findings; highlight 
indicators of medicalization at both the macro and micro level of analyses; propose specific 
forces that seem to be fueling the medicalization of sleeplessness; note the limitations of this 
research; suggest directions for future research; and propose public health implications of the 
medicalization of insomnia.  
 
 Brief summaries of findings  
Quantitative Findings 
I analyzed 14 years of data from the National Ambulatory Care Survey (NAMCS), a 
nationally representative data set of physician office visits for the following insomnia-related 
outcomes: insomnia as reason for office visit, insomnia diagnoses, and the prescription of 
sedative hypnotics.  
In 1993, insomnia was recorded as a reason for office visit in approximately 3.3 
million cases. This number increased to about 4.7 million in 2006 – representing about a 30% 
increase from first to last year of the time period.  Over this same time period, the number of 
office visits resulting in a diagnosis of insomnia increased about 6-fold, from 869,000 to 5.2 
million. Office visits resulting in a prescription for a benzodiazepine increased by nearly 40% 
- from an estimated 2.5 million to 3.5 million. Prescriptions of Trazodone nearly doubled, 
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going from about 2.8 million in 1993 to 5.8 million in 2006. The largest increase, 23-fold, 
was for the non-benzodiazepine sedative hypnotics (NBSHs). Their first year in the NAMCS 
database (1994) about 550,000 prescriptions were written. This increased to 12.8 million in 
2006.31   
Looking at the overall period, the slope and differences in proportion were both 
positive and statistically significant for insomnia diagnoses, NBSHs, and Trazodone. Results 
were mixed for insomnia complaint and benzodiazepines. Only for the NBSHs were the 
slope and proportion differences consistently positive and significant in each regime; other 
regime outcomes were either not significant, or had a mixture of significant and non-
significant results.  
Analyzing my independent variables (race, sex, age and insurance status) there were 
few significant trends. Women were significantly more likely than men to be prescribed 
Trazodone in all of the regimes tested; there were no other consistent, statistically significant 
trends when looking at sex and dependent variables. In each regime, patients 55 and older 
were significantly more likely to receive a prescription for a benzodiazepine or a NBSH, 
compared to younger patients. While racial differences were inconsistent based on regime 
and dependent variable, when compared to African American, Asians and Hispanic office 
visits, Caucasians were significantly more likely to receive a diagnosis or drug, if there was a 
significant difference to report. 
Of my hypotheses, only H2 (estimated mean number of office visits resulting in a 
diagnosis of insomnia will increase significantly between 1993 and 2006), and H4 (estimated 
mean number of office visits resulting in a prescription for a NBSH will increase 
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 As you will recall, NAMCS is representative of only some outpatient clinics, and excludes: hospitals and 
hospital affiliated clinics, certain physician subspecialties and all inpatient facilities. For a more comprehensive 
estimate of insomnia scripts dispensed in certain years, please see Table 17 (page 200). 
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significantly between 1993 and 2006), were fully supported. However, H2 and H4 are the 
strongest indicators of the medicalization process and thus their significance should not be 
minimized.  
Some of my hypotheses received partial support. In H1 (estimated mean number of 
office visits with a complaint of insomnia will increase significantly between 1993 and 2006) 
the difference in mean proportions from 1993 and 2006 was not significant, but the slope 
trend is significant and positive (P<0.000**). For H3 (estimated mean number of office visits 
resulting in a prescription of a sedative hypnotic will increase significantly between 1993 and 
2006) the slopes for each of the sedative hypnotics measures (Benzodiazepines, Trazodone 
and NBSHs) show significant and positive change over time. However, when comparing 
mean proportions, Trazodone and NBSHs remain significant; benzodiazepines are not. Due 
to the inconsistency in the measures of change over time for the benzodiazepines, I cannot 
fully reject the null hypothesis, but would argue that, when taken as a whole, the sedative 
hypnotics have seen significant and positive change between 1993 and 2006. For H5 (The 
estimated proportion of individuals from “non-traditional” populations [those who are male, 
non-white, and/or younger] who receive a diagnosis of insomnia and/or a prescription for a 
sedative hypnotic will increase significantly), the results were so inconsistent that I failed to 
disprove the null hypothesis. 
 
Qualitative Findings 
Physician interviews 
The 8 physicians in this sample seemed aware of the medicalization process and were 
able to discuss it using sociological terms such as “medicalize,” “disease mongering” and 
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“case-findingness.”32 They were able to give examples of other medicalized disorders (e.g. 
toenail fungus), identify fueling factors (e.g. direct-to-consumer advertising [DTCA]) and 
describe parts of the medicalization process (e.g. expansion of diagnostic criteria). In 
addition, these physicians did not view or describe insomnia as an independent disease state. 
Instead, they characterized it as a symptom of another disorder (typically a mood disorder) or 
a normal, if unfortunate, part of the aging process, or a reaction to life’s stressors. 
Perhaps because of this characterization, physicians preferred to treat sleeplessness 
with behavioral/lifestyles changes or “sleep hygiene” practices. Barring that, the doctors in 
this practice used Trazodone (preferred for its non-addictive nature) and benzodiazepines 
(particularly for people who had been using them for years); but the most requested and most 
prescribed drug was Ambien, or its generic, zolpidem. Every physician I interviewed 
expressed some degree of bias against these sleep medications, but most expressed a ‘soft’ 
bias – essentially the feeling that these drugs may not be ideal (typically embodied in 
concerns about dependence) but don’t seem to be generally harmful.  
For physicians in this sample, compliance appeared to be motivated by a variety of 
factors, including: time constraints, consumerism among patients, a pre-existing prescription 
from another physician, and the hope of gaining patient compliance with other regimens. As 
evidenced by these interviews, physician compliance may go beyond accepting patient 
expertise and/or complying with a request for medication. These physicians must make 
complex decisions in short periods of time while hoping to emerge with the best possible 
decision for the patient’s health. Pre-existing prescription was possibly the strongest 
motivator for physician compliance. Even the two physicians who told me that they do not 
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 These terms, though they have substantive overlap, do not have identical definitions. Ideally, ‘medicalization’ 
lacks judgmental connotations (see Williams et al. 2008). Nevertheless, they connote similar ideas and 
meanings. 
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prescribe sleep aids complied with requests for these drugs if the patient entered the 
interaction with a pre-existing prescription. 
Physicians at the IMC reported that their patients entered the office visit with medical 
knowledge from non-medical sources (‘rhetorical authority’).  Sources included the Internet 
and social networks, but by far the most commonly mentioned was direct-to-consumer 
advertising (DTCA). One physician, citing Gladwell’s The Tipping Point (2000), traced a 
conceptual path from DTCA to discussion among social networks to the social acceptability 
of sleep aids and patient request for a sleep aid. 
As these physicians do not see drug representatives, I did not necessarily expect the 
topic to arise in our interviews; however, several in the sample expressed disdain for drug 
companies, drug representatives and their profit-making motives. An unexpected finding was 
the influence of insurance companies on the office visit. Some insurance companies have 
recently limited the amount of sleep aid pills prescribed in one month to 15. Physicians did 
not necessarily see this as a negative limitation, but were not happy about the extra 
paperwork required by patients who requested more than the 15 pill per month maximum. 
 
Patient interviews 
I had 27 interview participants; all were patients of the IMC physicians previously 
interviewed. Each patient had received a prescription for a sedative hypnotic within the six 
months prior to my IMC data query of June, 2008. A few patient interviews were conducted 
in person, but most took place over the phone. Unique to these interviews was the individual 
experience of, and perspective on, insomnia. I also focused on their interactions with 
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physicians, their attitudes toward prescription treatments and their sources of rhetorical 
authority. 
Patient descriptions of insomnia included images of discomfort, unrest and anxiety. 
Like their physicians, patients did not seem to conceptualize insomnia as a disease state. 
When asked to speculate as to the cause of their sleeplessness, most said it was the product of 
stressful lives or anxious thoughts. Many of these patients discussed other health issues. 
Respondents disclosed, among other health conditions, heart disease, arthritis, fibromyalgia, 
depression and obsessive-compulsive disorder. Nevertheless, they most strongly associated 
stressful life issues with the onset or continued cause of their issues with sleep. These issues 
included demanding jobs, multiple care-giving roles and family deaths.  
 Despite their self-identified life or psychological struggles, all of the patients in this 
sample had sought a medical solution to their sleep problem in the form of a prescription 
drug. Most had tried other forms of self-treatment, including over the counter sedatives and 
melatonin, prior to seeking a prescription drug. Patients confirmed that their physicians 
discussed lifestyle and behavioral changes and/or the tenets of sleep hygiene prior to writing 
a prescription. Despite this information, some patients revealed that they routinely engaged in 
poor sleep hygiene practices (e.g. watching TV or playing on the computer late at night). 
Most rejected the “impractical” and “ineffective” behavioral solutions suggested by their 
physicians in favor of medication. 
 Patients noted several influential factors mediating their physician interaction. These 
often echoed physician-mentioned issues and included: time constraints, having a pre-
existing prescription, consumerism and, to a lesser degree, the role of the insurance company. 
Patients who had special insight into physician time constraints tended to work in health care, 
167 
or have relatives in health care. Many of the patients in this sample entered the office visit 
with a pre-existing prescription from another physician. These participants were the least 
likely to recall details of their interaction with their IMC physician. Others did not have prior 
prescriptions, but had ‘sampled’ the prescription sleep aids of family or friends. 
 Paralleling physician statements were patient insights about rhetorical authority. 
Numerous sources of medical information were mentioned, including friends, family, print 
media and the Internet. However, DTCA was the most discussed form of rhetorical authority. 
Interestingly, patients in this sample were apt to say that, though aware of DTCA, it did not 
affect them. But when asked if they thought it influenced others, they invariably assumed that 
it did.  
 Unlike physicians, patients in this sample did not seem explicitly aware of the 
medicalization process. In fairness, I was not explicit about the medicalization-related 
portion of my research agenda and I did not use the term “medicalize” at any point in the 
patient interviews. However, patients were keenly aware of some fueling factors, particularly 
DTCA. Conversely, some patients exhibited attitudes that might be interpreted as ‘anti-
medicalization.’ 
 
Macro indicators of the medicalization of sleeplessness 
 In this section I highlight some of the macro indicators of the medicalization of 
insomnia as evidenced by NAMCS data. I use evidence from patient and physician 
interviews to speculate about some of the fueling factors behind these macro trends.  
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1. There was a striking difference in the rates of insomnia complaint and diagnosis as 
compared to sleep aids prescribed.  
People have complained of insomnia for millennia (Sumners-Bremner 2008) and thus 
increased complaints of insomnia are not, in and of themselves, sufficient to argue the 
occurrence of medicalization. Increased diagnoses are more compelling indicators that 
medicalization is occurring (Conrad and Potter 2000). Most compelling, I argue, is the use of 
a medical treatment for a formerly ‘normal’ biological process or social issue. Thus, while 
only two of my initial hypotheses were fully supported by these analyses (H2 and H4), the 
significant, positive trends I found in both diagnosis and prescription treatment offer 
compelling evidence of the medicalization of sleeplessness at the national level. 
However, while both outcomes were significant and positive, the two trends did not 
increase in tandem, nor did they exactly mirror the trend in insomnia complaint. To recap, 
between 1993 and 2006 insomnia complaints increased by about 30% (from 2.3 million to 
4.7 million). Comparatively, diagnoses of insomnia increased about 6-fold (from 869,000 to 
5.2 million) This increase was positive and significant over time on all statistical measures, 
as was the nearly 100% increase in Trazodone33 prescriptions (2.8 million to 5.8 million). 
 Benzodiazepines also experienced increase a 40% increase in prescriptions over time 
(from 2.5 to 3. 5 million), but statistical measures of change were not uniformly significant. 
Most striking was the positive and significant 23-fold increase in the number of office visits 
resulting in the prescription of a non-benzodiazepine sedative hypnotics [NBSH] (from 
550,000 in 1994 to 12.8 million in 2006). The primary indication for NBSHs is the treatment 
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 Although the primary indication for Trazodone is depression, it is not considered a very effective anti-
depressant. The significant increase in its use is almost certainly indicative of its increased use as a sleep aid 
(personal communication, Head of UNC Psychiatry Department, 2008). 
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of short-term insomnia (Physician’s Desk Reference 2006: 2868), making the interpretation 
of these drug trends less ambiguous than for either Trazodone or the benzodiazepines.  
 While this 23-fold increase is striking, perhaps more interesting is the gap between 
insomnia complaints and diagnoses, compared to sleep aids prescribed. Please see the circled 
area in Figure 16 below for a visual representation of this gap.  
Figure 16. Trends over time in Insomnia Complaint, Diagnosis and prescription of Non-
benzodiazepines sedative hypnotics (1993-2006) with discrepancy highlighted. 
 
 
In short, by 2006, there were 8.1 million more office visits resulting in a prescription for 
a NBSH than office visits with a complaint of insomnia. Similarly, there were 7.6 million 
more office visits resulting in a prescription for a NBSH than office visits resulting in a 
diagnosis of insomnia. 
In an age of medical bureaucracy, the prescription of a medical treatment is not 
necessarily tied to a diagnosis (Thomas et al. 2006). In addition, the design of NAMCS may 
lend itself to producing a disparity between diagnoses and medications. For each office visit, 
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only 3 diagnoses, but between 5 and 8 medications may be listed.34 If the participants in my 
sample are any indication, individuals who suffer from insomnia may have multiple, 
concurrent health issues. This listing bias could be one reason that complaint and diagnosis 
of insomnia lag well behind the prescription of sedative hypnotics. 
Even with this limitation the large and growing disparity between diagnosis and 
prescription is still noteworthy and deserving of further exploration. I argue that this gap may 
be, in part, due to the increasing medicalization of sleeplessness. Motivated by DTCA and 
rhetorical authority, patients may be self-diagnosing at increasing rates and asking for 
specific sleep medications by name. Physicians in this sample indicated that this was fairly 
common in their patient population. Patients interviewed were not likely to admit to self-
diagnosis, but some allowed that they had asked for a prescription by name (particularly if 
they came in with a pre-existing prescription or had tried someone else’s.) 
There may also be evidence that physicians are increasingly willing to treat patient’s 
social problems with medical solutions. Physicians in this sample noted that insomnia in their 
patients only rarely had a biological origin. Nevertheless, they all prescribed sleep aids  As 
seen in patient and physician interviews, patient compliance is motivated by a number of 
factors. These potential fueling forces should be explored in greater detail. 
 
2. The lines for complaint and diagnosis converge.  
Another outcome worth noting is the convergence of the trend lines for complaint and 
diagnosis of insomnia (see Figure 16 above).  Regardless of the non-significant trend in 
complaint, diagnoses are increasing significantly over time, and thus the number of 
complaints and diagnoses appear to converge in 2006. Other research has indicated that past 
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complaints of sleeplessness were more likely to result in the diagnosis of a mental illness 
(Skaer et al. 1999). Trends in these data seem to indicate that a complaint of sleeplessness 
may be more likely to result in a diagnosis of insomnia. However, insights gleaned from 
patient and physician interviews lead me to suggest that a separate or complementary 
phenomenon might be occurring. Patients and/or physicians may be increasingly likely to 
bring up the topic of sleep in the context of an unrelated office visit.  
According to my physician subjects, insomnia was almost never the primary reason 
for office visit, but patients were likely to raise the subject and/or ask for medication. This 
may be partially fueled by increased consumerism among patients. [See page 98 for example 
of physician quote]. Although physicians in this sample said it was more likely for the patient 
to bring up insomnia or request a sleep aid during the course of an office visit, a couple of 
patients felt that insomnia drugs were being pushed by physicians. [See page 148 for 
example of patient quote]. 
Whether by patient request or physician push, or both, the convergence in these trend 
lines indicates at least partial support for the medicalization hypothesis and in particular 
points to the possibility of increased consumerism among patients. While not likely in the 
physician population I interviewed, it is also possible that physicians are increasingly likely 
to “push” diagnoses or drugs.  
 It is worth noting that insomnia complaints appear to have decreased by 22% from 
2005 to 2006. Only future releases of NAMCS data can help me determine if this dip is an 
anomaly or evidence of a trend. Regardless, the fact that diagnoses and drug prescriptions 
continue to increase in that same year may also be interpreted as further evidence of 
medicalization 
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3. The process of medicalization does not seem to occur uniformly over time and is 
likely influenced by a variety of social forces and institutional factors.  
Breaking the 14-year time period into three distinct regimes offered insight into nuances 
of the data that would have been otherwise obscured. It would appear that, even of the 
statistically significant trends, the changes in my dependent variable outcomes did not 
happen uniformly over time. I will address statistically significant regime trends here 
(significant overall trends have been previously discussed). 
 For diagnosis of insomnia, only the first regime indicates significant, positive change. 
As I discuss later, it is possible that the introduction of the NBSH hypnotics is fueling the 
diagnosis of insomnia. A more significant increase occurred in the time period [1993-1997] 
when these drugs were introduced, compared to later regimes.  
 Prescription of NBSHs is the only dependent variable for which an increase in 
prescriptions in every regime was significant. However the steepest rate of increase appears 
to occur in Regime 3. This may be linked to increased DTCA spending between 2002 and 
2006.  (see Table 15 on page 183) 
 Prescriptions of benzodiazepines had positive, significant change in Regime 3 for 
both mean proportion differences and slope statistics. I speculate that perhaps there was an 
increase of benzodiazepine use in Regime 3 as a lingering after effect of September 11. More 
likely, the aging of the population may play a role as older age is significantly associated 
with the prescription of the less expensive benzodiazepines (Rasu et al. 2005). 
 Trazodone is interesting because there is a significant difference in the mean 
proportion differences only for Regime 3. The slope calculation for this regime was not 
significant because in 2006, Trazodone prescriptions decreased by about 23% from the 
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previous year, negating an otherwise positive and significant trend line. It is possible that, 
again 9/11 and/or the increase in DTCA spending and/or the aging of the population may be 
fueling this significant trend in Regime 3. One reason that the trend may have taken a 
downward turn in 2006 is because of the introduction of the newer NBSHs (Lunesta, Sonata, 
etc.) and the increased DTCA spending on the NBSHs in 2006. 
 In terms of independent variables, there were few consistent, noteworthy patterns in 
relation to dependent variables, but I will examine the significant trends more closely here.  
In each regime, older persons are more likely than those under age 55 to receive a 
prescription for a benzodiazepine. This finding supports other research on sleep aids using 
NAMCS (see Rasu et al. 2005). Government insurance is also significantly associated with 
the prescription of a benzodiazepine in each regime (when compared to private or “other” 
insurance options). I hypothesize that this is likely due to the use of Medicare and Medicaid 
by older populations, confirming the findings of Rasu and colleagues (2005).  
 When considering Trazodone there are three significant trends. In terms of the 
likelihood of having an office visit result in a prescription of Trazodone: women are more 
likely than men, whites are more likely than minorities, and those with government insurance 
are more likely than those with private or other insurance. I believe these are related to the 
demographic trend of an aging population and the social fact that women exhibit more help-
seeking behaviors than men in healthcare settings, are more likely to be depressed, and are 
more likely to use medication (Green and Pope 1999; Kaye, Crittendon and Charland 
2008).35 
Finally, older age and Caucasian race were significantly associated with an office 
visit resulting in the prescription of a NBSH. In two of the regimes, government insurance 
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 Trazodone is commonly indicated for the treatment of insomnia with comorbid depression. 
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had a significant association to this outcome, compared to private or other insurance. Once 
more, I think that age and insurance are likely collinear.  
I can only speculate as to the causes of significant versus non-significant change 
across regime, and it is beyond the scope of this work to determine all possible causes. 
However, it is possible that social,  institutional or demographic forces such as the 
introduction of the NBSHs to the market, the passage of the FDA Modernization Act in 
1997, its full implementation in 1999, the tragedy of 9/11, and the aging of the US population 
may all have played roles in speeding or slowing the medicalization process. These data 
suggest that the medicalization process has a variety of fueling factors that may evolve over 
time.  
In sum, these quantitative data offer a picture of trends occurring between 1993 and 
2006. These trends did not occur uniformly over time. This leads me to conclude that 
developing a measure for the medicalization of sleeplessness, and other medicalized 
disorders, may be quite useful in pinpointing these fueling factors. I will further discuss this 
concept later in the chapter.  
Dividing the 14 year time period into 3 distinct regimes may have aided in the 
identification of potential fueling factors, and identification of changing rates of the 
medicalization process over time. Although I speculate about the factors that fuel these 
trends, these macro outcomes are the sum product of a multitude of individual office visits 
over time. In order to gain further insight into what occurs in these individual interactions, I 
have incorporated findings from the qualitative interviews to fill some of the interpretive 
gaps. I now focus on these qualitative data and some of the micro indicators of the 
medicalization of sleeplessness.  
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Micro indicators of the medicalization of sleeplessness 
Qualitative data from interviews  
Patient and physician perspectives added interpretive depth to the national level trend 
statistics presented in Chapter 3 and revisited in this chapter. In addition, conducting these 
separate patient and physician interviews allowed me to see points of agreement or dissent in 
accounts of the office visit. Overall, patient interviews confirmed physician accounts of the 
interaction and added additional insight into some of the forces that may be influencing 
office visit outcomes.  
 
1. Life problems are being treated with medical solutions.  
Physicians in this sample told me that they did not view insomnia as a primarily medical 
issue. Instead of categorizing insomnia as a disease process, these physicians typically 
described it as a) a normative process, particularly when viewed in the context of aging or b) 
a symptom of another disease or disorder, typically a mood disorder.  
Similarly, patients ‘normalized’ their sleeplessness by relating to personality (“I’m a 
worrier”), aging (“It could be related to getting older.”), age-related hormonal changes 
(menopause or enlarged prostate), and stressful lives.  None of these patients seemed to view 
their sleeplessness as a discreet disease state. In fact, when asked directly to assess the 
cause(s) of their insomnia, patient responses typically centered on accounts of stress or 
symptoms of anxiety. In fact, this sample had many reasons to be over-burdened. Patients 
disclosed past trauma, multiple care-giving roles, sick relatives, deaths in the family, 
demanding jobs and a myriad of physical and mental health issues. In sum, there was no 
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shortage of reasons that these people lay awake at night, or were awoken repeatedly by 
nothing more than their restless minds.  
This begs the question, if both the patients and physicians in this sample 
independently demonstrated awareness that insomnia was most often caused by life issues, 
why then are physicians prescribing these drugs and why are patients requesting and 
consuming them? I argue that the findings of this study are indicative of social and cultural 
trends that have been explored in depth by other scholars (see Elliot 2003; Conrad 2007; 
Rosenfeld and Faircloth 2006; Groopman 2002; Rothman and Rothman 2003; Horwitz and 
Wakefield 2007; Lane 2007; Herzberg 2009). Life and life processes are increasingly thrust 
into the province of medical authority and treated with medical solutions (Conrad 2007). 
Sleeplessness may be just the latest in a long line of formerly ‘normal’ life experiences, that 
can now be ‘fixed’ with a pill.  
 
2. Consumerism, a fueling factor of the medicalization process, was abundantly present 
in this sample. 
Increasingly, patients challenge medical authority by seeking medical knowledge from 
non-medical sources (rhetorical authority) and view the physician’s office as one more venue 
for the buying and selling of goods (Kroll-Smith 2003; Conrad 2007). The trend of 
consumerism in medicine was well-documented in the 1983 book by Haug and Lavin, and 
appears to have only strengthened with time. 
Physicians described a variety of consumerist behaviors exhibited by their patients. 
Asking for specific name brand sleep aids was fairly common. The use of coupons was less 
common but was mentioned by a few physicians. One physician referred to the healthcare 
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system as a “marketplace” and doctors in this sample seemed well aware that some patients, 
if not prescribed the drug of their choice would “find a doctor who will give it to them. And 
that’s not too hard” (Doc 1).  Physicians didn’t seem too bothered by these attitudes and 
practices, but I was struck by the fact that this was an incredibly caring and conscientious 
group of physicians. I wondered if targeted probing would have revealed more candid 
responses.  
 Patients were less forthcoming about doctor shopping, although a couple of them 
made it clear that they were willing to switch physicians in order to get their preferred drugs. 
None of them mentioned coupons, but several did discuss trying the prescription sleep aid of 
a family member or friend before seeking a prescription from an MD. In exercising this 
‘hyper-consumerist’ behavior of seeking sleep drugs from friends or family members, these 
individuals were able to bypass potential rejection and sample a drug before committing to its 
purchase. Again, I wonder if their conscious or unconscious desire to be seen as ‘good’ 
patients restricted them from expressing more consumerist attitudes and behaviors. 
 Despite my sense that further probing would have revealed even more consumerism 
in these office interactions, I found the concept to be alive and well in this sample. While 
shifts in the patient-physician relationship have eroded physician power, and rhetorical 
authority ensures that they are no longer the sole holders of an esoteric body of knowledge, 
physicians are still seen as the gatekeepers to prescription medications (Kroll-Smith 2003; 
Conrad 2007; Charles et al. 1999) except when patients can easily ‘sample’ pills of friends or 
family members. I suggest that the lack of stigma attached to the use of prescription sleep 
aids, as noted in both patient and physician interviews, makes consumerist attitudes and 
behaviors more socially acceptible. Drug companies are likely aware of this perception, and 
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as I discuss in a subsequent section, sleep drugs are some of the most heavily marketed drugs 
on the market.  
 
3. Sleeplessness appears to be only partially medicalized.  
As I described in Chapter 4 and reviewed in this chapter, physicians in this sample 
seemed intensely aware of medicalization and demonstrated this awareness through their use 
of sociological language (“medicalize,” “disease mongering,” etc.); ability to relate 
sleeplessness to other medicalized conditions (e.g. toenail fungus); knowledge of fueling 
factors (e.g. DTCA); and ability to identify key parts of the process (e.g. expansion of 
diagnoses).  
 In this instance, patient interviews were quite distinct from physicians’ interviews. 
Patients were initially unaware that I was interested in exploring medicalization and, not 
surprisingly, lacked the meta-awareness about the process that was so striking in the 
physician interviews. Some patients demonstrated knowledge of fueling factors, particularly 
DTCA, and a couple made connections to drug commercials for other medicalized disorders 
(e.g. erectile dysfunction, fibromyalgia) (see Rosenfeld and Faircloth 2006; Barker 2008).  
Similar to a physician in the sample, one patient was able to trace a conceptual path from 
DTCA to conversations among social networks to, ultimately, a request for a prescription. 
Other patients suggested that DTCA might make people believe they are sick or at least in 
need of a certain medication. One patient told me “I’m like, gosh, everywhere I go I see sleep 
commercials in newspaper and in print and media. It’s like this whole country is sleepless!” 
(PT 14).  
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However, some of the patient observations were more indicative of an anti-
medicalization attitude toward sleeplessness. One woman proclaimed, when referring to all 
her friends who had sleep issues “We can’t all be sick!”  Although she said this with a laugh, 
some would argue that it belies the messages that direct-to-consumer advertising promotes – 
that we are, in fact, all sick enough to need medication (Conrad 2007; Elliot 2003; Moynihan, 
Heath and Henry 2002). Another patient told me “I didn’t really think of [sleep] in terms of a 
problem that a doctor might help me with” (PT 46). In addition, these patients did not express 
unambiguously positive attitudes toward sleep aids or the taking of medication in general. 
Some opined that taking pills wasn’t “natural”; more commonly patients expressed fears or 
concerns about the potentially addictive nature of sleep drugs.  
These findings suggest that the medicalization of sleeplessness is only partial. In 
order for it to be more advanced, I argue that perception of sleeplessness needs to be shifted 
away from a symptom, a reaction to stress, or a part of the natural aging process to one of a 
disease state. The notion that insomnia is a symptom rather than a disease, and that this 
conceptualization is actually constructed and reinforced by the British media was recently 
written about by Williams and colleagues (2008). However, it would not surprise me to see 
this conceptual shift occur over time, and particularly in the US where the drug companies 
hold tremendous authority over the promotion and pricing of sleep drugs. 
Despite the lack of evidence in my small qualitative sample, conceptual change may 
already be occurring on other levels. An article entitled “Insomnia: Symptom or Diagnosis?” 
explicitly addresses the symptom versus diagnosis distinction and concludes that “viewing 
insomnia as a symptom or epiphenomenon of other disorders can be unfounded. This view 
may deprive patients of treatment, which might not only cure their insomnia, but may also 
180 
reduce symptoms associated with the assumed ‘primary’ disorder” (Harvey 2001: 1037). 
Interestingly, this viewpoint is shared by many in the pharmaceutical industry (Nelson 2007; 
Koroneos 2007). 
Finally, even if the conceptualization of and explanations for insomnia are not 
currently presented in a strictly medical context, what these data draw pointed attention to is 
the fact that –with or without a formal diagnosis - the availability of a ‘safe’ and convenient 
medical treatment and the insurance companies’ willingness to pay for this treatment (within 
their proscribed limits) provides alleviation from – and thus medicalizes -  these life 
problems. 
 
Forces that may be fueling the medicalization of sleeplessness  
For years the (pharmaceutically funded) National Sleep Foundation (NSF) has been 
sounding a warning that we are in the throes of an insomnia epidemic (Weiss 2008). 
Recently, however, a University of Maryland study (2008) indicated that Americans may be 
getting enough sleep, after all. Although the National Sleep Foundation claims the average 
US adult sleeps only 7 hours or less, nightly, the University of Maryland study shows an 
increase in time slept, from about 8 hours a night a decade ago to 8.4 hours a night in 2005 
(University of Maryland 2008; Lloyd 2008). 
 So what to believe? Unfortunately, these data cannot answer the question of whether 
the sleeplessness epidemic is real. But, the data reported in this dissertation do indicate 
significant shifts in the increased diagnosis and treatment of insomnia. The US may not have 
an epidemic of insomnia. But, to borrow a phrase, we may have an “epidemic of diagnoses” 
(Welch, Schwartz and Woloshin 2007) and, I would add, an epidemic of treatments. 
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  In the previous pages I suggested macro and micro indicators from my analyses that 
support the medicalization hypotheses. In the following section I highlight some potential 
fueling forces of this process. I will now touch briefly on the changing patient-physician 
relationship and the possibility that the introduction of a newer, ‘safer’ treatment (NBSHs) 
has fueled increased awareness and treatment of insomnia. I then focus on the growth and 
influence of direct to consumer advertising (DTCA) and its relationship to the medicalization 
of insomnia. 
 
1. Changes in the patient physician relationship. 
In the ‘golden age of doctoring’ commonly thought of as the time period from about 1950 
until the 80’s, physicians assumed the dominant role in the patient-physician dyad. 
‘Paternalism’ was the prevalent approach to medical care and patients assumed deference to 
the specialized body of knowledge held by physicians (Freidson 1988; Charles, Gafni and 
Whelan 1999).  
Since the introduction of managed care, the patient-physician interaction has been 
increasingly influenced by outside factors including time constraints, fragmentation of care 
and the authority of insurance companies. Two of these influences may be speeding the 
medicalization of sleeplessness, while the third, may actually be constraining it.  
Both patients and physicians in this study noted multiple factors that influenced or 
constrained the office-visit interaction. These limitations – consumerism, desire for patient 
compliance, rhetorical authority, ‘soft’ bias, etc. -  may be in fact fueling the medicalization 
process as they make it easier for a physician to write a prescription than refuse a patient’s 
request for a medication. A countervailing factor may be the power of the insurance company 
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to limit the number of sleep aids that may be prescribed in a month. However, physicians did 
not seem to mind the possibly ‘helpful’ limitations put in place by the insurance companies; 
although they did find the additional paperwork necessary to bypass these limitations an 
extra hassle that they tried to avoid.  
 
2. Invention of a cure pushed the disease 
The medicalization of some disorders appears to be linked to the development and 
promotion of related medical or pharmaceutical treatments (e.g. gastric bypass and obesity, 
hormone replacement therapy and menopause) (Conrad 2007; Rothman and Rothman 2003). 
These data suggest that the development and promotion of non-benzodiazepine hypnotics, 
introduced to the US market in 1993, has been concomitant with increased diagnosis and 
treatment of insomnia. I assert that the introduction of the NBSHs in 1993 are paramount to 
the increases in people being diagnosed and/or treated for a sleep disorder.  
 Most physicians in this sample admitted to having only a ‘soft’ bias against the 
NBSHs, despite recent increased warnings about strange side effects (Saul 2007), evidence 
that they are only marginally effective in providing more sleep time and that they may be 
better amnesiacs than sleep aids (Saul 2007B) 
 The role of a new drug in creating or expanding a medicalized disorder is not new 
(Tone 2009: Herzberg 2009), so what makes Ambien so different from Milltown? The 
answer to this question may be the advent of legal, widespread, multi-media, multi-million 
dollar campaigns featuring creative and catchy ‘hooks.’ In short, the invention of the 
treatment may only take a disorder so far, it is up to the advertising executives to ensure the 
branding and success of the drug. 
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3. The influence of DTCA 
While I posit that the pharmaceutical industry is a key fueling force of the medicalization 
of sleeplessness, I am unable to measure the impact directly using these data. Data on direct 
to consumer advertising spending are available, but as this was not the key focus of my 
dissertation and I lacked the funds to purchase independently collected data, I present here 
facts and figures that were published elsewhere. For an overview of prescription drug 
promotional spending, please see Table 15. 
Table 15: Prescription Drug Promotion and Research and Development, 1997-2005.  
Year 
Spending on 
DTC 
advertising 
Spending on 
promotion to 
physicians 
Retail value 
of samples 
Research & 
Development 
1997 $1.1 $3.9 $6.0 $15.5 
1998 $1.3 $4.6 $6.6 $17.1 
1999 $1.8 $4.8 $7.2 $18.5 
2000 $2.5 $5.6 $8.5 $21.4 
2001 $2.7 $5.9 $10.5 $23.5 
2002 $2.6 $6.6 $11.9 $25.7 
2003 $3.3 $7.4 $13.5 $27.1 
2004 $4.0 $7.8 $15.9 $29.8 
2005 $4.2 $7.2 not available $31.4 
Average annual 
% increase 19.6 9.0 14.9 9.3 
Total 
%increase, 
1997-2005 
296.4 86.0 162.4 103.3 
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(Source: U.S. Government Accountability Office, Prescription Drugs: Improvements 
Needed in FDA's Oversight of Direct-to-Consumer Advertising', GAO report Number 
GAO-07-54, December 14, 2006. (All figures in Billions)Reprinted from: 
http://www.sourcewatch.org/index.php?title=Direct-to-
consumer_advertising_in_the_United_States 
 
As seen in Table 15, the average annual percentage increase in DTC spending is about 
20% from 1997 to 2005. This trend increased in 2006, and some estimates indicate that from 
1997 to 2006, direct-to-consumer spending increased by 320%, from just over $1 billion to 
$4.5 billion (Kelly 2007). From 2000 to 2006, DTC growth increased more sharply, as drug 
companies shifted their dollars away from physician detailing in order to increase advertising 
dollars on TV and magazine campaigns (Kelly 2007).  In the same six year period, the use of 
prescription sleep aids increased by more than 60%. 
 In 2006, makers of all sleeping pills combined spent more than $600 million on 
advertising (Saul 2007). Of the top ten most advertised brands, Lunesta had the highest 
budget of any brand ($300 million) (Kelly 2007). By comparison, about $200 million was 
spent on the Ambien brand (West 2007). Trying to grab a share of the market, newcomer 
Rozerem spent about $100 million in advertising (West 2007). Despite Lunesta’s impressive 
advertising budget, Ambien and Ambien CR held onto the lion’s share of the sleep aid 
market – accounting for 27.6 million out of 44 million sleep drug prescriptions written in the 
US. Restoril (temazepam) came in second place with 7.3 million prescriptions, and was 
followed by Lunesta at 5.8 million prescriptions (Saul 2007). 
By comparison, in 2005, the makers of Lunesta spent about $215 million, while Sanofi-
Aventis, the makers of Ambien, spent approximately $90 million in an effort to compete – 
nearly double what they spent in 2004 (Saul 2006; West 2007). In the past few years, several 
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of the NBSHs (notably Ambien and Lunesta) have appeared on Top 20 and Top 10 lists for 
highest DTCA budgets. 
 These large advertising budgets seem to have paid off. In 2006, sales for Lunesta and 
Ambien alone totaled more than $3 billion (Saul 2007). In just the first quarter of 2007, the 
best selling NBSHs have earned the following: Ambien - $653 million; Lunesta $181 
million; Rozerem $28.1 million (Koroneos 2007). Moreover, figures from IMS Health 
statistics indicate that comparing 2001 to 2005, insomnia sales increased by over $1.5 billion. 
Please see Table 16 below. 
Table 16. Insomnia Medications – Total U.S. Sales $ in Thousands (000) 
Rank Drug 2001 2002 2003 2004 2005 
Class 
total 
 $1,143,346 $1,443,885 $1,761,430 $2,113,025 $2,757,063 
1 Ambien $986,000 $1,273,624 $1,574,643 $1,899,648 $2,139,192 
2 Lunesta *** *** *** *** $321,794 
3 Sonata $93,407 $105,798 $112,906 $121,728 $117,282 
4 Ambien 
CR 
*** *** *** *** $72,951 
5 Restoril $12,835 $19,865 $33,788 $39,614 $42,875 
(Table reproduced from IMS Health, IMS National Sales Perspective, 2/2006) 
  
 It would be naïve to propose that DTCA is solely responsible for changes in 
consumer behavior. More likely, to be influential is the domino effect that DTCA may 
engender. As noted in patient and physician interviews, DTCA enables topics like sleeping 
pills to become part of the conversation at a cocktail party or by the water cooler, where it is 
then filters into common social exchange and is normalized among social groups. According 
to Katz and Lazarsfeld (1955), knowledge from DTCA is dispersed into the public and then 
when an “opinion leader” mentions the ad or the drug at a social gathering or at work, the 
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message flows to a broader, more receptive audience (Katz and Lazarsfeld 1955).36 One or 
more of the audience members may seek a prescription of the drug from their physician and 
not realize that they have been influenced by DTCA. This may, in part, explain the responses 
of most of my patient sample who claim to not be influenced at all by DTCA. (A 
reproduction of the two-step flow model is available below in Figure 17. 
Figure 17.Katz and Lazarfeld Two-step flow model of communication. 
 
Source:  Katz and Lazarsfeld (1955) 
 To clarify, it is not merely the availability of a drug treatment that has been critical to 
the medicalization of sleeplessness, but the influence and success of their marketing 
campaigns in spreading the three-fold message: a) you may have an undiagnosed issue with 
sleep b) there is a safe and effective treatment for your issue c) all you need do is talk to your 
doctor about getting Drug X.   
                                                          
36
 Interestingly, the original study on ‘opinion leaders’ was carried out in a physician population. 
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Conclusions 
The findings of these analyses allow me to draw several inferences: 
1) The medicalization of sleeplessness is being propelled by both the introduction and 
the marketing of a new medical treatment (the non-benzodiazepine sedative hypnotics). 
Marketing campaigns encourage patients to ask their doctor if the advertised drug is “right” 
for them, creating a “medicalization-amplifying feedback loop” (Conrad 2007). 
2) Although physicians still act as ‘gatekeepers’, patients wield increasing power in 
the patient-physician dynamic and physician compliance is influenced by a multitude of 
mitigating factors, including: time constraints, consumerist attitudes, increased fragmentation 
of care and the influence of rhetorical authority.  
3) Measuring the rapid uptake of NBSHs provides one measure of the medicalization 
of sleeplessness – confirming the work of other social scientists and medical doctors who 
assert that life problems are increasingly likely to be treated with medical solutions.  
 
Contributions to the literature 
This research offers contributions to multiple disciplines and interest areas: the 
sociology of sleep, medicalization theory, and health research.   
 
Sociology of sleep 
The study of sleep and sleep disorders are relatively recent topics of interest. Sleep is 
also an increasingly vibrant area of sociological study (see Williams et al. 2008; Wolf-Meyer 
2008; Williams 2005; Seale et al. 2007; Hislop and Arbor 2003; Kroll-Smith 2003 Meadows 
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2005). However, to the best of my knowledge, only Hislop and Arbor (2003) have researched 
the medicalization of sleeplessness at the individual level; their work, and their collaboration 
with Meadows, looked at the sleep practices of couples. No research that I’m aware of has 
investigated the medicalization of sleeplessness at the level of patient-physician interaction; 
nor has other sociological work measured sleep-related trends across time using a 
representative data set of physician office visits.  
 
Medicalization theory 
A great deal of excellent work has been carried out in the area of medicalization 
theory (please see Chapter 2 for a detailed description of medicalization theory and its 
contributors). However, much of the research on medicalization has been historical, 
qualitative and descriptive in nature. In addition, prior medicalization research has focused 
on the ways in which illness is conceived, described and legitimized by pinpointing the social 
construction at the conceptual and institutional levels (Conrad and Schneider 1992; Conrad 
2007). Notable exceptions, and good examples of the exploration of medicalization at the 
interactional level include work by Barker (2008), Kroll-Smith and Floyd (1997), and Hislop 
and Arbor (2003). However, in general, the interactional level of medicalization has largely 
been understudied and few have tried to pinpoint possible measures of medicalization. 
This work also emphasizes the outcomes of the patient-physician interaction. While 
the factors and forces that lead an individual or group of individuals to enter the physician’s 
office are important, I argue that if diagnoses are not being made and/or prescriptions are not 
being written then how can we conclusively assert that the process of medicalization is 
occurring? Some might point to the example of the newly recognized genetic disorders that 
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have been conceptualized and are recognized at an institutional level, but do not yet have 
medical treatments. Although a salient point, I would argue that researchers and 
pharmaceutical companies are racing to find medical treatments for these disorders and that 
they will not be fully medicalized until such treatments have been discovered and made 
available to the public.  
In addition, I suggest that mixed-methods studies of medicalization are under-utilized. 
Had I pursued a strictly quantitative dissertation, I would have likely argued that the 
medicalization of sleeplessness is further along. However, insights gained from the physician 
and patient interviews allowed me to better understand the nuances of this phenomenon and 
determine that the medicalization of sleeplessness is still underway. 
The work of Conrad is important and a foundation to this, and any good piece of 
medicalization research. However, I would challenge Conrad and Potter’s (2000) assertion 
that the conceptual level is “key” to the medicalization process. I assert that if (or when) 
shifts in perception from symptom to diagnosis, or life problem to disease state occur, the 
most compelling evidence of increased medicalization will not be found in Diagnostic and 
Statistical Manuals, or even in broader definitions of insomnia in the International 
Classifications of Disease, but in the context and outcomes of the physician office visit. More 
specifically, it appears that the invention, introduction and uptake of a medical treatment 
provides a short-cut to the medicalization process. 
The relationship between medical classification and medical treatment must also be 
further scrutinized. In the case of sleeplessness, despite patient and physician 
acknowledgment that insomnia is not necessarily a disease, but a symptom (this viewpoint 
also appears to be prominently portrayed in the UK media, see Williams et al. 2008), it is 
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possible that physicians are ‘diluting’ the power of certain medical diagnoses by using them 
as a) shorthand for unpleasant symptoms that are related to life circumstance and/or b) a 
necessary box to check in order to fulfill the requirements of an insurance form. If this is the 
case, then the use of a medical treatment might be a more ‘robust’ indicator that an issue has 
been ‘made medical.’  
Further, the sequencing of the medicalization process could be a fruitful area of 
academic interest. While this particular example of a medicalized disorder seems to imply a 
pattern of Treatment – Diagnosis – Conceptualization, this does not seem to be the case for 
other disorders (e.g. genetic disorders). It might be interesting to discern if certain sequences 
lead to more rapid medicalization than others. In order to assess rate of medicalization, 
however, we will need to construct a testable scale (or other instrument) than can offer a 
reliable measurement of medicalization. 
 
Measurement of Medicalization 
Few have attempted to measure medicalization, or even to define what that process 
might look like. In his 2007 Book, “The Medicalization of Society” Conrad takes this issue 
on directly. Interestingly, the examples he uses of the measurement of medicalization are 
centered on treatments (Hormone replacement therapy (HRT) for menopause, breast implants 
for small breasts, increasing prescriptions of psychotropic medications for adolescents with 
Attention Deficit Hyperactivity Disorder). Moreover, as he documents the rise and fall of 
HRT for menopause and breast implants, he concludes that despite their rise and fall “the 
medicalization itself – the defining of the problem in medical terms – did not change. What 
changed was the implementation of medicalized interventions” (2007: 126). However, 
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sleeplessness may better be viewed as a problem which is more defined by the medical 
intervention, than by being conceptualized as a medical problem. Evidence for this view is 
provided by the inconsistency in insomnia definitions.  
One way I have tried to measure the medicalization of sleeplessness is by tracking 
trends over time in a nationally representative data set of physician office visits. While I do 
not assume this to be the only, or even the ideal measure, charting trends in insomnia-related 
outcomes at a national level does offer some insight into the growth of medicalization of 
sleeplessness over time. This type of measurement also allows me to infer factors that might 
have been more critical to the medicalization process – in this case the introduction and 
promotion of the newer, non-benzodiazepine sedative hypnotics [NBSHs]. 
 
Health Research 
Many of the findings of this research re-affirm or closely approximate those from 
other studies using the NAMCS dataset to look at insomnia-related outcomes (Namen et al. 
2002; Skaer et al. 1999; Rasu et al. 2005; Balkrishnan et al. 2005 ). However, to the best of 
my knowledge, no other study in the health (or sociological) literature has looked at a time 
period of this length (14 years) or this particular time period (1993-2006); nor have they 
subdivided the time period into analytic regimes based on possible social and institutional 
‘fault lines.’ My research contributes not only a longer span of time in which to analyze 
trends, but adds a sociological dimension. In addition, I emphasize the differences in the 
proportions of my dependent variable, rather than raw or weighted totals; thus taking into 
account certain established social trends (e.g., women are more likely to utilize health 
services and use prescription drugs). 
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Limitations and Future Research  
The limitations of these data are myriad and are detailed on pages 43, 83, and 123 of 
this manuscript; thus, I will not reproduce them here. However, I will re-address some of the 
major concerns and introduce some new insights on one limitation in particular (the setting of 
the Internal Medicine Clinic). 
 
Quantitative  
NAMCS was neither intended nor designed to capture or measure the medicalization 
process. Although I feel it is the best currently available data set with which to do these 
analyses, the NAMCS data are limited in several respects. NAMCS captures only specific 
subsets of office-based physician visits. NAMCS does not capture the type of physicians or 
patients(based in an academic center) who participated in the qualitative portion of this 
research. 
NAMCS data include only patients who have both the motivation and means to make 
it to a physician’s office. This selection effect may under-represent lower-income groups 
who mainly use emergency services as their primary means of accessing health services. In 
addition, the patient is not the unit of analysis; the unit of analysis is the office visit. Thus, 
results are suggestive of, but not equivalent to, patient outcomes.  
The increasing number of drugs that physicians are allowed to list over time 
potentially complicates interpretation of my findings (going from 5 to 8 over the 14 year 
period). This potential for “listing bias” is a serious, potential confounder to my findings. 
However, as descriptive statistics on pages 72-73 indicate, the mean number of reported 
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drugs increased by only 1 drug on average over a 14 year period of time, even though the 
allowable drug listings went up by 3. I argue that, while the increase in allowable categories 
may have had some impact on the significant increase in sedative hypnotics over this time 
period, it cannot fully explain the increase and does not negate or substantially diminish my 
findings, particularly the 23-fold increase in prescription of NBSHs over time. 
Finally, due to the cross-sectional nature of the NAMCS data it is impossible for me 
to tell if the increase in uptake of sleep medications is via new patients or returning patients. 
It is possible, though not probable, that these data are capturing not only non-unique patients 
across years, but also within a year. This is, however, unlikely given that the data collection 
periods for physician offices are one week in duration, and thus less likely to capture repeat 
visitors. And while I do not think this potential issue negates the robust finding of the 23-fold 
increase in NBSHs, it might be more problematic for the less dramatic increases in 
benzodiazepines, or perhaps even Trazodone.  
In order to address some of these concerns and further my research agenda, I intend to 
work with future releases of NAMCS data and propose the following analyses:  
a) generating proportion comparisons over time and slope trends for the dependent variables 
in office visits for those 65+ and those under 65. (In order to assess the usefulness of these 
different age distinctions compared to the 55+ and under 55 age categories originally used).  
b) a multivariate analysis that takes into account whether or not the regime interacts with the 
different demographics and whether demographic categories are interacting with one another 
(for instance  race and insurance status, gender and age). 
c) uploading and analyzing the NAMCS 2007 data as soon as they are available. 
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Qualitative 
A previously noted limitation, the setting of the Internal Medicine Clinic (IMC), may 
in fact be considered a strength of my research design.37 Although I had originally 
conceptualized multiple pathways through which the pharmaceutical companies are able to 
influence the patient-physician interaction, by choosing the setting of a university-affiliated 
Internal Medicine Clinic where physicians are not allowed to see drug company 
representatives, I have perhaps created a sort of ‘natural experiment.’ That is, if only one 
pathway is available for the drugs companies (DTCA as opposed to DTCA and physician 
detailing) I am in a sense controlling for the influence of physician detailing and providing a 
stronger analysis of consumerism. My findings suggest that one pathway alone may be more 
than adequate to influence the patient-physician interaction. It may also have heightened the 
awareness of the physicians in this sample to the power of DTCA. 
This does, however, highlight another limitation. Although the physicians in this 
sample seem critical of, if not occasionally hostile to, the influence of ‘Big Pharma,’ they still 
prescribe these popular and heavily advertised sleep aids. It is possible that by invoking other 
constraints – time, pre-existing prescription, patient compliance, etc. – they are presenting 
themselves in a more favorable light. 
Conversely, the vast majority of patients in this sample claimed to view DTCA in a 
negative light and discern its profit-making motives (although, apparently, the rest of us are 
not so insightful). Some patients seemed to go out of their way to assure me that they didn’t 
want to, and had no intention of, taking these drugs every night or becoming “hooked” on 
them. But again, the obvious irony is that every single one of these patients had a prescription 
                                                          
37
 I would like to acknowledge Bob Konrad for his ability to see the potential strengths of this limitation.  
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for a sleep aid – the majority for the most popular and heavily advertised38 sleep aid in the 
world – Ambien 
I would argue that patients, and physicians, were not generally or consciously 
presenting their actions in a deceptive way; but I must acknowledge the possibility that they 
were unconsciously presenting themselves in the most positive light and that that is a 
limitation of this work.  
 
Future Research 
          A critical limitation of this work is the lack of a comparison group for my patients with 
insomnia. By design, all patient participants used, at least occasionally, a prescription sleep 
medication. While effective as a recruitment strategy, this exclusion negates the participation 
or input of patients who have effectively treated their insomnia with the following methods: 
cognitive behavioral therapy [CBT], sleep hygiene, or any number of complementary or 
alternative treatments. It also excludes patients who suffer from sleeplessness, but have been 
refused a prescription for a sleep medication. Future research should actively attempt to 
recruit individuals who did not meet the inclusion criteria of this study; their input could be 
invaluable in further exploring the medicalization of sleeplessness. In addition, the small 
sample size of this study makes it impossible to generalize these findings to larger or more 
diverse populations. A follow-up study with a larger and more varied sample would provide 
additional insights and enhance generalizability of findings. 
As previously noted, the physicians in this sample were cognizant and critical of the 
medicalization process. This is likely due to the academic culture in which they practice. 
                                                          
38
 Although in recent years Lunesta has spent more advertising dollars (Kelly 2007) the Ambien brand is still 
the most advertised, over time.   
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Replication of this research in other practice settings – e.g. community clinics or private 
practice where physicians interact with drug representatives – would, I predict, be far less 
likely to find physicians who share the attitudes and insights of my sample. Meso-level 
factors such as clinic culture and setting, presence of peer-influence, relationship with drug 
representatives, use of drug samples and time spent with patient are worthy of deeper 
consideration in future work.  
Though this study was limited in its exploration of the physician-patient interaction 
surrounding sleeplessness, future research could focus on other means of capturing and 
analyzing this interaction. Direct observation of the patient and physician interaction would 
be ideal. Alternately, the use of videotaped patient complaint (using real or representative 
patients) or standardized case-study narratives could be used to elicit physician response. 
This study has underscored the importance of examining the interactional level of 
medicalization. In addition, I suggest that the use of a mixed methodology aids not only in 
the identification of both macro and micro indicators of medicalization, but sheds light on the 
way in which these factors and forces interact and influence one another. Future work – 
whether exploring the medicalization of sleeplessness or some other medicalized issue - 
should consider the patient-physician interaction a rich source of data about the process of 
medicalization, the factors that influence it and the outcomes it produces. 
My research also raises questions about the sequencing and measurement of 
medicalization. I propose the following research questions be explored: Does sequence of 
medicalization process differ by disorder? Is it related to rate of medicalization? How can 
medicalization be effectively and reliably measured? 
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Finally, I would suggest that the medicalization of insomnia is a topic of interest 
engaging to scholars in disciplines outside of sociology. Dialogue and collaboration with 
researchers in the fields of public health, medicine, anthropology, psychology, health 
services and economics (to name a few), could be enormously fruitful in providing insights 
into causes of sleeplessness, the medicalization process and the patient-physician interaction. 
 
Implications for Public Health 
Despite multiple limitations, this research has important implications for public 
health. Physicians in this sample did not view insomnia as an epidemic or a public health 
problem. Most classified it as either a normative process or an uncomfortable part of the 
aging process. One physician went into some detail as to why he did not view insomnia as a 
public health issue [see quote on page 90]. 
While physicians did discuss the potential side effects and potential for addiction with 
the sleep drugs, they did not address the potential public health impacts of the medicalization 
of insomnia. As noted in the introductory chapters of this research, the FDA raised concerns 
about the safety and efficacy of the non-benzodiazepine hypnotics just a few years after they 
were introduced to the market (Wagner et al. 1998) and mandated additional warnings for the 
makers of Lunesta, Ambien and 11 other sleep medications in 2007. 
 Although only a small number of my non-representative sample reported odd side 
effects from taking Ambien, hosts of other patients across the country have reported bizarre 
behaviors including sleep-driving, sleep-eating, sleep-walking and making purchase while 
“asleep” (Saul 2007). Increasingly, Ambien is found in the bloodstream of impaired 
motorists (Barclay 2006). 
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 Another risk, discussed in both my physician sample and in the literature (see 
Siversten et al. 2006) is the use of sedative hypnotics among older adults. This group is at 
greater risk from unnecessary falls, if they are in a sedated state. Given the demonstrated 
efficacy of cognitive behavioral therapy (CBT) in this population, falling injuries related to 
sleep drug sedation may be largely avoidable (Siversten et al. 2006). 
 Treating sleeplessness with sedative hypnotics may be unnecessarily costly to both 
our health care system and our public health. Other, non-drug based treatments have proven 
equally or more effective. A review of 48 clinical trials found that 70 to 80 percent of 
patients benefit from behavioral therapies for at least 6 months after completion of treatment 
(Morin 2005). Behavioral therapies are cost-effective and have no known side effects. The 
practice of sleep hygiene offers guidelines on health practices (diet, exercise, substance use) 
and environmental factors (light, temperature, noise control) and can benefit anyone who 
lives in a setting shaped by artificial light and 24-hour access to communications technology 
(IOM 2006).  
Despite the fact that behavioral therapies and sleep hygiene practices have 
demonstrated efficacy, prescription sleep aids are still the treatment of choice for the vast 
majority of physicians who see patients with insomnia (Rybarczyk et al. 2005). Clinicians are 
not necessarily unwilling to utilize non-prescription treatments for sleeplessness, but most 
lack awareness of their efficacy and training in their implementation (IOM 2006). Patients, in 
turn, lack awareness of many of the health implications associated with sleeplessness and 
their “education” in sleep aids is more likely to come from a television advertisement starring 
a glowing moth than from a medical professional or trained educator. 
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Recently, the Institute of Medicine reviewed public education efforts made by the 
National Center on Sleep Disorders Research, Centers for Disease Control and Prevention 
and private foundations, and found the current investment in education and awareness 
campaigns to be “limited” (IOM 2006: 175). Preventive techniques such as reduction of 
occupational stress, job-sharing, flexible hours and the implementation of sleep hygiene into 
school curricula could all be important in reducing the public health burden of sleeplessness. 
"Sleeplessness" may very well be a public health problem, but its medicalization as 
insomnia--a transformation into a diagnostic entity with a predominantly pharmacological 
solution--is also problematic.  Such a process may entail unnecessary costs to the health care 
system and increase the risk of harming the population being diagnosed and treated, thus 
posing a related but distinct public health issue.    
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Table 17. Insomnia Medications – Total U.S. Dispensed Scripts in Thousands (000) 
Rank Drug  2001 2002 2003 2004 2005 
Class total  $29,183 $32,548 $35,211 $38,103 $43,126 
1 Ambien $17,319 $20,601 $23,324 $25,700 $26,556 
2 Temazepam $6,969 $7,059 $7,122 $7,681 $8,094 
3 Lunesta *** *** *** *** $3,333 
4 Sonata $1,791 $1,886 $1,775 $1,652 $1,452 
5 Triazolam $1,277 $1,269 $1,274 $1,313 $1,322 
(Table reproduced from IMS Health, IMS National Sales Perspective, 2/2006) 
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Appendix 1: 
Additions to the ICD-9-CM 
ICD-9-CM COORDINATION AND MAINTENANCE COMMITTEE MEETING 
OCTOBER 7-8, 2004 
Topic: Insomnia, hypersomnia and sleep apnea 
Sleep medicine is a new but growing medical subspecialty. The American Academy 
of Sleep Medicine has published “The International Classification of Sleep Disorders” that 
contains diagnostic, severity, and duration criteria to aid clinical diagnosis and treatment 
of sleep disorders. The Academy has been working with NCHS staff to bring the ICD up 
to date with the current classification of sleep disorders. 
Below are proposals to expand the ICD-9-CM in the areas of insomnia, hypersomnia 
and sleep apnea. In future revision, additional modifications will be proposed for others sleep 
disorders. 
TABULAR MODIFICATIONS 
291 Alcohol-induced mental disorders 
291.8 Other specified alcohol-induced mental disorders 
New code 
291.82 Alcohol-induced sleep disorders 
Alcohol-induced hypersomnia 
Alcohol-induced insomnia 
292 Drug-induced mental disorders 
292.8 Other specified drug-induced mental disorders 
New code 
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292.85 Drug-induced sleep disorders 
Drug-induced hypersomnia 
Drug-induced insomnia 
307 Special symptoms or syndromes, not elsewhere classified 
307.4 Specific disorders of sleep of non-organic origin 
Add 
Excludes: organic hypersomnia (349.40-349.49) 
organic insomnia (349.30-349.39) 
307.41 Transient disorder of initiating or maintaining sleep 
Add 
Adjustment insomnia 
29 
Page 30 
ICD-9-CM COORDINATION AND MAINTENANCE COMMITTEE MEETING 
OCTOBER 7-8, 2004 
307.42 Persistent disorder of initiating or maintaining sleep 
Add 
Idiopathic insomnia 
Add 
Paradoxical insomnia 
Add 
Primary insomnia 
Add 
203 
Psychophysiological insomnia 
307.44 Persistent disorder of initiating or maintaining wakefulness 
Add 
Idiopathic hypersomnia with long sleep time 
Add 
Idiopathic hypersomnia without long sleep time 
Add 
Insufficient sleep syndrome 
Primary hypersomnia 
Add 
Excludes: sleep deprivation (V69.4) 
349 Other and unspecified disorders of the nervous system 
New sub- 
349.3 Organic disorders of initiating and maintaining sleep [Organic 
category 
insomnia] 
Excludes: insomnia NOS (780.52) 
insomnia not due to a substance or known physiological 
condition (307.41-307.42) 
insomnia with sleep apnea NOS (780.51) 
New code 
349.30 Organic insomnia, unspecified 
New code 
204 
349.31 Insomnia due to non-mental health condition classified 
elsewhere 
Code first underlying condition 
New code 
349.32 Insomnia due to mental health condition 
Code first mental health condition 
Add 
Excludes: alcohol-induced insomnia (291.82) 
drug-induced insomnia (292.85) 
New code 
349.39 Other organic insomnia 
New sub- 
349.4 Organic disorder of excessive somnolence [Organic 
category 
hypersomnia] 
Excludes: hypersomnia NOS (780.54) 
hypersomnia not due to a substance or known physiological 
condition (307.43-307.44) 
hypersomnia with sleep apnea NOS (780.53) 
30 
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ICD-9-CM COORDINATION AND MAINTENANCE COMMITTEE MEETING 
OCTOBER 7-8, 2004 
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New code 
349.40 Organic hypersomnia, unspecified 
New code 
349.41 Recurrent hypersomnia 
Klein-Levin syndrome 
Menstrual related hypersomnia 
New code 
349.42 Hypersomnia due to non-mental health condition 
classified elsewhere 
Code first underlying condition 
New code 
349.43 Hypersomnia due to mental health condition 
Code first mental health condition 
Add 
Excludes: alcohol-induced hypersomnia (291.82) 
drug-induced hypersomnia (292.85) 
New code 
349.49 Other organic hypersomnia 
New sub- 
349.5 Organic sleep apnea 
category 
Excludes: Cheyne-Stokes breathing (786.04) 
hypersomnia with sleep apnea NOS (780.53) 
206 
insomnia with sleep apnea NOS (780.51) 
sleep apnea in newborn (770.81-770.82) 
sleep apnea NOS (780.57) 
New code 
349.50 Organic sleep apnea, unspecified 
New code 
349.51 Primary central sleep apnea 
New code 
349.52 High-altitude periodic breathing 
New code 
349.53 Obstructive sleep apnea (adult) (pediatric) 
New code 
349.54 Idiopathic sleep-related non-obstructive alveolar 
hypoventilation 
Sleep related hypoxia 
New code 
349.55 Sleep-related hypoventilation/hypoxemia in conditions classifiable elsewhere 
Code first underlying condition 
New code 
349.56 Central sleep apnea in conditions classified elsewhere 
Code first underlying condition 
New code 
349.59 Other organic sleep apnea 
207 
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ICD-9-CM COORDINATION AND MAINTENANCE COMMITTEE MEETING 
OCTOBER 7-8, 2004 
780 General symptoms 
780.5 Sleep disturbances 
Add 
Excludes: organic hypersomnia (349.40-349.49) 
organic insomnia (349.30-349.39) 
organic sleep apnea (349.50-349.59) 
Revise 
780.51 Insomnia with sleep apnea, unspecified 
Revise 
780.52 Other Insomnia, unspecified 
Delete 
Insomnia NOS 
Revise 
780.53 Hypersomnia with sleep apnea, unspecified 
Revise 
780.54 Other Hypersomnia, unspecified 
Delete 
Hypersomnia NOS 
Revise 
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780.57 Other and unspecified sleep apnea 
V69 Problems related to lifestyle 
New code 
V69.5 Behavioral insomnia of childhood 
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Appendix 2: 
 Email from Clinic Director to the IMC Physicians 
 
Mairead Moloney, a doctoral candidate working with XX at the XX is studying the 
medicalization of insomnia.  She would like to interview you about your experience with this 
phenomenon and, with your permission, interview several of your patients who have 
problems with insomnia.  She has IRB approval for her project and plans to get started next 
week.  She can meet with you in the clinic or in your office at a time that is convenient for 
you and she will not be approaching patients in the clinic.  I think you will find her work 
interesting and I hope you will lend your support to her project. 
XX 
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Appendix 3: 
 Physician Interview Guide 
 
(all prompts are response-dependent and noted in italics) 
Hello Dr. X, thank you so much for taking the time to talk to me today. I’d like to ask you 
some questions about your interactions with patients who complain of insomnia.  
 
To begin our interview will you please briefly describe the type of patients that you see in 
your practice (in terms of age, SES, burden of disease, gender, insurance status)? 
What is the average length of your office visits?  
 
As you know, I’m trying to learn more about how patients and doctors interact on the topic of 
insomnia. As I understand it, insomnia is defined as the inability to fall asleep or stay asleep. 
Is this correct?  
 
I’d like to get a general sense of how you evaluate and manage insomnia in your patients, but 
if you have any specific examples you could use to illustrate your points, that would be very 
helpful to me. 
 
First, tell me how do you evaluate patients with insomnia? (How do you medically evaluate 
whether you are looking at primary insomnia v. transient insomnia? Do you do a full 
physical? Who brings it up? How does it come up in the context of the office visit?) 
 
Do you ever: 
Talk to your patients about making behavioral or lifestyle changes? ( Under what 
circumstances? If so, could you give me an example? Who initiated this conversation – you 
or the patient?) 
Talk to your patients about sleep hygiene (a more formal set of behavioral and lifestyle 
suggestions)? (Under what circumstances? If so, could you give me an example? Who 
initiated this conversation – you or the patient?) 
Talk to your patients about over the counter medications for insomnia? (Under what 
circumstances? If so, could you give me an example? Who initiated this conversation – you 
or the patient?) 
Talk to your patients about herbal or alternative treatments? (Under what circumstances? If 
so, could you give me an example? Who initiated this conversation – you or the patient?) 
Refer patients with insomnia to a psychologist? (Under what circumstances? Examples? 
What factors might lead you to this decision? Who initiated this conversation – you or the 
patient?)  
Refer patients to a sleep clinic? (Under what circumstances? Examples? What factors might 
lead to this decision? Did you initiate this conversation or did the patient? Do you find sleep 
clinic evaluations to be helpful in these circumstances?) 
Design a treatment plan based on how well you think a patient will comply with it? (Under 
what circumstances? Example?) 
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General Treatment Questions 
I’d like to get your take now on the different kind of prescription medication options that are 
available for insomnia.  
Do you have particular medications that you tend to prescribe for patients with insomnia? 
(Why or why not?) 
How long do you typically prescribe these medications for? (Why do you choose that time 
period? What if they ask for refills?) 
How common is it for patients to request a specific medication such as Ambien or Lunesta? 
(How do you feel about this? Do you think that patients are influenced by advertisements for 
certain hypnotic drugs? Do they ever request older-generation hypnotics such as valium, to 
help them sleep?) 
Does the patient request for a specific drug influence what you choose to prescribe, or not 
prescribe? 
Can you give me an example of a time when you did not choose to prescribe a hypnotic 
medication to a patient who had requested one? (How did they react?) 
 
Now that we have talked about how you generally manage and treat insomnia. I was 
wondering if you could walk me through a couple of different, specific, anonymous 
examples of patients you have seen for insomnia. 
 
First Example39 
First, I’d like to ask you to walk me through the most recent (OR, a recent) visit you had by a 
patient who complained of sleeplessness.  
 (When was it? What were the patient’s basic characteristics? How did the issue arise in the 
context of the office visit? Who brought it up? Was it the patient’s main complaint or did they 
come to the visit because of another complaint? How did they present it/what language did 
they use to talk about it?   What affect was the insomnia having on their life? How did you 
determine the origin of the issue? Any co-morbidities? Would you say this is a fairly typical 
insomnia case? Why or why not?) 
  
Diagnosis 
Did he or she identify their sleeplessness as being the result of a life circumstance (social 
issue), a mental issue, or a physical issue?  
Do you think the patient’s insomnia was the result of a life circumstance (social issue), a 
mental issue or a physical issue?  
Did you offer the patient a diagnosis?  
Had the patient already diagnosed him or herself?  
Did the patient agree/disagree with your diagnosis? 
 
Treatment 
                                                          
39
 Physicians who agree to be interviewed will be notified in advance that I will be asking them for recent 
examples of patients they have seen who suffer from insomnia. This is expected to aid in physician recall during 
this interview.  
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What type of treatment did you decide upon? (Did the patient have any input in this? Did the 
patient request a specific treatment/medication?) 
 
Second Example 
Can you give me an example of an interaction with a patient around this issue that didn’t go 
well? (“not going well” could include issues of pt/phys disagreement, non-compliance, not 
getting better?, etc.) 
Repeat Diagnosis and Treatment Questions 
 
Education 
I’ve read that there is not a lot of training on sleep disorders, including insomnia, in medical 
school or residency. Do you agree with that?  
How comfortable were you in diagnosing and treating insomnia when you first began 
practicing medicine? How about now?  
What sources of information have you used to learn more about insomnia? 
 
Do you think that the number of patients you have seen for insomnia over the years has 
increased, decreased, or stayed about the same? 
 
Do you think there is a specific “type” of patient (general, stereotype) who complains of 
insomnia in terms of race, sex, SES, age?  
 
Do you think that DTCA (direct to consumer advertising) has any influence on the treatment 
a patient will request? (Do patients ever refer to specific advertisements?) 
 
Do you think that drug companies have any influence on the treatment choices physicians in 
your practice make?  
 
This completes the interview portion of our time together today. Thank you! Is there 
anything else you would like to add?  
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Appendix 4: 
 Physician Interview code list 
 
Free Nodes Tree Nodes 
Aging Issues Addiction Issues 
Consumerism Attitudes 
Doc Exper Sleeplessness Attittude twd Dx  (diagnosis)- Patient 
Effects of Sleeplessness Attitude twd Dx – Physician 
Gender Attitude twd Tx – Physician 
Insomnia Context Atttitude twd Tx - Patient 
Insomnia Definition Comorbidities 
Insomnia Trends Comorbidities - Physical 
Medicalization Comorbidities – psych 
Physician Compliance Comorbidities – OSA 
Physician Edu - Training Physician Information Sources 
Practice Type Phys Info – CMEs 
Primary Insomnia Phys Info – Colleagues 
Patient Type Phys Info - Drug Reps 
Patient visit - example Phys Info - Experience - trial and error 
Patient-Doc Interaction Phys Info – Jrnls 
Race Misc. 
Role of Drug Co. PT stereotype 
Role of US Hlthcare - insurance Rhetorical Authority 
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SES RA - DTC advert 
Stigma RA - friends and family 
Symptom v. Disease RA - Internet 
Time RA - magazines, books, news, tv 
 Referals 
 Referral - Psych 
 Referral - sleep clinic 
 Rx Related 
 Rx by Prev Doc 
 Rx Name Brand Request 
 Side effects-Effectiveness 
 Treatments 
 Sleep Hygeine 
 Tx - Anti-Depressant 
 Tx - Bnzo 
 Tx - CAM 
 Tx - NonBnzo 
 Tx - OTC 
 Tx - Trazadone 
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Appendix 5: 
 Memos from Coding process 
February 22, 2009 
Preliminary Findings 
1. Doctors in this sample are savvy about medicalization. They bring it up in the interview 
and sometimes even use that term. This degree of self-awareness and sociological insight is 
likely due to the fact that they are trained and practice in a highly respected academically-
oriented medical center. While this is an interesting finding, it must also be noted in my 
limitations section that these docs are not representative of the types of clinicians represented 
by the NAMCS survey. It is possible that docs in private practice would be less likely to 
discuss the medicalization process. While a limitation, I also think that this is a solid reason 
to do a follow up study with private practice docs. 
Example quotes: 
I:  Ok, so you mention psychiatric diagnosis, do you see insomnia as a psychiatric 
diagnosis or more physiological or could it be both? 
A:  Yeah, I think we tend to do that and I think we tend to medicalize insomnia to a 
large degree.  I think it is not, I think the majority of cases of insomnia are due to 
stressors in life and normal variance and I think they are usually not psychiatric 
diagnoses but I think to gain the diagnosis of insomnia it ought to be that.  It is 
getting ahead of myself, for the majority of patients I see I feel like are normal life 
variance of that and there is relatively few cases that I see where I would say this is a 
medical diagnosis of insomnia.  If that make sense. (Doc 4) 
 
2. Physician compliance is presented in a framework of limitations – (too little) time; 
effort of negotiation; patients will go elsewhere is they don’t give in; feeling they can do their 
pts a lot of good in other areas and giving in this one is no big deal as, so far, these drugs 
seem fairly benign.  
Example quote:  
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KI: yeah, so sometimes one thing I didn’t mention was sometimes if a patient has a lot 
of complaints and other health problems and they mention their insomnia and they’re 
interested in a medication sometimes it’s easier to write the prescription than it is to 
take a lot of time talking about behavioral modification. I always do try to talk about 
it, but sometimes there are just I think there are days that you write it, without. And 
you, well, you readdress it, but you do write it without much more discussion than 
that. (Doc 2) 
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Appendix 6: 
 Follow-up letter for Physicians Interviewed 
Dear Dr. X,  
Thank you again for our recent interview. As we discussed, I’d like to follow up with you on 
the patient interview piece of my project.  
Enclosed are two documents. One is a list (generated by a request to the ISD) of your 
patients who have received sedative hypnotics in the last 6 months. The other is an IRB 
approved lead letter that I will ask you to sign before I send it to potential patient 
participants. Enclosed with the letter will be a postage-paid card they can drop in the mail if 
they do not wish to participate.  
Please look this over when you have a chance and let me know if there are patients I 
should *rule out* as potential contacts. Please rule out patients who have:  
a) taken sedative hypnotics for less than a month OR  
b) been prescribed these drugs primarily for travel purposes OR  
c) have minimal English-speaking skills (unfortunately, I am not fluent in another language). 
At your convenience, you may return the patient list to me with *non-eligible 
patients crossed out or deleted*. Please let me know if you have any questions.  
 
Best,  
Mairead 
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Appendix 7: 
 Patient Lead Letter 
 
Sleeplessness in America Project 
DATE 
PATIENT NAME 
PATIENT ADDRESS 
 
Dear PATIENT, 
I am writing to ask you to consider participation in a research study about sleep problems 
here at the XXX Carolina’s Internal Medicine Clinic. Mairead Eastin Moloney, a doctoral 
candidate at the University of North Carolina at Chapel Hill, is interested in learning more 
about why increasing numbers of people seem to be experiencing sleep problems in this 
country and how people talk to their doctors about these problems.  
If you choose to participate, you will be called by Ms. Moloney. She will describe the 
study to you in more detail and ask you if you would be willing to participate in either an in-
person or a phone survey. After you complete the interview you will be given a Target gift 
card worth $25 to thank you for your time.  
Your participation is completely voluntary and deciding not to participate in this 
study will not change your ability to get health care at XXX. This study has been reviewed 
and approved by the School of Medicine’s Institutional Review Board on Research Involving 
Human Subjects. All information you give to Ms. Moloney will be kept completely 
confidential and will be used only for research purposes.   
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As a follow-up to this letter, Ms. Moloney will call you. If you do not want to participate in 
this study, you may return the postage-paid postcard, enclosed.  Alternately, you may also 
tell Ms. Moloney when she calls that you are not interested in participating in the study. 
It is important that we learn more about sleep problems, including insomnia. Ms. Moloney’s 
work hopes to promote better understanding of how patients experience and treat sleep 
problems and how they talk to their physicians about these problems. I hope that you will 
consider participating in this study. 
Sincerely, 
Dr. XXXXX, MD 
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Appendix 8: 
Text of self-addressed, postage paid, opt-out postcard 
 
 
Sleeplessness in America Project 
 
 
 
Return this postcard only if you DO NOT want to be contacted for the Sleeplessness in 
America Project. 
 
 
 
Please print name 
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Appendix 9: 
Introductory phone script for insomnia patients 
 
Hello, my name is Mairead and I’m calling to follow-up on the letter you received from Dr. 
X. I would like to ask you to be in a research study on people who have been treated for sleep 
issues including insomnia. As a doctoral student, I want to find out what people like you do 
about sleeplessness and the types of treatments that you try. Sleep issues seem to be a 
growing problem in our country and your participation in this research may help us better 
understand what people are dealing with, and how they are interacting with their physicians 
about these matters.  
 
I’d like to ask you some questions about your health and your medical care related to your 
sleep problems. The interview would take about 30 minutes and may be completed in person. 
Your participation is voluntary. If you choose not to agree to an interview, it will not affect 
your ability to get health care at XXX. Anything you tell me will be kept completely 
confidential and will be used only for research purposes. Your doctor will not know if you 
choose to participate and your responses will never be shared with him or her.  After you 
complete the interview, you will receive a $25 gift card to Target to thank you for your time.  
 
As part of this study I will collect your name, address and telephone number. However, if 
you choose to complete an interview, all this information and the information you give me 
about your health and health care will be stored only with an identification number, not with 
your name. Information that could identify you will be stored in a locked file cabinet in a 
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locked office until the research is completed. Any reports on the interviews carried out for 
this research will use pseudonyms (or fake names) only and will not contain identifying 
information of any kind.  
 
If you have any questions about this study, or your rights as a human subject, you can call 
Dr. X at XXXXXXX. Additionally you may contact my faculty advisor, Dr. Victor Marshall 
at 919-843-8067 or the UNC IRB at 919-966-3113. I also have their email addresses here if 
you would like to write those down as well (marshall@schsr.unc.edu or 
IRB_subjects@unc.edu). 
 
Are you willing to participate in this study by participating in an interview?  
 
If yes: Thank you. Would you like to schedule an in-person interview?  
 
If yes: Would you prefer an in-person or phone interview? 
If no: Thank you for your time. End call.  
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Appendix 10: 
 Patient Information Form 
 
Patient Information Form    Participant # ________ 
 
Year of Birth: __________ 
 
Sex:  M  F 
 
Highest Level of Education Achieved: 
(Please circle one) 
Less than high school 
Some high school 
High school diploma 
Some college 
AA or technical degree 
BA or BS 
Some graduate school 
MA or MS  
PhD or MD 
 
How would you describe your race or ethnicity? _____________________ 
 
 
Do you have private insurance?  Yes  No 
 
Medicare? Yes  No 
 
Medicaid?  Yes  No 
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Appendix 11: 
 Patient Interview Questions 
 (all prompts are response-dependent and noted in italics) 
 
I’m interested in learning more about how people experience sleep issues in America. Are 
you willing to talk with me today about your experiences with sleep issues? (If yes go to 
intro…) (If NO, Would you like to reschedule our interview or decline future participation? 
If DECLINE,Thank you so much for your time.)  
Intro  
I’d like to start out by asking you a few basic questions about your sleeplessness and then 
talk to you specifically about your interaction with Dr. X, and any other medical 
professionals you may have talked with about your sleep issues. 
So, first, please tell me a little bit about your issues with sleep.40 
 (How often do you experience it? How long have you been experiencing it? What did you do 
when you first began experiencing issues with your sleep? Have your issues with sleep 
changed over time or stayed pretty much the same?)  
 
Do you engage in shift work or other kinds of work that might make your sleep issues worse? 
 
Has your sleep issues affected the rest of your life/work/daily routines? (If so, how?) 
 
What do you think is the cause of your issue(s) with sleep? 
 
Were there other health problems you thought were related to your sleep issues? (Did you 
bring them up or did your doctor? OR Did your doctor agree/disagree?) 
 
Before seeing a doctor, how did you try to deal with your sleep issues? 
 
What made you decide to talk to Dr. X. about your sleep issues?   
 
Interaction 
At this point, I would like you to describe for me, in as much detail as you care to provide, 
your office visit with Dr. X where the two of you discussed your sleeplessness. (prompts: 
Who brought it up? How did you describe your sleep issues to the doctor? What was his/her 
reaction? (or) How receptive was the doctor to your concerns?) 
Diagnosis 
Did he/she offer you a diagnosis?  
Do you agree with that diagnosis?  
Were there other health problems that your doctor thought might be related to your sleep 
issues? (What do you think?) 
Treatment 
                                                          
40
 I will begin by using vague terms such as “sleeplessness” or “issues with sleep” and then transition into 
using whatever language they use when answering (e.g. if they talk about their insomnia, then that is the term 
I will adopt.) 
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How did you decide upon a treatment? (Did your doctor suggest a course of action? Did you 
suggest a course of action?) 
Did you discuss any over the counter treatments?  
How about any alternative or herbal treatments?  
How about behavioral or lifestyle changes?  
Did you and your doctor discuss the idea of you seeing another kind of professional about 
your sleep issuess, like a psychologist or a sleep specialist?  
If you receive a prescription for an Rx, did you get it filled? (How long did you take the drug 
for? What was your experience like?) 
 
Have you had any more recent interactions with Dr. X about your sleep issue? (If so, how did 
they go?) 
 
Have you had interactions with other physicians about your sleep issue? (if yes) 
Was this before or after seeing Dr. X? 
 
Please tell me about your best and worst interactions surrounding these encounters. 
Some doctors are very knowledgeable about sleep issues wheras others are less so because 
sleep issues are a new topic of interest and they may not have much training in them. In your 
encounters, how knowledgeable did you find your doctors to be?  
 
Some doctors are very open to prescribing medications for sleep issues, other doctors are 
more reluctant to do so. What types of physicians have you encountered?  
 
Other than doctors, were there other sources that you used to gain knowledge about sleep 
issues, such as the internet, watching tv, reading books/magazines/newspapers, talking to 
friends and family?  
Did you gain this knowledge before or after your encounters with doctors? (If so, what?)  
Do you think this knowledge had any influence on your interaction with your doctor? 
Do you think that, specifically, advertisements for prescription sleep drugs had any influence 
on your interaction with your doctor?  
 
Thank you so much for talking to me today! Is there anything else you would like to add?  
226 
Appendix 12: 
 Patient Interview Code List 
Free Nodes Tree Nodes 
Consumerism Attitudes 
Patient Experience of sleeplessness Attittude twd Dx  (diagnosis)- Patient 
Patient Effects of Sleeplessness Attitude twd Dx - Doc 
Gender Attitude twd Tx - Doc 
Insomnia Context Atttitude twd Tx - Patient 
Burden of insomnia Comorbidities 
Normalization of insomnia Comorbidities - Physical 
Medicalization Comorbidities - psychological 
Physician Compliance Comorbidities - OSA 
Satisfaction with Physician Insomnia Cause 
Addiction Issues Anxiety/stress 
Aging Issues Trauma/tragedy 
Time Age-related 
Symptom v. Disease Gender-related 
Patient-Doc Interaction Other illness related 
Race Don’t know 
Role of Drug Co. Rhetorical Authority 
Role of US Hlthcare – insurance Misc. or multiple 
SES RA - DTC advert 
Stigma RA - friends and family 
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 RA - Internet 
 RA - magazines, books, news, tv (print 
media) 
 Referals 
 Referral - Psych 
 Referral - sleep clinic 
 Rx Related 
 Rx by Prev Doc 
 Rx Name Brand Request 
 Side effects-Effectiveness 
 Treatments 
 Sleep Hygeine 
 Tx - Anti-Depressant 
 Tx – Bnzo 
 Tx – CAM 
 Tx - NonBnzo 
 Tx – OTC 
 Tx – Trazadone 
 Tx – home remedies 
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